A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Phase: PHASE3
Conditions: Atopic Dermatitis
Sponsor: LEO Pharma

Page 1 of 1
Cover Page 
Official title: A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of tralokinumab 
monotherapy in subjects with moderate-to-severe atopic dermatitis who are candidates for systemic therapy 
LEO Pharma number: LP0162-1326 
NCT number: NCT03160885 
Date: 14-Aug-2018 

Updated Clinical Trial Protocol 
LP0162-1326 
Tralokinumab monotherapy for moderate-to-severe atopic dermatitis 
ECZTRA 2 (ECZema TRAlokinumab trial no. 2)  
Phase 3 - Efficacy and safety trial 
A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and 
safety of tralokinumab monotherapy in subjects with moderate-to-severe atopic dermatitis 
who are candidates for systemic therapy 
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH-GCP 
and the applicable regulatory requirement(s). 
LEO Pharma A/S 
Trial ID: 
LP0162-1326 
Date: 
14-Aug-2018
EudraCT No: 
2016-004201-13 
Version: 
5.0 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 2 of 156 
1 Clinical trial protocol statement  
1.1 Approval statement LEO Pharma A/S 
The following persons have approved this clinical trial protocol by using electronic signatures 
as presented on the last page of this document: 
, MSc Stat 
Biostatistics Lead, Global Clinical Operations 
, MD, PhD 
Medical Lead, Medical Sciences and Safety 
, RN, PhD 
Clinical Operations Lead, Global Clinical Operations 
1.2 Approval statement international coordinating investigator 
The international coordinating investigator approves the clinical trial protocol and 
consolidated clinical trial protocol(s) comprising any subsequent amendment(s) by manually 
signing the International Coordinating Investigator Clinical Trial Protocol Approval Form, 
which is a separate document adjoined to this document. 
The following person has approved this clinical trial protocol: 
Eric Simpson, MD, MCR 
International coordinating investigator 
1.3 Acknowledgement statement investigator(s) 
Each participating investigator must agree to the approved clinical trial protocol and 
consolidated clinical trial protocol(s) comprising any subsequent amendment(s) by signing a 
Clinical Trial Protocol Acknowledgement Form or a similar document. 
eDoc-00648766 - Version
5. 0
PPD
PPD
PPD

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 3 of 156 
Protocol amendment summary of changes table 
Document history 
Date 
Type of amendment 
Amendment 4 (Substantial) 
14-Aug-2018 
Global 
Amendment 3 (substantial) 
12-Dec-2017 
Global 
Amendment 2 (substantial) 
28-Aug-2017 
Global 
Amendment 1 (non-substantial) 
15-Jun-2017 
Global 
Original protocol 
17-Mar-2017 
Amendment 4 (14-Aug-2018) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European 
Union (32).  
Overall rationale for the amendment 
The main reason for the amendment is that a new anti-drug antibodies (ADA) assay has been 
developed with improved tralokinumab tolerance. This means that the presence or absence of 
ADA can be determined in serum samples with tralokinumab present. Previously, this was not 
possible and therefore ADA sampling at the end of the 14-week off-treatment safety follow-up 
was originally required for the ADA evaluation. Thus, the new ADA assay will allow eligible 
subjects who have completed the treatment periods of trial LP0162-1326 to continue into the 
long-term extension trial (conducted under a separate protocol [LP0162-1337, ECZTEND]) 
without completing the safety follow-up period in the present trial. These subjects will have 
their safety follow-up period after end-of-treatment in the long-term extension trial.  
In addition, the amendment includes other changes, as presented in the table below. 
Note: The table below describes the changes in each section. Changes have either been 
summarised (written with plain text only) or marked as tracked changes (text added to the 
protocol is written in bold and deleted text has a line through it). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 4 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 4 
Schedule of 
procedures (SoP), 
Panel 2 
(footnote 2), Panel 
3 (footnote 2) and 
Panel 4 
(footnote 2);  
Section 7.1 
Overall trial design; 
Section 7.3 
End of trial 
definition 
Subjects will have a final safety follow-up 
visit 16 weeks after the last dose of IMP 
(which is also considered end of trial visit), 
except subjects who enter the long-term 
extension trial (conducted under a separate 
protocol [LP0162-1337, ECZTEND]). The 
subjects may enter ECZTEND at any time 
during the off-treatment safety follow-up 
period. For these subjects, the end of trial 
visit will be the last visit in trial LP0162-
1326. The subjects entering ECZTEND after 
completion of the end of treatment visit 
(Week 52) will also be considered as trial 
completers. For all subjects assigned 
treatment, an end of treatment form and end 
of trial form will be completed in the eCRF. 
To clarify that eligible 
subjects who have completed 
the treatment periods of trial 
LP0162-1326 may continue 
into the long-term extension 
trial (conducted under a 
separate protocol 
[LP0162-1337, ECZTEND]) 
without completing the 
safety follow-up period. 
Section 4 
Schedule of 
procedures (SoP), 
Panel 2 
(footnote 4), and 
Panel 4 
(footnote 3); 
Section 7.1 
Overall trial design; 
Section 9.2 
Administration of 
investigational 
medical products  
Subjects eligible for home-use will receive 
proper training at 3 dosing visits in the 
open-label period after additional consent has 
been obtained. 
To clarify what is considered 
proper training of the 
subjects or caregivers in 
home-use (that is 3 dosing 
visits during open-label 
treatment). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 5 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 9.5 
Concomitant 
medication and 
procedures; 
Section 9.7 
Rescue treatment 
In addition, the use of topical treatments is 
permitted during safety follow-up (from 
Week 52) at the investigator’s discretion. 
From Week 16 through safety follow-up 
(Week 66) subjects may use mild to moderate 
strength TCS and/or TCI as needed (prn 
usage) on lesional skin at the investigator’s 
discretion (see Appendix 9 for TCS 
classification and examples). Use of such 
TCS and TCI should be recorded as 
concomitant medication. 
To clarify that the use of 
topical treatments is 
permitted during the safety 
follow-up period. 
To clarify that subjects in the 
open-label tralokinumab arm 
are allowed to use TCS as 
well as TCI. 
Section 9.9.2 
Storage of IMPs 
The IMP must be stored at 2 to 8°C at the 
site. The temperature during storage must be 
monitored by a calibrated, stationary, and 
continuously monitoring recording system. 
Minimum requirement is a calibrated 
min/max thermometer.  
To clarify that the storage of 
IMP will be monitored. 
Section 9.9.3 
Drug accountability 
Used syringes will be destroyed at the trial 
site provided the trial site has procedures in 
place for such IMP destruction; this requires 
that the trial site is able to issue a certificate 
documenting the kit number(s) that were 
destroyed. 
Trial sites which do not have such IMP 
destruction procedures in place will dispose 
used syringes in sharps bins which will be 
shipped to the contract manufacturing 
organisation (CMO) at the end of the trial. 
For more information about IMP 
accountability, please refer to the IMP 
manual. 
To clarify that a certificate of 
destruction is not required 
for used IMP. 
To also allow shipment of 
sharps bins to the CMO 
during the trial. 
Section 10.3.2.8 
EQ-5D-5L  
The second section consists of a vertical 
visual analogue scale anchored at 0 (‘the 
worst best health you can imagine’) and 100 
(‘the best worst health you can imagine’). 
To correct the definition of 
extremes in the vertical 
visual analogue scale. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 6 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 11.1 
Collection of 
adverse events; 
AEs must be collected from time of first trial-
related activity after the subject has signed 
the informed consent form until completion 
of the clinical trial (defined as the safety 
follow-up visit 16 weeks after last injection).  
For subjects entering the long-term 
extension trial (LP0162-1337, ECZTEND), 
any (S)AE with onset before the final visit 
in LP0162-1326 should be reported in 
LP0162-1326. If ongoing, the (S)AE will 
also be recorded as medical history in 
ECZTEND. 
To clarify how (S)AEs 
occurring in subjects 
entering ECZTEND will be 
collected if visits in 
LP0162-1326 overlap with 
visits in ECZTEND. 
Section 11.5.1 
Adverse events of 
special interest 
Panel 13 
(Footnote 1) 
The additional data to be recorded in the 
eCRF are not a requirement, but are to be 
reported by the investigator, if available, 
for example as part of standard clinical 
practice. 
To clarify that additional 
information is to be provided 
only if available and is not a 
requirement. 
Section 12.3.7 
Analysis of safety 
Adverse events of special interest (AESIs) 
will be tabulated and listed instead of being 
presented in a narrative 
Tabulation and listings are 
considered a more practical 
and informative way of 
presenting data on AESIs. 
This will enable easier 
overview of the individual 
cases as well as sorting and 
pooling of data from several 
trials. 
Section 12.3.7.5 
Anti-drug 
antibodies 
Evaluations of nAB will be conducted on 
those serum samples that test positive for 
ADA. The test sample is deemed positive or 
negative for the presence of nAb to 
tralokinumab relative to a pre-determined (in 
assay validation), statistically derived cut 
point. Samples positive for nAb to 
tralokinumab are then titrated to determine 
relative amounts of nAb present in each test 
sample. 
To reflect that titre 
information will not be 
available from the nAB 
assay. 
Appendix 1 
Protocol summary 
Updated with the changes described above, as 
applicable. 
To reflect updated text in the 
protocol. 
Throughout 
Minor editorial and document formatting 
revisions. 
Minor, have therefore not 
been summarised. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 7 of 156 
Table of contents 
1 Clinical trial protocol statement ............................................................................................ 2 
1.1 Approval statement LEO Pharma A/S ............................................................................... 2 
1.2 Approval statement international coordinating investigator ............................................. 2 
1.3 Acknowledgement statement investigator(s) .................................................................... 2 
Protocol amendment summary of changes table ........................................................................ 3 
Table of contents ........................................................................................................................ 7 
List of panels ............................................................................................................................ 12 
List of abbreviations ................................................................................................................. 13 
2 Trial identification ............................................................................................................... 16 
3 Schematic of trial design ..................................................................................................... 16 
4 Schedule of procedures (SoP).............................................................................................. 17 
5 Introduction and rationale .................................................................................................... 26 
5.1 Atopic dermatitis ............................................................................................................. 26 
5.2 Experience with investigational medicinal product ........................................................ 26 
5.3 Trial rationale .................................................................................................................. 27 
5.4 Justification for dose ....................................................................................................... 28 
5.5 Benefit/risk assessment ................................................................................................... 29 
5.6 Ethical considerations ...................................................................................................... 30 
6 Trial objectives and endpoints ............................................................................................. 32 
6.1 Initial treatment period of Weeks 0 to 16 ........................................................................ 33 
6.2 Maintenance treatment period of Weeks 16 to 52 for responders at Week 16 ................ 35 
7 Trial design .......................................................................................................................... 36 
7.1 Overall trial design .......................................................................................................... 36 
7.2 Number of subjects needed ............................................................................................. 39 
7.3 End of trial definition ...................................................................................................... 39 
8 Trial population and withdrawal .......................................................................................... 40 
8.1 Subject eligibility ............................................................................................................ 40 
8.2 Inclusion criteria .............................................................................................................. 40 
8.3 Exclusion criteria ............................................................................................................. 42 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 8 of 156 
8.4 Screening, screening failures, and randomisation ........................................................... 45 
8.5 Discontinuation ............................................................................................................... 46 
9 Treatments ........................................................................................................................... 48 
9.1 Trial product description ................................................................................................. 48 
9.2 Administration of investigational medical products ....................................................... 49 
9.3 Treatment assignment ...................................................................................................... 51 
9.3.1 
Blinding ....................................................................................................................... 52 
9.3.2 
Emergency unblinding of individual subject treatment ............................................... 52 
9.4 Background treatment (emollients) ................................................................................. 53 
9.5 Concomitant medication and procedures ........................................................................ 53 
9.6 Prohibited medication and procedures ............................................................................ 54 
9.7 Rescue treatment ............................................................................................................. 55 
9.8 Dose modification and IMP discontinuation rules .......................................................... 56 
9.8.1 
Reasons for permanent discontinuation of IMP .......................................................... 56 
9.8.2 
Reasons for temporary discontinuation of IMP .......................................................... 56 
9.9 Treatment logistics and accountability ............................................................................ 57 
9.9.1 
Labelling and packaging of IMPs ............................................................................... 57 
9.9.2 
Storage of IMPs ........................................................................................................... 57 
9.9.3 
Drug accountability ..................................................................................................... 58 
9.9.4 
Trial product destruction ............................................................................................. 59 
9.9.5 
Treatment compliance ................................................................................................. 59 
9.10 Provision for subject care following trial completion ..................................................... 59 
9.11 Reporting product complaints ......................................................................................... 60 
10 Trial schedule and assessments ........................................................................................... 61 
10.1 Overview ......................................................................................................................... 61 
10.2 Assessments performed only at screening/baseline ........................................................ 62 
10.2.1 Columbia-Suicide Severity Rating Scale .................................................................... 62 
10.2.2 Demographics .............................................................................................................. 62 
10.2.3 Medical history ............................................................................................................ 63 
10.2.4 Height and weight ....................................................................................................... 63 
10.2.5 Body surface area involvement ................................................................................... 63 
10.3 Efficacy assessments ....................................................................................................... 64 
10.3.1 Investigator assessments .............................................................................................. 64 
10.3.1.1 Investigator’s Global Assessment ............................................................................ 64 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 9 of 156 
10.3.1.2 Eczema Area and Severity Index ............................................................................. 64 
10.3.1.3 Scoring Atopic Dermatitis ....................................................................................... 66 
10.3.2 Subject assessments ..................................................................................................... 67 
10.3.2.1 Eczema-related Sleep numeric rating scale ............................................................. 67 
10.3.2.2 Worst Daily Pruritus numeric rating scale ............................................................... 67 
10.3.2.3 Average Daily Pruritus numeric rating scale ........................................................... 67 
10.3.2.4 Patient Global Impression of Bother ....................................................................... 67 
10.3.2.5 Patient Global Impression of Severity ..................................................................... 67 
10.3.2.6 Patient-Oriented Eczema Measure .......................................................................... 68 
10.3.2.7 Dermatology Life Quality Index ............................................................................. 68 
10.3.2.8 EQ-5D-5L ................................................................................................................ 68 
10.3.2.9 SF-36........................................................................................................................ 69 
10.3.2.10 Work Productivity and Activity Impairment – General Health ............................... 69 
10.3.2.11 Hospital Anxiety and Depression Scale ................................................................... 70 
10.3.2.12 Treatment Satisfaction Questionnaire for Medicine ................................................ 70 
10.4 Safety assessments .......................................................................................................... 70 
10.4.1 Vital signs .................................................................................................................... 70 
10.4.2 Physical examination ................................................................................................... 71 
10.4.3 Digital ECG ................................................................................................................. 71 
10.4.4 Pregnancy test .............................................................................................................. 72 
10.4.5 Laboratory testing ........................................................................................................ 72 
10.4.6 Pharmacokinetic assessments ...................................................................................... 74 
10.4.7 Anti-drug antibodies measurements ............................................................................ 74 
10.5 Other assessments ............................................................................................................ 75 
10.5.1 Photography (selected trial sites)................................................................................. 75 
10.6 Estimate of total blood volume collected ........................................................................ 75 
11 Adverse events ..................................................................................................................... 76 
11.1 Collection of adverse events ............................................................................................ 76 
11.2 Reporting of adverse events ............................................................................................ 76 
11.3 Reporting of serious adverse events ................................................................................ 77 
11.3.1 Investigator reporting responsibilities ......................................................................... 77 
11.3.2 LEO reporting responsibilities .................................................................................... 78 
11.4 Other events that require expedited reporting ................................................................. 78 
11.4.1 Pregnancy .................................................................................................................... 78 
11.5 Reporting of other events ................................................................................................ 79 
11.5.1 Adverse events of special interest ............................................................................... 79 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 10 of 156 
11.5.2 Overdose ...................................................................................................................... 80 
11.5.3 Medication error .......................................................................................................... 80 
11.5.4 Misuse ......................................................................................................................... 80 
11.5.5 Abuse ........................................................................................................................... 80 
11.5.6 Aggravation of condition ............................................................................................. 81 
11.6 Follow-up for final outcome of adverse events ............................................................... 81 
11.7 Handling of an urgent safety measure ............................................................................. 81 
12 Statistical methods ............................................................................................................... 82 
12.1 Sample size ...................................................................................................................... 82 
12.2 Trial analysis sets ............................................................................................................ 82 
12.3 Statistical analysis ........................................................................................................... 84 
12.3.1 Disposition of subjects ................................................................................................ 84 
12.3.2 Demographics and other baseline characteristics ........................................................ 84 
12.3.3 Exposure and treatment compliance ............................................................................ 84 
12.3.3.1 Exposure .................................................................................................................. 84 
12.3.3.2 Treatment compliance .............................................................................................. 85 
12.3.4 Multiple testing procedure ........................................................................................... 85 
12.3.5 Analysis of initial treatment ........................................................................................ 86 
12.3.5.1 Analysis of primary endpoints ................................................................................. 86 
12.3.5.1.1 Primary estimand: ‘composite’ ............................................................................ 87 
12.3.5.1.2 Secondary estimand: ‘hypothetical’ ..................................................................... 88 
12.3.5.1.3 Tertiary estimand: ‘treatment policy’ ................................................................... 91 
12.3.5.2 Analysis of secondary endpoints ............................................................................. 92 
12.3.5.2.1 Primary estimand for the continuous secondary endpoints: ‘hypothetical’ ......... 92 
12.3.5.2.2 Secondary estimand for the continuous secondary endpoints: ‘treatment policy’94 
12.3.5.3 Analysis of additional secondary endpoints ............................................................ 95 
12.3.5.4 Analysis of other endpoints ..................................................................................... 96 
12.3.5.4.1 Efficacy over time ................................................................................................ 96 
12.3.5.4.2 Patient-reported outcomes .................................................................................... 97 
12.3.6 Analysis of maintenance treatment ............................................................................. 98 
12.3.6.1 Analysis of maintenance endpoints ......................................................................... 98 
12.3.6.2 Analysis of other maintenance endpoints .............................................................. 100 
12.3.6.2.1 Time to relapse ................................................................................................... 100 
12.3.6.2.2 Continued treatment for non IGA responders .................................................... 101 
12.3.6.2.3 Supportive maintenance ..................................................................................... 101 
12.3.7 Analysis of safety ...................................................................................................... 101 
12.3.7.1 Adverse events ....................................................................................................... 101 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 11 of 156 
12.3.7.2 Vital signs .............................................................................................................. 102 
12.3.7.3 Clinical laboratory evaluation ................................................................................ 102 
12.3.7.4 Pharmacokinetics ................................................................................................... 102 
12.3.7.5 Anti-drug antibodies .............................................................................................. 103 
12.3.8 Interim analysis ......................................................................................................... 103 
12.3.9 Analysis of data per last subject’s Week 52 visit ...................................................... 103 
12.3.10 General principles ...................................................................................................... 104 
12.3.11 Handling of missing values ....................................................................................... 104 
13 References ......................................................................................................................... 105 
Appendix 1: Protocol summary .............................................................................................. 109 
Appendix 2: Definitions of adverse events and serious adverse events ................................. 114 
Appendix 3: Classification of adverse events ........................................................................ 116 
Appendix 4: Trial governance considerations ........................................................................ 119 
Appendix 4A: Regulatory and ethical considerations ............................................................ 119 
Appendix 4B: Informed consent process ............................................................................... 119 
Appendix 4C: Subject and data confidentiality ...................................................................... 120 
Appendix 4D: Record keeping, quality control, and data handling ....................................... 121 
Appendix 4E: Registration, reporting and publication policy ................................................ 126 
Appendix 4F: Insurance ......................................................................................................... 127 
Appendix 4G: Financial disclosure ........................................................................................ 127 
Appendix 4H: Committee structure ....................................................................................... 127 
Appendix 4I: Trial and site closure ........................................................................................ 128 
Appendix 4J: Responsibilities ................................................................................................ 129 
Appendix 5: Hanifin and Rajka (1980) diagnostic criteria for AD ........................................ 130 
Appendix 6: Guidance for anaphylaxis diagnosis .................................................................. 131 
Appendix 7: Country-specific requirements .......................................................................... 133 
Appendix 8: Contact list ......................................................................................................... 134 
Appendix 9: WHO model prescribing information for classification of topical corticosteroids
 ........................................................................................................................................... 137 
Appendix 10: Protocol amendment history ............................................................................ 139 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 12 of 156 
List of panels 
Panel 1  Trial design ................................................................................................................. 16 
Panel 2  Schedule of trial procedures: screening and initial treatment period ......................... 17 
Panel 3  Schedule of trial procedures: maintenance treatment period and follow-up .............. 21 
Panel 4  Schedule of trial procedures: open-label tralokinumab and follow-up ...................... 24 
Panel 5  Objectives and endpoints: initial treatment period ..................................................... 33 
Panel 6  Objectives and endpoints: maintenance treatment period .......................................... 35 
Panel 7  Identification of investigational medicinal products .................................................. 48 
Panel 8  Overview of schedules of procedures ........................................................................ 61 
Panel 9  Investigator’s Global Assessment .............................................................................. 64 
Panel 10  Calculation of the Eczema Area and Severity Index ................................................ 65 
Panel 11  EASI severity score scale and area score scale ........................................................ 65 
Panel 12  Central laboratory testing ......................................................................................... 73 
Panel 13  Adverse events of special interest ............................................................................ 79 
Panel 14  Testing procedure for primary, secondary, and maintenance endpoints ................... 85 
Panel 15  Transmission of electronic data .............................................................................. 125 
Panel 16  Classification of topical corticosteroids ................................................................. 137 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 13 of 156 
List of abbreviations 
AD 
atopic dermatitis 
ADA 
anti-drug antibodies 
AE 
adverse event 
AESI 
adverse event of special interest 
ALT 
alanine aminotransferase 
ANCOVA 
analysis of covariance 
AST 
aspartate aminotransferase 
BP 
blood pressure 
BSA 
body surface area 
CCL 
C-C motif chemokine
CI 
confidence interval 
CMO 
contract manufacturing organisation 
CRA 
clinical research associate 
CRO 
contract research organisation 
C-SSRS
Columbia-Suicide Severity Rating Scale  
CTR 
clinical trial report 
DLQI 
Dermatology Life Quality Index 
DMC 
Data Monitoring Committee 
EASI 
Eczema Area and Severity Index 
EASI50 
At least 50% reduction in EASI score 
EASI75 
At least 75% reduction in EASI score 
EASI90 
At least 90% reduction in EASI score 
ECG 
electrocardiogram 
eCRF 
electronic case report form 
eDiary 
electronic diary 
ePRO 
electronic patient-reported outcome 
EQ-5D-5L 
EuroQoL 5-Dimension Health Questionnaire 5 Level 
FU 
follow-up visit 
GCP 
Good Clinical Practice 
HADS 
Hospital Anxiety and Depression Scale 
HCP 
healthcare professional 
HQoL 
health-related quality of life 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 14 of 156 
ICF 
informed consent form 
ICH 
International Council for Harmonisation 
ID 
identification number 
IEC 
independent ethics committee 
IGA 
Investigator’s Global Assessment 
IgE 
immunoglobulin E 
IL 
interleukin 
IMP 
investigational medicinal product 
IRB 
institutional review board 
IWRS 
interactive web response system 
LEO 
LEO Pharma A/S 
LOCF 
last observation carried forward 
nAB 
neutralising antibodies 
NRS 
numeric rating scale 
PDE-4 
phosphodiesterase 4 
PGI-B 
Patient Global Impression of Bother 
PGI-S 
Patient Global Impression of Severity 
PK 
pharmacokinetics 
POEM 
Patient Oriented Eczema Measure 
PRO 
patient-reported outcome 
Q2W 
every 2 weeks 
Q4W 
every 4 weeks 
SAE 
serious adverse event 
SC 
subcutaneous 
SCORAD 
Scoring Atopic Dermatitis  
SCORAD50 
At least 50% reduction in SCORAD score 
SF-36 
36-Item Short Form Health Survey
SoP 
schedule of procedures 
TCI 
topical calcineurin inhibitor 
TCS 
topical corticosteroid 
Th2 
T-helper-2
TSQM 
Treatment Satisfaction Questionnaire for Medication 
ULN 
upper limit of normal 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 15 of 156 
UV 
ultraviolet 
WPAI-GH 
Work Productivity and Activity Impairment – General Health 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 16 of 156 
2 Trial identification 
EudraCT number: 2016-004201-13 
IND number: 123797 
ClinicalTrials.gov number: NCT03160885 
3 Schematic of trial design 
Panel 1  Trial design 
EASI 75, at least 75% reduction in EASI score; IGA, Investigator’s Global Assessment; No, number; rando, 
randomisation; TCS, topical corticosteroid; w, week.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 17 of 156 
4 Schedule of procedures (SoP) 
Panel 2  Schedule of trial procedures: screening and initial treatment period 
Screening1 
Initial treatment period 
Visit 
11 
2 
3 
4 
5 
6 
7 
8 
9 
10 
112 
Week 
-6
-2
0 
2 
4 
6 
8 
10 
12 
14 
16 
Day 
-42
-14
0 
14 
28 
42 
56 
70 
84 
98 
112 
Visit window (days) 
±3 
-3
NA 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Trial population and eligibility (Section 8 and Appendix 4B) 
Informed consents 
X3 
X4 
Eligibility 
X 
X 
Trial products and randomisation (Section 9) 
Initiation of emollients (bcg. treatment)5 
X 
Concomitant medication/procedures 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Randomisation 
X 
X6 
IMP administration and compliance
X7 
X7 
X7 
X 
X 
X 
X 
X 
X6,7 
Investigator assessments at screening/baseline (Section 10.2) 
C-SSRS
X 
Demographics (age) and BSA 
X 
X 
Other demographics and medical history 
X 
Height and weight 
X 
Investigator assessments of efficacy (Section 10.3.1) 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 18 of 156 
Panel 2  Schedule of trial procedures: screening and initial treatment period (continued) 
Screening1 
Initial treatment period 
Visit 
11 
2 
3 
4 
5 
6 
7 
8 
9 
10 
112 
Week 
-6
-2
0 
2 
4 
6 
8 
10 
12 
14 
16 
Investigator assessments of efficacy (Section 10.3.1) 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Subject assessments of efficacy (Section 10.3.2) 
eDiary training 
X 
eDiary completion8 
<- =========================================================================== -> 
POEM and DLQI 
X 
X 
X 
X 
X 
X 
X 
EQ-5D-5L and HADS 
X 
X 
X 
X 
X 
SF-36 and WPAI-GH 
X 
X 
X 
TSQM 
X 
X 
Safety assessments (Sections 10.4 and 11) 
Vital signs 
X 
X7 
X7 
X7 
X 
X 
X 
X 
X 
X7 
Physical examination 
X 
X 
X 
X 
ECG 
X 
X 
X 
X 
Serum pregnancy test 
X 
Urine pregnancy test 
X 
X 
X 
X 
X 
Hepatitis B, C and HIV 
X 
Serum chemistry, haematology, and IgE 
X9 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 19 of 156 
Panel 2  Schedule of trial procedures: screening and initial treatment period (continued) 
Screening1 
Initial treatment period 
Visit 
11 
2 
3 
4 
5 
6 
7 
8 
9 
10 
112 
Week 
-6
-2
0 
2 
4 
6 
8 
10 
12 
14 
16 
Safety assessments (Sections 10.4 and 11) 
Pharmacokinetics 
X 
X 
X 
ADA 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Other assessments (Section 10.5) 
Photography10 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1)
For subjects who do not require a wash-out, visits 1 and 2 will be combined and screening will be reduced to 2 weeks; hence, these subjects will only attend
visit 2 (Week -2) which will include all assessments shown under Week -6. Similarly, for subjects who only require a 2-week wash-out, screening visits 1 and 2
will be combined (Week -2). The screening period has a maximum duration of 6 weeks.
2)
Assessments performed at Week 16 are also to be done at an early termination visit and at a nominal Week 16 visit, if applicable. See Section 8.5 for further
details. All subjects will have a final safety follow-up (FU) 16 weeks after the last dose of IMP, except subjects who enter the long-term extension trial
(conducted under a separate protocol [LP0162-1337, ECZTEND]). Subjects may enter ECZTEND at any time during the safety follow-up period (see
Section 7.1). An end of treatment form and end of trial form must be completed in the eCRF for all subjects assigned treatment.
3)
Additional informed consents are required for participation in the photograph component (selected trial sites only).
4)
Subjects who are eligible for home-use during open-label treatment will have to provide additional informed consent before the training at the site
(Section 9.2); home-use will only commence after proper training of the subject or caregiver (at 3 dosing visits after the additional consent has been obtained)
and after 3 doses of open-label tralokinumab administered at the trial site, i.e., starting no earlier than Week 22, depending on when the subject transfers to
open-label treatment (selected countries only).
5)
All subjects must use an emollient twice daily (or more, as needed) for at least 14 days before randomisation and must continue this treatment throughout the
trial.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 20 of 156 
6)
Subjects who achieve a clinical response (IGA 0/1 or EASI75) at Week 16 will be re-randomised into the maintenance period and then receive the first
injections of maintenance treatment (Panel 3). Subjects that do not achieve clinical response at Week 16 will be transferred to open-label tralokinumab 300 mg
Q2W treatment with optional use of TCS and then receive the first injections of open-label treatment (Panel 4).
7)
For the first 3 IMP dosing visits in both the initial and open-label treatment period, subjects will be monitored after IMP administration for immediate drug
reactions for a minimum of 2 hours with vital signs taken every 30 minutes or until stable, whichever is later (Section 9.2).
8)
The eDiary consists of (i) Eczema-related Sleep NRS, (ii) Worst Daily Pruritus NRS, (iii) Average Daily Pruritus NRS, (iv) PGI-B, and (v) PGI-S. The eDiary
will be completed daily from Week -2 to Week 52.
9)
IgE not assessed at screening.
10) Optional, selected trial sites only.
ADA, anti-drug antibodies; Bcg, background; BSA, body surface area; C-SSRS, Columbia-Suicide Severity Rating Scale; DLQI, Dermatology Life Quality Index; 
EASI, Eczema Area and Severity Index; EASI75, at least 75% reduction in EASI score; ECG, electrocardiogram; eDiary , electronic diary; EQ-5D-5L, EuroQoL 
5-Dimension Health Questionnaire 5 Level; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator’s Global Assessment; IgE, immunoglobulin E;
IMP, investigational medicinal product; NA, not applicable; NRS, numeric rating scale; PGI-B, Patient Global Impression of Bother; PGI-S, Patient Global 
Impression of Severity; POEM, Patient Oriented Eczema Measure; Q2W, every 2 weeks; SCORAD, Scoring Atopic Dermatitis; SF-36, 36-Item Short Form Health 
Survey; TSQM, Treatment Satisfaction Questionnaire for Medication; WPAI-GH, Work Productivity and Activity Impairment – General Health.     
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 21 of 156 
Panel 3  Schedule of trial procedures: maintenance treatment period and follow-up 
Maintenance treatment period 
FU2 
Visit 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
291 
30 
Week 
18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
42 
44 
46 
48 
50 
52 
66 
Visit window (days) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Trial products (Section 9) 
IMP administration and compliance
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medication/procedures 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Investigator assessments of efficacy (Section 10.3.1) 
IGA 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X 
EASI 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X3 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Subject assessments of efficacy (Section 10.3.2) 
eDiary4 
<- =========================================================================== -> 
POEM and DLQI 
X 
X 
X 
X 
X 
EQ-5D-5L and HADS 
X 
X 
X 
X 
X 
SF-36 and WPAI-GH 
X 
X 
X 
X 
X 
TSQM 
X 
X 
Safety assessments (Sections 10.4 and 11) 
Vital signs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
X 
X 
X 
X 
ECG 
X 
X 
X 
X 
X 
X 
Urine pregnancy test 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 22 of 156 
Panel 3  Schedule of trial procedures: maintenance treatment period and follow-up (continued) 
Maintenance treatment period 
FU2 
Visit 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
291 
30 
Week 
18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
42 
44 
46 
48 
50 
52 
66 
Safety assessments (Sections 10.4 and 11) 
Serum chemistry, haematology, and IgE 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
Pharmacokinetics 
X 
X 
X 
ADA 
X 
X 
X 
Adverse events 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Other assessments (Section 10.5) 
Photography5 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1)
Assessments also to be done at an early termination visit.
2)
Subjects will have a safety follow-up (FU) 16 weeks after last injection of IMP; this is considered the end of trial visit. For subjects who are enrolled into the
long-term extension trial (conducted under a separate protocol [LP0162-1337, ECZTEND]), the end of trial visit will be the last visit in trial LP0162-1326
before transfer to the extension.
3)
Subjects who meet the following criteria will be transferred to open-label treatment (tralokinumab 300 mg Q2W with optional use of TCS [Panel 4]):

Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieving EASI75 over at least a 4-week period (i.e., over 3 consecutive visits).

Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e., over 3 consecutive visits).

Subjects with IGA >1 at Week 16: not achieving EASI75 over at least a 4-week period (i.e., over 3 consecutive visits).
The first injections of open-label treatment will be given at the visit in the maintenance period where the subject meets these criteria. 
4)
The eDiary consists of (i) Eczema-related Sleep NRS, (ii) Worst Daily Pruritus NRS, (iii) Average Daily Pruritus NRS, (iv) PGI-B, and (v) PGI-S.
5)
Optional, selected trial sites only.
ADA, anti-drug antibodies; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; EASI50, at least 50% reduction in EASI score; 
EASI75, at least 75% reduction in EASI score; ECG, electrocardiogram; eDiary , electronic diary; EQ-5D-5L, EuroQoL 5-Dimension Health Questionnaire 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 23 of 156 
5 Level; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator’s Global Assessment; IgE, immunoglobulin E; IMP, investigational medicinal product; 
NRS, numeric rating scale; PGI-B, Patient Global Impression of Bother; PGI-S, Patient Global Impression of Severity; POEM, Patient Oriented Eczema Measure; 
Q2W, every 2 weeks; SCORAD, Scoring Atopic Dermatitis; SF-36, 36-Item Short Form Health Survey; TCS, topical corticosteroids; TSQM, Treatment 
Satisfaction Questionnaire for Medication; WPAI-GH, Work Productivity and Activity Impairment – General Health. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 24 of 156 
Panel 4  Schedule of trial procedures: open-label tralokinumab and follow-up 
Open-label tralokinumab treatment 
FU2 
Visit 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
291 
30 
Week 
18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
42 
44 
46 
48 
50 
52 
66 
Visit window (days) 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
Trial population and eligibility (Section 8 and Appendix 4B) 
Informed consent (home-use)3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Trial products (Section 9) 
IMP administration and compliance
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4 
X4,5 
Concomitant medications/procedures 
X 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X 
Investigator assessments of efficacy (Section 10.3.1) 
IGA 
X 
X 
X 
X 
X 
X 
X 
X 
X 
EASI 
X 
X 
X 
X 
X 
X 
X 
X 
X 
SCORAD 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety assessments (Sections 10.4 and 11) 
Vital signs 
X4 
X4 
X4,6 
X4 
X4,6 
X4 
X4,6 
X4 
X4,6 
X4 
X4,6 
X4 
X4,6 
X4 
X4,6 
X4 
X4,6 
X 
X 
Physical examination 
X 
X 
X 
X 
ECG 
X 
X 
X 
X 
X 
X 
Urine pregnancy test 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum chemistry, haematology, and IgE 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
X 
X 
X 
X 
X 
Pharmacokinetics 
X 
X 
X 
ADA 
X 
X 
X 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 25 of 156 
Panel 4  Schedule of trial procedures: open-label tralokinumab and follow-up (continued) 
Open-label tralokinumab treatment 
FU2 
Visit 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
291 
30 
Week 
18 
20 
22 
24 
26 
28 
30 
32 
34 
36 
38 
40 
42 
44 
46 
48 
50 
52 
66 
Safety assessments (Sections 10.4 and 11) 
Adverse events 
X 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X6 
X 
X 
Other assessments (Section 10.5) 
Photography7 
X 
X 
X 
X 
X 
X 
X 
X 
X 
1)
Assessments also to be done at an early termination visit.
2)
All subjects will have a safety follow-up (FU) 16 weeks after last injection of IMP, except subjects who are enrolled into the long-term extension trial
(conducted under a separate protocol [LP0162-1337, ECZTEND]) after completion of the treatment periods.
3)
Subjects who are eligible for home-use during open-label treatment will have to provide additional informed consent before the training at the site
(Section 9.2); home-use will only commence after proper training of the subject or caregiver (at 3 dosing visits after the additional consent has been obtained)
and after 3 doses of open-label tralokinumab administered at the trial site, i.e., starting no earlier than Week 22, depending on when the subject transfers to
open-label treatment (selected countries only).
4)
For the first 3 IMP dosing visits in the open-label treatment period, subjects will be monitored after IMP administration for immediate drug reactions for a
minimum of 2 hours with vital signs taken every 30 minutes or until stable, whichever is later (Section 9.2).
5)
No IMP administration at Week 52; subjects who self-administer tralokinumab at home will have compliance of Week 50 administration checked at Week 52.
6)
Not applicable for subjects self-administering tralokinumab (home-use; selected countries only; Sections 7.1 and 9.2).
7)
Optional, selected trial sites only.
ADA, anti-drug antibodies; EASI, Eczema Area and Severity Index; ECG, electrocardiogram; IGA, Investigator’s Global Assessment; IgE, immunoglobulin E; 
IMP, investigational medicinal product; SCORAD, Scoring Atopic Dermatitis. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 26 of 156 
5 Introduction and rationale 
5.1 Atopic dermatitis 
Atopic dermatitis (AD) is a chronic inflammatory skin disease that may affect up to 20% of 
children and up to 10% of adults. In its severe form, AD is characterised by widespread skin 
lesions, intractable itch, as well as enhanced susceptibility to bacterial, viral, and fungal skin 
infections (1-4). AD is associated with a substantial patient burden that typically includes poor 
quality of life, sleep disturbance, and reductions in work productivity (5). 
Treatment recommendations for AD include topical therapies, the main being topical 
corticosteroids (TCS). Unfortunately, TCS and topical calcineurin inhibitors (TCIs) have 
limited efficacy in patients with moderate-to-severe disease. TCS and non-biologic systemic 
therapies are all associated with toxicities with long-term use (6-8). 
AD is characterised by an activated T-helper-2 (Th2) pathway with increased skin expression 
of key Th2 cytokines including interleukin (IL)-13 (9, 10). The expression of IL-13 is 
increased in lesional skin compared to non-lesional skin, and the proportion of CD4+ and 
CD8+ cells expressing IL-13 is upregulated in AD patients compared to individuals without 
AD (9, 11).  
IL-13 acts on keratinocytes to release C-C motif chemokine 22 (CCL22) and recruit more 
IL-13 expressing Th2 cells, decrease differentiation, and contribute to decreased barrier 
function (12). IL-13 also drives immunoglobulin E (IgE) production and contributes to mast 
cell activation status and, once allergen cross-links IgE on the cell surface, drives histamine 
release and induces itch (13, 14). Indeed, itch is a key issue in AD, which drives significant 
mechanical damage to the skin and further facilitates allergen and pathogen entry.  
All of these effects together drive and exacerbate the disease phenotype. A review of the 
available preclinical literature from mouse and human ex vivo models suggests IL-13 as a, if 
not the, central mediator of the AD skin phenotype. Indeed, there is evidence that blocking the 
IL-4 receptor (which is part of the receptor complex which also binds IL-13) with the 
monoclonal antibody dupilumab leads to clinical improvement in AD subjects (15). 
5.2 Experience with investigational medicinal product 
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that 
specifically binds to human IL-13 and blocks interaction with the IL-13 receptors (16-18). A 
compilation of clinical and nonclinical data on tralokinumab including pharmacokinetics (PK) 
is given in the current Investigator’s Brochure. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 27 of 156 
In total, 13 clinical trials with tralokinumab have been completed to date, with phase 3 
development ongoing in asthma and AD. Other clinical trials with tralokinumab have been 
conducted in subjects with ulcerative colitis, idiopathic pulmonary fibrosis, and in healthy 
subjects. Further information on these trials can be found in the current Investigator’s 
Brochure. 
In a phase 2b trial (D2213C00001), adults with moderate-to-severe AD on a background of 
mild to moderate TCS, were treated with 3 different regimens of tralokinumab (45 mg every 
second week [Q2W], 150 mg Q2W, or 300 mg Q2W) or placebo to evaluate the safety and 
efficacy over a treatment period of 12 weeks. The primary endpoints were change from 
baseline in Eczema Area and Severity Index (EASI) at Week 12 and the percentage of 
subjects achieving IGA response of 0 (clear) or 1 (almost clear) at Week 12. Secondary 
endpoints included change from baseline in EASI and Scoring Atopic Dermatitis (SCORAD) 
scores, the percentage of subjects achieving at least 50% reduction from baseline in EASI and 
SCORAD scores (EASI50 and SCORAD50). In the overall intent-to-treat phase 2b 
population, an improvement in EASI score at Week 12 was seen in the tralokinumab 300 mg 
Q2W group versus placebo. 26% of subjects achieved an IGA of 0 or 1 in the tralokinumab 
300 mg Q2W group versus 12% in the placebo group. The most commonly reported causally 
related treatment-emergent adverse event was upper respiratory tract infection (6 [3.9%] 
subjects in the combined tralokinumab group [45 mg, 150 mg, and 300 mg] and 2 [3.9%] 
subjects in the placebo group). 
In total, more than 2,343 subjects have been treated with tralokinumab (cut-off date: 
18-Aug-2017) based on actual exposure data from any completed clinical trials and the
enrolment/randomisation schemes for ongoing trials. The safety of all doses studied so far has 
been with an acceptable benefit-risk profile and no major safety concerns have been 
identified. Possible risks associated with use of tralokinumab are summarised in Section 5.5. 
5.3 Trial rationale 
The purpose of this phase 3 trial is to provide evidence of the efficacy and safety of 
tralokinumab monotherapy in the treatment of subjects with moderate-to-severe AD 
inadequately controlled with topical therapies. Such subjects would be candidates for 
systemic therapy.  
The primary objective of this trial is to demonstrate that tralokinumab provides more effective 
control of the skin manifestations of AD than placebo. The trial will evaluate the percentage 
of subjects achieving IGA response of 0 (clear) or 1 (almost clear) and the percentage of 
subjects achieving at least 75% reduction in EASI score (EASI75) at Week 16, with 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 28 of 156 
secondary endpoints addressing symptom scores and extent of AD (SCORAD), itch severity, 
and health-related quality of life (HQoL) measures related to AD.  
As AD is a chronic disease requiring long-term treatment, it is also relevant to evaluate the 
efficacy of tralokinumab as maintenance treatment. After the 16-week initial treatment period, 
the trial will evaluate 2 different treatment options for maintenance therapy (300 mg Q2W and 
300 mg every 4 weeks [Q4W]).  
The trial will further characterise the benefit-risk profile of the drug and understand how best 
to position tralokinumab in the AD treatment pathway. 
5.4 Justification for dose 
The selected dose for the initial treatment period in trial is subcutaneously administered 
300 mg tralokinumab Q2W. All subjects randomised to receive treatment with tralokinumab 
will get an initial loading dose of 600 mg on Day 0 (baseline). The administration of the 
loading dose of tralokinumab will allow systemic concentrations to reach steady-state faster, 
and potentially reduce the time to onset of clinical effect. The serum concentrations of 
tralokinumab after the 600 mg loading dose will not exceed the serum tralokinumab 
concentrations at steady state for the 300 mg Q2W. 
The tralokinumab 300 mg Q2W dose was chosen based on the results of the phase 2b trial in 
subjects with moderate to severe AD (trial D2213C00001) described in Section 5.2. The 
subjects were treated with 3 different fixed dose regimens of tralokinumab (45, 150, or 
300 mg Q2W) or placebo to evaluate safety and efficacy over a treatment period of 12 weeks. 
In the overall intention-to-treat phase 2b population, a statistically significant improvement in 
EASI change from baseline at Week 12 was observed in the tralokinumab 300 mg group 
versus placebo; however, formal statistical significance was not demonstrated for the 
co-primary endpoint IGA. The key secondary and exploratory endpoint results from 
trial D2213C00001 also support the selection of the tralokinumab Q2W 300 mg dose for 
phase 3 development; and overall, larger numerical differences were observed for 300 mg 
tralokinumab dose than for 150 mg compared to placebo for most of the trial endpoints. 
Since the safety profile in trial D2213C00001 was acceptable in all treatment cohorts and no 
clear safety related dose-response pattern was identified, the dose of 300 mg Q2W has been 
selected for evaluation in this trial.  
In the maintenance treatment period, 1 of the treatment arms will be dosed with tralokinumab 
Q4W. This approach will allow the sponsor of the trial, LEO Pharma A/S (hereinafter 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 29 of 156 
“LEO”), to establish whether less frequent dosing of tralokinumab may be sufficient for long-
term maintenance of efficacy. 
5.5 Benefit/risk assessment 
There is an unmet medical need for new therapies for use in subjects with moderate-to-severe 
AD as current immunosuppressive medications, such as cyclosporine, methotrexate, and 
azathioprine, have associated long-term toxicities.  
Tralokinumab has already demonstrated efficacy in both moderate-to-severe AD as well as in 
a severe asthma population in phase 2 trials, and has shown an acceptable safety profile in 
AD, asthma, ulcerative colitis, idiopathic pulmonary fibrosis, and in trials with healthy 
subjects. The evidence discussed in Section 5.2 further supports the hypothesis that 
tralokinumab may benefit individuals with AD. 
In clinical trials completed to date, tralokinumab was well tolerated. A number of theoretical 
potential risks have been identified that are described in the current Investigator’s Brochure, 
including hypersensitivity reactions, immune complex disease, severe infections, 
malignancies, and interference with reproductive function; measures are in place in this trial 
to protect participating subjects as follows: 

Close monitoring of subjects during the trial with trial visits every 2 weeks
during the treatment period as described in the SoP (Section 4). Where
home-use is appropriate (open-label treatment only), trial visits will be
scheduled every 4 weeks.

Close monitoring of subjects during the post-dosing period (at the first
3 investigational medicinal product [IMP] dosing visits in initial treatment
period and in open-label treatment) as a precautionary measure against
hypersensitivity reactions (further details are given in Section 9.2).

Monitoring of subjects for clinical manifestations that may be associated with
the development of specific antibodies to tralokinumab (i.e., immune complex
disease).

Exclusion of subjects with untreated systemic helminth infestations or subjects
who have failed to respond to standard of care therapy (neutralisation of IL-13
might theoretically cause a worsening of parasitic infestation, in particular,
prevention of expulsion of gastrointestinal worms (helminths) [28])
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 30 of 156 

Exclusion of subjects with a history of tuberculosis requiring treatment within
12 months prior to the screening visit.

Exclusion of subjects with a history of a clinically significant infection
(defined as a systemic or serious skin infection requiring parenteral antibiotics,
antiviral, or anti-fungal medication; see Section 8.3) within 4 weeks prior to
baseline which, in the opinion of the investigator or sponsor’s medical expert,
may compromise the safety of the subject in the trial.
In conclusion, previous clinical experience with tralokinumab shows no major safety or 
tolerability concerns and appropriate measures have been instituted in this trial to protect 
subjects from possible risks that have been previously identified and to closely monitor each 
subject. The current risk/benefit ratio is favourable and supports the administration of 
tralokinumab for the purposes of achieving the objectives of this trial. 
5.6 Ethical considerations 
No children or other vulnerable subjects incapable of giving informed consent will be 
enrolled in this clinical trial. Furthermore, women who are pregnant, breastfeeding, or trying 
to become pregnant will not be enrolled in this clinical trial. Women of child-bearing potential 
have to agree to use a highly effective method of contraception to prevent pregnancy during 
the clinical trial and until 16 weeks after discontinuation of treatment with the IMP. In 
addition, all female subjects of child-bearing potential will have a pregnancy test performed 
before, during and at End of Treatment to ensure that no foetuses are exposed to the IMP. 
In this clinical trial, the efficacy of tralokinumab will be evaluated in adult subjects with 
moderate-to-severe AD who are otherwise healthy. Tralokinumab treatment will be compared 
with a placebo control group. Subjects who do not achieve a clinical response (IGA 0/1 or 
EASI75) at Week 16 will be transferred to open-label tralokinumab 300 mg Q2W treatment 
with optional use of TCS. Similarly, during the maintenance treatment period, subjects who 
meet the protocol definition of transfer to open-label will be treated with open-label 
tralokinumab 300 mg Q2W with optional use of TCS. 
Altogether, the risks associated with participating in this clinical trial are considered very low 
and outweighed by the benefit of a potential future treatment option for moderate-to-severe 
AD. Moreover, 75% of the subjects will be randomised to active treatment with tralokinumab 
in the initial treatment phase and those who do not achieve a clinical response at Week 16 
(including subjects randomised to placebo) will be treated with open-label tralokinumab in the 
maintenance phase with a potential effect and benefit for the individual subject. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 31 of 156 
In accordance with the current version of the International Council for Harmonisation (ICH) 
Good Clinical Practice (GCP) guidelines, qualified medical personnel employed by LEO will 
be readily available to advise on trial-related medical questions. Medical monitoring will be 
performed throughout the trial. Safety data will be reviewed regularly by Global 
Pharmacovigilance, LEO and an independent Data Monitoring Committee (DMC; see 
Appendix 4H) to ensure that prompt action is taken, if needed, to maximise patient safety.  
In conclusion, the trial design chosen for this efficacy and safety trial on tralokinumab is 
regarded as ethically justified and adherent with ethical requirements. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 32 of 156 
6 Trial objectives and endpoints 
The initial treatment period (randomisation until Week 16) will be analysed separately from 
the maintenance treatment period (Week 16 until Week 52; subjects who responded and were 
re-randomised at Week 16). For this reason, the objectives and endpoints for the 2 treatment 
periods are listed separately in Panel 5 and Panel 6. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 33 of 156 
6.1 Initial treatment period of Weeks 0 to 16 
Panel 5  Objectives and endpoints: initial treatment period  
Objectives 
Endpoints 
Primary objective 
Primary endpoints 
To evaluate the efficacy of 
tralokinumab compared with placebo 
in treating moderate-to-severe AD. 

IGA score of 0 (clear) or 1 (almost clear) at
Week 16

EASI75 at Week 16
Secondary objectives 
Secondary endpoints 
To evaluate the efficacy of 
tralokinumab on severity and extent of 
AD, itch, and health related quality of 
life compared with placebo.  
Severity and extent of AD 

Change in SCORAD from baseline to Week 16
Itch 

Reduction of Worst Daily Pruritus NRS (weekly
average) of at least 4 from baseline to Week 16
Quality of life 

Change in DLQI score from baseline to Week 16
Additional secondary objectives 
Additional secondary endpoints 
To evaluate the safety and tolerability 
of tralokinumab when used to treat 
moderate-to-severe AD for 16 weeks. 
Safety and tolerability 

AE/SAE frequency by preferred term

Frequency of anti-drug antibodies
To support the primary and secondary 
objectives in the trial. 
Supporting primary endpoints 

EASI50 at Week 16

EASI90 at Week 16

Change from baseline to Week 16 in EASI score
Supporting severity and extent of AD 

SCORAD75 at Week 16

SCORAD50 at Week 16
Supporting itch 

Change from baseline to Week 16 in Worst Daily
Pruritus NRS (weekly average)

Reduction of Worst Daily Pruritus NRS (weekly
average) of at least 3 from baseline to Week 16
Supporting quality of life 

Reduction from baseline to Week 16 of DLQI of ≥4
points among subjects with baseline DLQI ≥4
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 34 of 156 
Panel 5  Objectives and endpoints: initial treatment period (continued) 
Objectives 
Endpoints 
Other objectives 
Other endpoints 
To evaluate the efficacy over time of 
tralokinumab on severity and extent of 
AD, itch, and health-related quality of 
life compared with placebo. 

IGA 0/1 at each scheduled assessment until
Week 14

EASI75 at each scheduled assessment until
Week 14

Change in SCORAD from baseline to each
scheduled assessment until Week 14

Change from baseline to each week through
Week 1 to 15 in Worst Daily Pruritus NRS (weekly
average)

Reduction of Worst Daily Pruritus NRS (weekly
average) of at least 4 from baseline to each week
through Week 1 to 15

Change in DLQI score from baseline to each
scheduled assessment until Week 14
To evaluate the efficacy of 
tralokinumab compared with placebo 
on patient-reported outcomes and 
health care resource utilisation. 

Reduction of Worst Daily Pruritus NRS (weekly
average) of at least 3 from baseline to Week 2

Change from baseline to Week 16 in
Eczema-related Sleep NRS (weekly average)

Change from baseline to Week 16 in HADS

HADS anxiety and HADS depression scores <8 at
Week 16 in subjects with baseline HADS anxiety
or HADS depression subscale scores of ≥8

Change from baseline to Week 16 in POEM

Reduction from baseline to Week 16 of POEM of
≥4 points among subjects with baseline POEM ≥4

Change from baseline to Week 16 in SF-36

Change from baseline to Week 16 in EQ-5D-5L

Change from baseline to Week 16 in WPAI-GH

Treatment satisfaction (TSQM) at Week 16
AD, atopic dermatitis; AE, adverse event; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and 
Severity Index; EASI50, at least 50% reduction in EASI score; EASI75, at least 75% reduction in EASI score; 
EASI90, at least 90% reduction in EASI score; EQ-5D-5L, EuroQoL 5-Dimension Health Questionnaire 5 
Level; HADS, Hospital Anxiety and Depression Scale; IGA, Investigator’s Global Assessment; NRS, numeric 
rating scale; POEM, Patient Oriented Eczema Measure; SAE, serious adverse event; SCORAD, Scoring Atopic 
Dermatitis; SCORAD50, at least 50% reduction in SCORAD score; SCORAD75, at least 75% reduction in 
SCORAD score; SF-36, 36-Item Short Form Health Survey; TSQM, Treatment Satisfaction Questionnaire for 
Medication; WPAI-GH, Work Productivity and Activity Impairment – General Health.    
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 35 of 156 
6.2 Maintenance treatment period of Weeks 16 to 52 for responders at 
Week 16 
Panel 6  Objectives and endpoints: maintenance treatment period 
Objectives 
Endpoints 
Maintenance objective 
Maintenance endpoints 
To evaluate maintenance of effect 
with continued tralokinumab dosing 
up to 52 weeks compared to placebo 
for subjects achieving clinical 
response at Week 16. 

IGA of 0/1 at Week 52 among subjects with IGA
of 0/1 at Week 16 achieved without rescue
medication after initial randomisation to
tralokinumab

EASI75 at Week 52 among subjects with EASI75
at Week 16 achieved without rescue medication
after initial randomisation to tralokinumab
Other maintenance objectives 
Other maintenance endpoints 
To evaluate the safety and tolerability 
of tralokinumab when used to treat 
moderate-to-severe AD for 52 weeks. 

AE/SAE frequency by preferred term

Frequency of anti-drug antibodies
To evaluate time to relapse in the 
maintenance treatment period. 

Time to relapse applying IGA of 0/1

Time to relapse applying EASI75
To evaluate the efficacy of 
maintenance treatment up to Week 52 
among subjects randomised to the 
maintenance treatment period with 
EASI75 and IGA≥2 at Week 16. 

IGA of 0/1 at Week 52 among subjects with
EASI75 and IGA≥2 at Week 16
To support the maintenance objective 
in the trial. 

IGA 0/1 or EASI75 at Week 52 among subjects
with IGA 0/1 or EASI75 at Week 16 achieved
without rescue medication
AD, atopic dermatitis; AE, adverse event; EASI75, at least 75% reduction in Eczema Area and Severity Index 
score; IGA, Investigator’s Global Assessment; SAE, serious adverse event. 
The maintenance endpoints of IGA 0/1 and EASI75 at Week 52 for subjects achieving clinical 
response at Week 16 without rescue medication are considered secondary endpoints. The 
additional maintenance endpoints are considered other endpoints. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 36 of 156 
7 Trial design  
7.1 Overall trial design 
Overview 
This is a phase 3, randomised, double-blinded, placebo-controlled trial in adult subjects with 
moderate-to-severe AD. The trial will consist of a screening period of 2 to 6 weeks 
(Weeks -6/-2 to 0), an initial treatment period of 16 weeks (Weeks 0 to 16) and a maintenance 
treatment period of 36 weeks (Weeks 16 to 52). The last dose of IMP will be given at 
Week 50. The primary endpoint is assessed at Week 16, and the final efficacy assessment will 
be conducted at Week 52. A 14-week off-treatment follow-up period for the assessment of 
safety is also included (Weeks 52 to 66). Subjects not achieving a clinical response at 
Week 16 as well as those who meet certain criteria during maintenance treatment will be 
transferred to open-label tralokinumab 300 mg Q2W treatment with optional use of TCS up to 
Week 52. An overview of the different parts of the trial is provided in Panel 1 and Panel 8. 
Screening period (Week -6 to Week 0) 
The screening period has a minimum duration of 2 weeks and a maximum duration of 
6 weeks and includes 1 or 2 screening visits. The exact duration of the screening period 
depends on the washout period defined by the exclusion criteria (Section 8.3). If a washout is 
not required, screening will be reduced to 2 weeks and only requires 1 visit (Week -2; visit 2), 
i.e., the 2 screening visits will be merged. Similarly, if only a 2-week wash-out is required,
screening visits 1 and 2 will be combined (Week -2; visit 2). Eligibility will be assessed at the 
(first) screening visit and on Day 0 prior to randomisation. 
All subjects will attend a screening visit 14 days before baseline (Week -2; visit 2) where they 
will receive electronic diary (eDiary) training and start the eDiary. Data entered in the eDiary 
during the 2 weeks before randomisation will be used to calculate baseline values of the 
patient-reported outcomes (PROs). 
All subjects will use an emollient twice daily (or more, as needed) for at least 14 days before 
randomisation and will continue this treatment throughout the trial. Subjects will initiate 
emollient treatment no later than the Week -2 visit. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 37 of 156 
Initial treatment period (Week 0 to Week 16) 
Following the screening period, approximately 780 subjects will be randomised 3:1 to one of 
the following groups stratified by region and disease severity (IGA of 3 or 4) 

Tralokinumab 600 mg (4 mL) at Day 0 (hereinafter “baseline”), then 300 mg
(2 mL) Q2W.

Placebo (4 mL) at baseline, then placebo (2 mL) Q2W.
Maintenance treatment period (Week 16 to Week 52)  
Subjects achieving a clinical response at Week 16 will continue into maintenance treatment 
that will continue until Week 52 (the last dose of IMP will be given at Week 50). 
Clinical response is defined as IGA of 0 or 1, or at least 75% reduction in EASI score from 
baseline (EASI75). 
Subjects randomised to tralokinumab in the initial treatment period will be re-randomised 
2:2:1 to one of the following Q2W maintenance regimens stratified by region and IGA 
response at Week 16 (IGA 0/1 or IGA >1): 

Tralokinumab 300 mg (2 mL) (‘tralokinumab Q2W’).

Alternating dose administrations tralokinumab 300 mg (2 mL) and placebo (2 mL)
(‘tralokinumab Q4W’).

Placebo (2 mL).
Subjects randomised to placebo in the initial treatment period who achieve a clinical response 
at Week 16, defined by IGA of 0 or 1, or EASI75 will continue to receive placebo Q2W in the 
maintenance treatment period. 
Transfer to open-label treatment  
Subjects will be transferred from maintenance treatment to open-label treatment 
(tralokinumab 300 mg Q2W with optional use of TCS) if they meet the criteria listed below. 
Transfer to open-label may occur at any visit while the subject is in the maintenance treatment 
period but no earlier than Week 22. 
Subjects with IGA=0 at Week 16: 

IGA of at least 2 and not achieving EASI75 over at least a 4-week period (i.e., over
3 consecutive visits).
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 38 of 156 
Subjects with IGA=1 at Week 16: 

IGA of at least 3 and not achieving EASI75 over at least a 4-week period (i.e., over
3 consecutive visits).
Subjects with IGA >1 at Week 16: 

Not achieving EASI75 over at least a 4-week period (i.e., over 3 consecutive visits).
Subjects who are transferred to open-label treatment will continue their scheduled visit 
sequence. 
Open-label treatment (Week 16 to Week 52) 
Any subject that does not achieve the protocol defined clinical response at Week 16 will be 
treated with open-label tralokinumab 300 mg Q2W with optional use of TCS. The open-label 
treatment will extend to Week 52 (the last dose of open-label treatment will be given at 
Week 50). 
For selected countries 
Subjects transferring to open-label treatment will have the option to self-administer 
tralokinumab – or have tralokinumab administered by a caregiver – in their home after 
adequate training by site staff at the investigator’s discretion (Section 9.2). This home-use will 
only commence after 3 doses of tralokinumab have been administered at the trial site (i.e., 
starting no earlier than Week 22, depending on when the subject transferred to open-label) as 
a safety precaution for subjects receiving their first active therapy. After proper training of the 
subject and/or the caregiver that is, at 3 or more dosing visits during open-label treatment 
after additional consent for home-use has been obtained, these subjects will only have trial 
visits every 4 weeks. For subjects where home-use is inappropriate, tralokinumab will 
continue to be administered by site staff at the trial visit. 
Safety follow-up period (Week 52 to Week 66) 
All subjects, except for those who enter the long-term extension trial (LP0162-1337, 
ECZTEND, see below), will complete a 14-week off-treatment follow-up period for the 
assessment of safety and ADA at Week 66. 
Long-term extension trial 
Eligible subjects may be invited to enter a long-term extension trial conducted under a 
separate protocol (LP0162-1337, ECZTEND). Subjects who transfer to ECZTEND must have 
had their last visit in the treatment period (Week 52 [selected countries] under the current 
protocol (LP0162-1326).  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 39 of 156 
7.2 Number of subjects needed 
Assuming a screening failure rate of 25%, approximately 1040 subjects will be screened and 
approximately 780 subjects will be randomly assigned to trial treatment in the initial 
treatment period (3:1; 585 subjects in the tralokinumab arm and 195 subjects in the placebo 
arm). At Week 16, approximately 40% of the tralokinumab treated subjects are expected to be 
re-randomised (2:2:1 to tralokinumab Q2W, tralokinumab Q4W, and placebo, respectively) 
into the maintenance treatment period; any subject who does not achieve a clinical response at 
Week 16 will be treated with open-label tralokinumab Q2W. 
The statistical power considerations for this sample size (n=780) are described in 
Section 12.1. 
This trial will be conducted at approximately 130 sites in North America, Europe, Australia, 
and Korea. The anticipated minimum number of subjects per trial site is 4 and the maximum 
number of subjects is 30. 
7.3 End of trial definition 
A subject is considered to have completed the trial if they have completed all periods of the 
trial including the safety follow-up visit (Week 66). Subjects entering the long-term extension 
trial (LP0162-1337, ECZTEND) after completion of the end of treatment visit (Week 52) will 
also be considered as trial completers.  
The end of the trial is defined as the date of the last visit of the last subject in the trial 
globally. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 40 of 156 
8 Trial population and withdrawal 
8.1 Subject eligibility 
The investigator should only enrol subjects who meet all eligibility criteria, are not put at 
undue risk by participating in the trial and can be expected to comply with the protocol.  
The subject’s eligibility for the clinical trial must be checked according to the inclusion and 
exclusion criteria at visits specified in Panel 2. 
Any implementation of national requirements/law for the subject’s participation in the clinical 
trial will be ensured and described in the submission documentation to regulatory 
authorities/ethics committees, as applicable.  
8.2 Inclusion criteria 
1. Written informed consent and any locally required authorisation obtained from the
subject prior to performing any protocol-related procedures, including screening
evaluations.
2. Age 18 and above.
3. Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD (33;
Appendix 5).
4. Diagnosis of AD for ≥1 year.
5. Subjects who have a recent history (within 1 year before the screening visit) of
inadequate response to treatment with topical medications or for whom topical
treatments are otherwise medically inadvisable (e.g., due to important side effects or
safety risks).

Inadequate response is defined as failure to achieve and maintain remission or
a low disease activity state (comparable to IGA 0=clear to 2=mild) despite
treatment with a daily regimen of TCS of medium to higher potency (±TCI as
appropriate), applied for at least 28 days or for the maximum duration
recommended by the product prescribing information (e.g., 14 days for
super-potent TCS), whichever is shorter.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 41 of 156 

Subjects with documented systemic treatment for AD in the past year are also
considered as inadequate responders to topical treatments and are potentially
eligible for treatment with tralokinumab after appropriate washout.

Important side effects or safety risks are those that outweigh the potential
treatment benefits and include intolerance to treatment, hypersensitivity
reactions, significant skin atrophy, and systemic effects, as assessed by the
investigator or by the subject’s treating physician.
6. AD involvement of ≥10% body surface area at screening and baseline (visit 3).
7. An EASI score of ≥12 at screening and 16 at baseline.
8. An IGA score of ≥3 at screening and at baseline.
9. A Worst Daily Pruritus numeric rating scale (NRS) average score of ≥4 during the
week prior to baseline.

Worst Daily Pruritus NRS at baseline will be calculated from daily assessments
of worst itch severity (Worst Daily Pruritus NRS) during the 7 days
immediately preceding randomisation (Day -6 to 0). A minimum of 4 Worst
Daily Pruritus NRS scores out of the 7 days is required to calculate the
baseline average score. For subjects who do not have at least 4 scores reported
during the 7 days immediately preceding the planned randomisation date,
randomisation should be postponed until this requirement is met, but without
exceeding the 6 weeks maximum duration for screening.
10. Subjects must have applied a stable dose of emollient twice daily (or more, as needed)
for at least 14 days before randomisation (refer to exclusion criterion no. 8 for
limitations regarding emollients).
11. Women of childbearing potential must use a highly effective* form of birth control
(confirmed by the investigator) throughout the trial and at least for 16 weeks
(5 half-lives) after last administration of IMP.
*A highly effective method of birth control is defined as one which results in a low
failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine 
device (IUD), intrauterine hormone-releasing system (IUS), combined (oestrogen and 
progestogen containing) hormonal contraception associated with inhibition of 
ovulation (oral, intravaginal, transdermal), progestogen-only hormonal contraception 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 42 of 156 
associated with inhibition of ovulation (oral, injectable, implantable), sexual 
abstinence (when this is in line with the preferred and usual life style of the subject), 
vasectomised partner (given that the subject is monogamous). The subjects must have 
used the contraceptive method continuously for at least 1 month prior to the pregnancy 
test at baseline. A female is defined as not being of child-bearing potential if she is 
postmenopausal (at least 12 months with no menses without an alternative medical 
cause prior to screening), or surgically sterile (hysterectomy, bilateral salpingectomy 
or bilateral oophorectomy).  
8.3 Exclusion criteria 
1. Concurrent enrolment in another clinical trial where the subject is receiving an IMP.
2. Previous randomisation in tralokinumab trials.
3. Active dermatologic conditions that may confound the diagnosis of AD or would
interfere with assessment of treatment, such as scabies, cutaneous lymphoma, or
psoriasis.
4. Known active allergic or irritant contact dermatitis that is likely to interfere with the
assessment of severity of AD.
5. Use of tanning beds or phototherapy (narrow band ultraviolet B [NBUVB],
ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), within
6 weeks prior to randomisation.
6. Treatment with the following medications within 4 weeks prior to randomisation:

Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate,
cyclosporine, azathioprine, mycophenolate mofetil, Janus kinase inhibitors
etc.).

Systemic corticosteroid use (excludes topical, inhaled, or intranasal delivery).

Three or more bleach baths during any week within the 4 weeks.
7. Treatment with the following medications within 2 weeks prior to randomisation

TCS.

TCI.

Topical PDE-4 inhibitor.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 43 of 156 
8. Initiation of treatment of AD with prescription emollients or emollients containing
additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products
during the screening period (subjects may continue using stable doses of such
emollients if initiated before the screening visit).
9. Receipt of live attenuated vaccines 30 days prior to the date of randomisation and
during the trial including the safety follow-up period.

Receipt of inactive/killed vaccinations (e.g. inactive influenza) are allowed,
provided they are not administered within 5 days before/after any study visit.
10. Receipt of any marketed (i.e. immunoglobulin, anti-IgE) or investigational biologic
agent, including dupilumab:

Any cell-depleting agents including but not limited to rituximab: within
6 months prior to randomisation, or until lymphocyte count returns to normal,
whichever is longer.

Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to
randomisation.
11. Receipt of any investigational non-biologic agent within 5 half-lives prior to
randomisation.
12. Receipt of blood products within 4 weeks prior to screening.
13. Major surgery within 8 weeks prior to screening, or planned in-patient surgery or
hospitalisation during the trial period.
14. Known or suspected allergy or reaction to any component of the IMP formulation.
15. History of any active skin infection within 1 week prior to randomisation.
16. History of a clinically significant infection within 4 weeks prior to randomisation
which, in the opinion of the investigator or sponsor’s medical expert, may compromise
the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the
subject’s ability to participate in the trial. Clinically significant infections are defined
as:

a systemic infection.

a serious skin infection requiring parenteral (intravenous or intramuscular)
antibiotics, antiviral, or antifungal medication.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 44 of 156 
17. A helminth parasitic infection within 6 months prior to the date informed consent is
obtained that has not been treated with, or has failed to respond to, standard of care
therapy.
18. History of anaphylaxis following any biologic therapy.
19. History of immune complex disease.
20. History of cancer:

Subjects who have had basal cell carcinoma, localised squamous cell
carcinoma of the skin or in situ carcinoma of the cervix are eligible provided
that the subject is in remission and curative therapy was completed at least
12 months prior to the date informed consent was obtained.

Subjects who have had other malignancies are eligible provided that the
subject is in remission and curative therapy was completed at least 5 years
prior to the date informed consent was obtained.
21. Tuberculosis requiring treatment within the 12 months prior to screening. Evaluation
will be according to local guidelines as per local standard of care.
22. History of any known primary immunodeficiency disorder including a positive human
immunodeficiency virus (HIV) test at screening, or the subject taking antiretroviral
medications as determined by medical history and/or subject’s verbal report.
23. History of chronic alcohol or drug abuse within 12 months prior to screening, or any
condition associated with poor compliance as judged by the investigator.
24. History of attempted suicide or is at significant risk of suicide (either in the opinion of
the investigator or defined as a “yes” to suicidal ideation questions no. 4 or 5 or
answering “yes” to suicidal behaviour on the Columbia-Suicide Severity Rating Scale
[C-SSRS] Screening version).
25. Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic,
renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological,
immunological, psychiatric, or major physical impairment that is not stable, in the
opinion of the investigator, and could:

Affect the safety of the subject throughout the trial.

Influence the findings of the trial or their interpretations.

Impede the subject’s ability to complete the entire duration of trial.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 45 of 156 
26. Any clinically significant abnormal findings in physical examination, vital signs,
electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during the
screening period, which in the opinion of the investigator, may put the subject at risk
because of his/her participation in the trial, or may influence the results of the trial, or
the subject’s ability to complete entire duration of the trial.
27. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ≥2.0 times
the ULN (upper limit of normal) at screening.
28. Positive hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb),
hepatitis B core antibody (HBcAb) or hepatitis C virus antibody (anti-HCV) serology
at screening. Subjects with positive HBsAb may be randomised provided they are
hepatitis B vaccinated and have negative HBsAg and HBcAb.
29. Subjects who are not willing to abstain from donating blood and/or plasma from the
time of informed consent and for 16 weeks (5 half-lives) after last dose of IMP.
30. Subjects who are legally institutionalised.
31. Pregnant, breastfeeding, or lactating women.
32. Employees of the trial site or any other individuals directly involved with the planning
or conduct of the trial, or immediate family members of such individuals.
8.4 Screening, screening failures, and randomisation 
Trial participation begins once written informed consent is obtained (see Appendix 4B for 
details on the informed consent process). Once informed consent is obtained, a subject 
identification number (subject ID) will be assigned by a central interactive web response 
system (IWRS) and the screening evaluations to assess eligibility criteria may begin. The 
subject ID will be used to identify the subject during the screening process and throughout 
trial participation, if applicable. A master log of all consented subjects will be maintained at 
the trial site. 
Screening failures are defined as subjects who consent to participate in the trial but are not 
subsequently randomly assigned to trial treatment. A minimal set of screening failure 
information is required to ensure transparent reporting of screening failure subjects to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements (26) 
and to respond to queries from regulatory authorities. Minimal information includes 
demography, screening failure details, eligibility criteria, and any adverse events (AEs) and 
serious AEs (SAEs). Follow-up of SAEs must be carried out according to Section 11.6. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 46 of 156 
Individuals who do not meet the criteria for participation in this trial (screening failures) may 
not be re-screened. However, if the reason for screening failure is administrative and not due 
to the subject failing to meet the eligibility criteria, re-screening may be permitted (this will 
require approval by the sponsor’s medical expert after thorough review of all data from the 
original screening visit in the electronic case report form [eCRF]). Individuals who are 
re-screened will get a new subject ID. 
The investigator will maintain a list of all randomised subjects at the trial site including each 
subject’s identity, date of enrolment and corresponding subject ID so that any subject may be 
identified if required for any reason. The list must not be copied or retained by LEO. 
8.5 Discontinuation 
A subject may withdraw from trial or from treatment at any time (prior to first dose or during 
treatment period) at his/her own request. A subject may be withdrawn at any time at the 
discretion of the investigator. Discontinued subjects will not be replaced.  
Medical reasons for permanent discontinuation of IMP are given in Section 9.8.1. 
Assessments 
Subjects who permanently discontinue IMP for any reason will be asked to attend an early 
termination visit and return to the trial site for 1 or 2 additional visits as indicated below 
depending on the time of discontinuation of IMP (see the SoP [Section 4] for data to be 
collected at these visits). The investigator will review any AEs which will be followed-up 
according to Section 11.6, if the subject agrees. 
Subjects who permanently discontinue IMP prior to Week 16 will be asked to attend: 

Early termination visit.

Nominal Week 16 visit (16 weeks after randomisation).

Safety follow-up visit (16 weeks after last administration of IMP).
Subjects who permanently discontinue IMP at Week 16 or after Week 16 will be asked to 
attend:  

Early termination visit.

Safety follow-up visit (16 weeks after last administration of IMP).
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 47 of 156 
If a subject withdraws from the trial, he/she may request destruction of any samples taken and 
not tested, and the investigator must document this in the site’s trial records.  
Reason(s) for discontinuation from IMP and withdrawal from the trial must be recorded in the 
medical records and the eCRF (lack of efficacy, AE, withdrawal by subject, lost to follow-up, 
death, other). For subjects randomised to IMP but not attending any post-baseline visits, it 
will be recorded whether any safety evaluations were performed after exposure to IMP. 
Lost to follow-up 
A subject will be considered lost to follow-up if they repeatedly fail to return for scheduled 
visits and if the trial site is not able to get in contact with the subject.  
The following actions must be taken if a subject fails to return to the trial site for a required 
visit: 

The trial site must attempt to contact the subject and reschedule the missed visit as
soon as possible and counsel the subject on the importance of maintaining the
assigned visit schedule and ascertain whether or not the subject wishes to and/or
should continue in the trial.

Before a subject is deemed lost to follow-up, the investigator or designee must make
every effort to regain contact with the subject (where possible, 3 telephone calls and, if
necessary, a certified letter to the subject’s last known mailing address or local
equivalent methods). These contact attempts should be documented in the subject’s
medical record.

Should the subject continue to be unreachable, they will be considered to have
withdrawn from the trial with a primary reason of lost to follow-up.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 48 of 156 
9 Treatments 
9.1 Trial product description 
Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that 
specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is 
presented as a liquid formulation for subcutaneous (SC) administration. 
Tralokinumab and placebo will be packaged in individually numbered kits, each containing 
1 syringe. Refer to Panel 7 for further details. 
Panel 7  Identification of investigational medicinal products 
Investigational 
medicinal 
product 
Dosage form 
Concentration and 
formulation 
Manufacturer 
Tralokinumab 
150 mg/mL solution 
for injection in an 
accessorised pre-filled 
syringe, 1.0 mL fill 
volume. 
Formulated at a nominal 
concentration of 
150 mg/mL in 50mM 
sodium acetate/acetic 
acid buffer, 85mM 
sodium chloride, 0.01% 
(w/v) PS-80, pH 5.5 
solution. 
MedImmune 
Placebo 
Placebo solution for 
injection in an 
accessorised pre-filled 
syringe, 1.0 mL fill 
volume. 
Placebo contains the 
same excipients, in the 
same concentration only 
lacking tralokinumab 
MedImmune 
The accessorised prefilled syringe is a single use, disposable system that is designed to 
administer the labelled dose of the system to the subcutaneous space during 1 injection and 
automatically provide a safety mechanism to reduce the occurrence of accidental needle sticks 
during disposal of the system.  
The accessorised prefilled syringe consists of a prefilled syringe sub-assembly (1 mL prefilled 
syringe barrel with a 1/2 inch 27 gauge thin wall staked in needle, rigid needle shield, plunger 
stopper) and a safety device. 
No active comparators will be used in this trial. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 49 of 156 
9.2 Administration of investigational medical products 
The IWRS will assign the required kit numbers for each subject at each dispensing visit. 
The first day of dosing is considered Day 0 (visit 3). Each subject will receive 4 SC injections 
(each 1.0 mL) of 150 mg tralokinumab or placebo to receive a total loading dose of 
600 mg tralokinumab or placebo (4.0 mL). 
At subsequent visits (Q2W) in the initial treatment period, each subject will receive 2 SC 
injections (each 1.0 mL) of 150 mg tralokinumab or placebo to receive a total dose of 300 mg 
tralokinumab or placebo.  
Subjects in the maintenance period will receive either 

Tralokinumab Q2W (2 SC injections [each 1.0 mL] of 150 mg tralokinumab).

Tralokinumab Q4W (alternating dose administrations 2 SC injections [each
1.0 mL] of 150 mg tralokinumab and placebo).

Placebo (2 SC injections [each 1.0 mL] of placebo).
Subjects who have been transferred to open-label treatment will receive 2 SC injections (each 
1.0 mL) of 150 mg tralokinumab at each dosing interval. 
Dosing visits are shown in the SoP (Section 4). The last administration of IMP under this 
protocol will occur at Week 50. 
IMP will be administered by a qualified, unblinded healthcare professional (HCP; see 
Section 9.3.1 for blinding details), or by the subject or the subject’s caregiver (open-label 
treatment only; selected countries). A minimum interval of 7 days is required between 
2 dosing visits.  
The injections will be administered into the SC tissue of the upper arm, anterior thigh, or 
abdomen, separated by at least 3 cm. The injection site must be recorded in the source 
documents at each treatment visit and recorded in the eCRF.  
Further details on IMP administration are provided in an IMP manual. IMP administration 
must be carried out according to these instructions. 
After IMP administration 
For the first 3 IMP dosing visits in both the initial treatment period (i.e., Weeks 0, 2, and 4) 
and in open-label treatment, subjects will be monitored after IMP administration for 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 50 of 156 
immediate drug reactions for a minimum of 2 hours with vital signs taken every 30 minutes or 
until stable, whichever is later. Vital signs will be documented in the eCRF. 
As with any antibody, allergic reactions to dose administration are possible. The World 
Allergy Organization has categorised anaphylaxis into 2 subgroups: allergic anaphylaxis 
(mediated by an immunologic mechanism) and nonallergic anaphylaxis (which has a 
nonimmunologic cause) (30). The clinical criteria for defining anaphylaxis for this trial are 
listed in Appendix 6 (34). Appropriate drugs, such as epinephrine, antihistamines, 
corticosteroids, etc., and medical equipment to treat acute anaphylactic reactions must be 
immediately available at trial sites, and trial personnel should be trained to recognise and 
respond to anaphylaxis according to local guidelines. 
If an anaphylactic reaction occurs, a blood sample will be drawn from the subject as soon as 
possible after the event, at 60 minutes ± 30 minutes after the event, and at discharge for 
analysis of serum tryptase at the central laboratory. 
Conditions requiring IMP administration rescheduling 
If any of the following should occur, the investigator should reschedule the visit and IMP 
should not be administered until the rescheduled visit: 

The subject has an intercurrent illness, that in the opinion of the investigator
may compromise the safety of the subject in the trial (e.g., viral illnesses).

The subject is febrile (defined as ≥38°C; ≥100.4°F) within 72 hours prior to
IMP administration.
If the trial visit cannot be rescheduled in order to maintain minimum of 7 days to subsequent 
dose, the sponsor’s medical expert should be contacted. 
Home-use 
Subjects transferring to open-label treatment will have the option to self-administer 
tralokinumab – or have tralokinumab administered by a caregiver – in their home after 
training and at the investigator’s discretion (selected countries only). Subjects who do not 
want to self-inject may have the staff at the trial site administer all the injections at the trial 
site.  
Subjects who are found eligible for home-use will have to provide additional informed 
consent and home-use will only commence after 3 doses of tralokinumab have been 
administered at the trial site (i.e., starting no earlier than Week 22, see Section 7.1 and the SoP 
[Panel 4]). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 51 of 156 
Prior to self-administration at home, the individual who will be administering the injections 
(i.e., the subject and/or the caregiver) will receive proper training (that is, at 3 dosing visits 
during open-label treatment after additional consent has been obtained) in SC injection 
technique and on procedures to be followed in the event of an emergency during or following 
home-use of tralokinumab. This training will be conducted by the unblinded HCP.  
The subject and/or the caregiver must also undertake SC administration under HCP 
supervision on one or more occasions such that the HCP is satisfied with the individual’s 
understanding and confidence of the procedure. 
Subjects or their caregivers will only self-administer tralokinumab at home every 4 weeks, 
i.e., in weeks where no efficacy and safety assessments are scheduled (Panel 4; see also
Section 9.9.3). Where trial visits with efficacy and safety assessments are scheduled (every 
4 weeks), tralokinumab injections will be administered at the trial site, preferably by the 
subject or their caregiver, alternatively by the unblinded HCP, when all assessments have been 
completed.  
At each trial visit it will be recorded in the eCRF whether tralokinumab was administered by 
the subject or the unblinded HCP. 
9.3 Treatment assignment 
Subjects who have been found to comply with all the inclusion criteria and not to violate any 
of the exclusion criteria will be randomised at baseline (Day 0) to receive treatment with 
either tralokinumab or placebo in the initial treatment period. Treatment assignment will be 
pre-planned according to a computer-generated randomisation schedule in a 3:1 ratio 
(tralokinumab:placebo) stratified by region (North America, Europe, Australia, and Korea) 
and baseline disease severity (IGA 3 or 4).  
Subjects found to be eligible for maintenance treatment at Week 16 will be re-randomised to 
the maintenance treatment period in a 2:2:1 ratio (tralokinumab Q2W:tralokinumab 
Q4W:placebo) stratified by region and IGA response at Week 16 (IGA 0/1 or IGA >1).  
Subjects randomised to placebo in the initial treatment period who achieve a clinical response 
at Week 16 (IGA 0/1 or EASI75) will continue to receive placebo Q2W in the maintenance 
treatment period. 
Subjects not eligible for the maintenance part of the trial will be transferred to open-label 
tralokinumab Q2W treatment. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 52 of 156 
IWRS will be used to control randomisation and stratification factors, along with IMP supply 
chain and expiry tracking.  
9.3.1 Blinding 
This is a double-blinded trial in which tralokinumab and placebo are visually distinct from 
each other. Neither the subject nor any of the investigator or LEO staff who are involved in 
the treatment or clinical evaluation and monitoring of the subjects will be aware of the 
treatment received. The packaging and labelling of the IMPs will contain no evidence of their 
identity.  
Since tralokinumab and placebo are visually distinct and not matched for viscosity, IMP will 
be handled and administered by a qualified, unblinded HCP at the site who will not be 
involved in the management of trial subjects and who will not perform any of the 
assessments. 
In the event that the treatment allocation for a subject becomes known to the investigator or 
other study staff involved in the management of trial subjects, LEO must be notified 
immediately.  
Should an issue arise with the IMP (e.g., damaged kit or syringe that has been assigned to a 
subject prior to administration, or any other unexpected event with the kit or syringe [e.g., a 
malfunction during IMP administration]), the unblinded HCP at the site will contact the 
clinical research associate (CRA) to determine whether any specific actions are required. 
The trial site will maintain a written plan detailing which staff members are blinded/unblinded 
and the process of IMP administration used to maintain the blind. 
9.3.2 Emergency unblinding of individual subject treatment 
While the safety of a subject always comes first, it is still important to carefully consider if 
unblinding is necessary to ensure a subject’s safety. An emergency unblinding request can be 
made by the investigators, HCPs who are not members of the trial staff, or authorised LEO 
personnel. 
Provisions are in place for 24-hour emergency unblinding of individual subject treatment. If 
emergency unblinding is required, the investigator can unblind a subject’s treatment in the 
IWRS. For a requester who is not a member of the trial staff and who does not have access to 
the IWRS (e.g., a physician at an emergency room), a local contact number for the emergency 
unblinding contract research organisation (CRO) is provided on the subject card (see 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 53 of 156 
Appendix 4B) to be used if the investigator or delegated site staff cannot be reached. The 
requester will provide the trial ID and subject ID to the emergency unblinding CRO who will 
immediately reveal the individual treatment allocation. 
The emergency unblinding CRO will clarify that the requester requires immediate unblinding 
without further medical consultation. Should the requester wish to discuss whether unblinding 
is necessary, the emergency unblinding CRO will provide the requester with the LEO 24/7 
contact which will be diverted to the medical cover.  
9.4 Background treatment (emollients) 
All subjects must use an additive-free, basic bland emollient twice daily (or more, as needed) 
for at least 14 days before randomisation. Subjects are not allowed to start treatment with 
prescription emollients or emollients containing additives such as ceramide, hyaluronic acid, 
urea, or filaggrin, unless initiated prior to the screening visit (Section 9.6). Subjects must 
continue their background emollient treatment throughout the trial. 
9.5 Concomitant medication and procedures 
Any medication or vaccine that the subject receives from 3 months prior to screening through 
safety follow-up (Week 66) must be recorded in the subject’s medical record and the eCRF 
along with details such as: 

Reason for use.

Dates of administration including start and stop dates.

Dosage information including dose and frequency.

For topical treatments: size of treated area (≤250 cm2 or >250 cm2).
Similarly, concomitant procedures (including body location, diagnosis, and start and stop 
date) must also be recorded in the subject’s medical record and the eCRF. Note: in this trial, 
only surgical procedures will be recorded. 
Investigators may prescribe concomitant medications or treatments to provide adequate 
supportive care as deemed necessary, except for medications listed in Section 9.6. The 
sponsor’s medical expert should be contacted if there are any questions regarding concomitant 
or prior therapy. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 54 of 156 
Concomitant medication for conditions other than AD may be continued throughout the trial 
without any change in dosage whenever possible. 
The following concomitant medications related to AD treatment are permitted from screening 
through safety follow-up (Week 66): 

Oral antibiotics, antiviral, or antifungal therapy for skin infections as
appropriate.

Stable doses of an emollient (see Section 9.4 for allowed emollients; subjects
must apply such emollients twice daily [or more, as needed] for at least
14 days before baseline and throughout trial participation).

Oral anti-histamines.
In addition, the use of topical treatments is permitted during safety follow-up (from Week 52) 
at the investigator’s discretion. 
9.6 Prohibited medication and procedures 
The following medications are prohibited during the trial from randomisation through 
Week 52: 

TCS of any WHO class (except for subjects in open-label treatment).

Other topical medications used for the treatment of AD, such as TCI.

Use of ultraviolet A or B (UVA or UVB), psoralen + UVA (PUVA), other
phototherapy, or tanning beds.

Prescription emollients or emollients containing additives such as ceramide,
hyaluronic acid, urea, or filaggrin (unless treatment was initiated prior to
screening).

Three or more bleach baths per week.
Any prohibited topical treatments must be recorded as concomitant medication. 
The following medications are prohibited during the trial from randomisation through safety 
follow-up (Week 66): 

Investigational agents other than tralokinumab

Immunoglobulin or blood products

Systemic corticosteroids (nasal and inhaled corticosteroids are allowed)
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 55 of 156 

Systemic treatment for AD with an immunosuppressive/ immunomodulating
agent (e.g., cyclosporine, mycophenolate mofetil, azathioprine, methotrexate,
Janus kinase inhibitors, interferon-gamma, or other biologics)

Allergen immunotherapy

Live (attenuated) vaccine
The sponsor’s medical expert must be notified if a subject receives any of these medications 
during the trial. 
9.7 Rescue treatment 
Initial treatment period and maintenance treatment period 
If medically necessary (i.e., to control intolerable AD symptoms), rescue treatment for AD 
may be provided to trial subjects at the discretion of the investigator. For the purpose of 
efficacy analysis, subjects who receive rescue treatment during the initial treatment period 
will be considered as non-responders, but they will continue IMP treatment if rescue treatment 
consisted of topical medications.  
TCI may be used for rescue, but should be reserved for problem areas only, for example face, 
neck, intertriginous and genital areas, etc. If possible, investigators should attempt to limit the 
first step of rescue therapy to topical medications, and escalate to systemic medications only 
for subjects who do not respond adequately after at least 14 days of topical treatment.  
If a subject receives rescue treatment with systemic corticosteroids or non-steroidal systemic 
immunosuppressive drugs (cyclosporine, methotrexate, mycophenolate mofetil, azathioprine, 
etc.), IMP will be immediately discontinued (see Section 9.8.2, reasons for temporary 
discontinuation of IMP). After the treatment with these medications is completed, IMP may 
be resumed if deemed appropriate by the investigator and sponsor’s medical expert, but not 
sooner than 5 half-lives after the last dose of systemic rescue medication.  
Investigators should make every attempt to conduct efficacy and safety assessments (for 
example disease severity scores, safety labs) immediately before administering any rescue 
treatment. An unscheduled visit may be used for this purpose, if necessary. 
Open-label tralokinumab arm only 
From Week 16 through safety follow-up (Week 66) subjects may use mild to moderate 
strength TCS and/or TCI as needed (prn usage) on lesional skin at the investigator’s discretion 
(see 9 for TCS classification and examples). Use of such TCS and TCI should be recorded as 
concomitant medication. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 56 of 156 
9.8 Dose modification and IMP discontinuation rules 
9.8.1 Reasons for permanent discontinuation of IMP 
Subjects will be permanently discontinued from IMP in the event of: 

Anaphylactic reaction or other severe systemic reaction to IMP injection.

An AE that, in the opinion of the investigator or sponsor’s medical expert,
contraindicates further dosing.

Diagnosis of a malignancy during the trial, excluding carcinoma in situ of the
cervix, or localised squamous or basal cell carcinoma of the skin.

Evidence of pregnancy.

Any infection that is opportunistic, such as active tuberculosis and other
infections whose nature or course may suggest an immuno-compromised
status.

Severe laboratory abnormalities:
o
ALT and/or AST values >3x ULN with total bilirubin >2x ULN
(unless elevated bilirubin is related to Gilbert-Meulengracht
Syndrome)
o
Confirmed AST and/or ALT >5x ULN (for more than 2 weeks)
Subjects in open-label treatment (tralokinumab 300 mg Q2W with optional use of TCS) who 
in the opinion of the subject or investigator have unacceptable treatment effect of 
tralokinumab may discontinue open-label treatment and enter the safety follow-up period. 
9.8.2 Reasons for temporary discontinuation of IMP 
IMP dosing may be temporarily suspended in the event of: 

Other intercurrent illnesses or major surgery.

An infection that requires parenteral treatment with antibiotic, antifungal,
antiviral, anti-parasitic, or anti-protozoal agents.

Treatment with systemic corticosteroids or non-steroidal
immunosuppressive/immunomodulating medications (e.g., cyclosporine,
methotrexate, azathioprine, mycophenolate mofetil, Janus kinase inhibitors,
biologic agents).
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 57 of 156 
IMP dosing may resume after the medication leading to suspension of IMP is discontinued. 
A decision to discontinue IMP temporarily or to reinstitute IMP treatment must be discussed 
with sponsor’s medical expert. However, the investigator may suspend trial treatment at any 
time, even without consultation with sponsor’s medical expert if the urgency of the situation 
requires immediate action and if this is determined to be in the subject’s best interest. In such 
cases, sponsor’s medical expert should be informed as soon as possible.  
9.9 Treatment logistics and accountability 
9.9.1 Labelling and packaging of IMPs 
The IMP will be packaged in individually numbered kits, each containing 1 syringe 
(tralokinumab 150 mg or placebo). 
Primary and secondary packaging materials (syringe and outer carton, respectively) will be 
individually labelled. 
The labelling of IMPs will be in accordance with Annex 13, local regulations and trial 
requirements. Label text will be translated into local languages, as required. The inner label 
will be in English for kits used at trial sites. 
9.9.2 Storage of IMPs 
All LEO supplied IMPs must be stored in a secure and restricted area under the conditions 
specified on the label and remain in the original container until dispensed. 
The IMP must be stored at 2 to 8°C at the site. The temperature during storage must be 
monitored by a calibrated, stationary and continuously monitoring system. Minimum 
requirement is a calibrated min/max thermometer.  
A temperature log must be kept to document the storage within the right temperature interval. 
Storage facilities should be checked at least every working day. 
Storage of IMP may be delegated, e.g. to a hospital pharmacy, as locally applicable. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 58 of 156 
Note that in the cases listed below, site staff should not use the affected IMP and should 
immediately contact their CRA for further guidance: 

Temperature excursion upon receipt or during storage at the trial site.

Damaged kit upon receipt.

Damaged syringe/cartridge.
Damaged IMP should be documented via IWRS (refer to the IWRS manual for further 
details). Damaged IMP should not be used.  
9.9.3 Drug accountability 
The investigator is fully responsible for the IMPs at the trial site and for maintaining adequate 
control of the IMPs and for documenting all transactions with them. 
An inventory (trial medication inventory log) must be kept of the IMP administered to each 
subject randomised in the trial. The trial medication inventory log must be available for 
inspection during monitoring visits and will be checked by the CRA to ensure correct 
dispensing of the IMP.  
Full drug accountability will also be performed in the IWRS. 
Used syringes will be destroyed at the trial site provided the trial site has procedures in place 
for such IMP destruction. 
Trial sites which do not have such IMP destruction procedures in place will dispose used 
syringes in sharps bins which will be shipped to the contract manufacturing organisation 
(CMO). 
The trial site will maintain trial kit cartons from used kits until reconciliation. The IMP will be 
fully accounted for by the CRA with the help of the unblinded HCP. Accountability will be 
documented on the trial medication inventory log and in the IWRS. Following reconciliation, 
the trial kit cartons from used kits may be discarded.  
All unused IMP supplied by the CMO on behalf of LEO will be returned to the CMO. IMP 
may be returned from the trial site either to the CMO directly or via the LEO Pharma A/S 
affiliate or CRO responsible for the running of the clinical trial. The IMP returned to the CMO 
will be reconciled with the individual drug accountability forms. 
For more information about IMP accountability, please refer to the IMP manual. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 59 of 156 
Where home-use is appropriate, the following apply: 

Subjects will only attend trial visits every 4 weeks, i.e., in weeks where
efficacy and safety assessments are scheduled (Section 9.2). At these trial
visits, subjects will be provided with IMP to be administered at home at the
next dosing interval.

Subjects will be provided with sharps bins for used syringes. Filled sharps bins
will be returned to the trial site.

Subjects will return trial kit cartons, and any unused IMP at each trial visit.

Unused IMP returned by the subjects to the trial site can be stored at room
temperature and must be stored separately from non-allocated IMP.

The trial medication inventory log will document all IMP handed out to and
returned by each subject.
9.9.4 Trial product destruction 
Unused IMP(s) as well as used syringes returned to the CMO will be destroyed by the CMO 
according to approved procedures and/or local requirements.   
9.9.5 Treatment compliance 
IMP injections will be performed by site staff who will also keep the accountability records 
up to date. Any non-compliance and the reason for it must be recorded in the eCRF. 
Where home-use is appropriate, the following apply: 
Subjects will record date and injection site for each administration in a log of drug 
administration; these data will then be transcribed into the eCRF by site staff at the next trial 
visit. If a subject is found to be non-compliant, the investigator should remind the subject of 
the importance of following the treatment instructions including taking the IMP as prescribed. 
Any non-compliance and the reason for it must be recorded in the eCRF.  
Where tralokinumab is administered by the subject at the trial site (Section 9.2), the site staff 
will record compliance data in the eCRF. 
9.10 Provision for subject care following trial completion 
In order to ensure appropriate treatment of the subjects after they have completed the trial, the 
subjects will be treated at the investigator’s discretion or referred to other physician(s) 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 60 of 156 
according to standard practice. Subjects who qualify for the long-term extension trial (see 
Section 7.1) may be offered participation. 
9.11 Reporting product complaints 
Any defects or issues with the IMP as well as any device deficiency (including malfunctions, 
use errors, and inadequate labelling) must be reported to Global Pharmacovigilance, LEO on 
the trial-specific (paper) Complaint Form within 3 days of first knowledge.  
Critical complaints (defined as any issue, defect, or device deficiency that has or potentially 
could have a serious impact for the subject [e.g., SAE or large particles in the syringe]) must 
be reported to Global Pharmacovigilance, LEO within 24 hours.  
Complaint forms should contain a detailed description of the defect, issue, or device 
deficiency, including whether it led to an AE. (S)AEs which occur due to a defect or issue 
with the IMP or due to a device deficiency will be reported by the investigator as described in 
Sections 11.2 and 11.3. 
Refer to the IMP manual for information on how to update the kit status in the IWRS. 
During the investigation of the product complaint, the device must be stored at labelled 
conditions unless otherwise instructed; the trial site will be notified whether the device needs 
to be returned for further investigation or may be destroyed. 
Global Pharmacovigilance, LEO contact information for reporting product complaints: 
Fax number: +45 7226 3287  
E-mail address: drug.safety@leo-pharma.com
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 61 of 156 
10 Trial schedule and assessments 
10.1 Overview 
Evaluations to be done at each visit are shown in the schedule of procedures (SoP) in 
Section 4. Links to the relevant SoPs are given in Panel 8. Refer to Section 7.1 for further 
details on the trial design. 
Panel 8  Overview of schedules of procedures 
Period 
Start 
Stop 
Follow-up 
visit 
SoP 
Screening and initial treatment 
Week -61 
Week 16 
Not applicable 
Panel 2 
Maintenance treatment2 
Week 16 
Week 52 
Week 66 
Panel 3 
Open-label treatment3 
Week 16 
Week 52 
Week 66 
Panel 4 
1.
For subjects who do not require a wash-out, screening will start at Week -2 (Section 7.1).
2.
Subjects achieving a clinical response at Week 16 will continue into maintenance treatment that will
continue until Week 52 (Section 7.1).
3.
Subjects who do not achieve a clinical response at Week 16 will be treated with open-label tralokinumab
300 mg Q2W with optional use of TCS. In addition, subjects who meet certain criteria during maintenance
treatment will also be transferred to open-label treatment (Section 7.1).
Q2W, every 2 weeks; SoP, schedule of procedures; TCS, topical corticosteroids. 
During the course of the trial, subjects may need to be seen at unscheduled visits. The 
assessments to be performed at an unscheduled visit are left to the investigator’s discretion 
(could include any assessment performed at an early termination visit).  
Assessments/procedures at any trial visit should be performed in the following order: 

PROs.

Investigator assessments (performed only by adequately trained investigators;
the same investigator should perform all the evaluations for a given subject
throughout the entire trial period) in the following order:
1. SCORAD component C, then component A and B.
2. IGA.
3. EASI.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 62 of 156 

Safety and laboratory assessments.

Other assessments (photographs).

Administration of IMP.
Subjects participating in the trial will be under careful supervision of a dermatologist or 
allergist. Investigators must be experienced in treating AD and have documented experience 
and/or training in use of the assessments required by the protocol and must be either a 
physician, certified physician’s assistant, or advanced registered nurse practitioner. The 
investigators performing the assessments must not be involved in the administration of 
IMP (Section 9.3.1).  
10.2 Assessments performed only at screening/baseline 
Assessments performed only at the screening and/or baseline visit include: assessment of 
eligibility criteria (including review of scores on the Columbia-Suicide Severity Rating Scale 
[C-SSRS] Screening version), demographics, medical history, height and weight, and body 
surface area (BSA) affected by AD. These are described in further detail below. Laboratory 
tests include hepatitis B, hepatitis C, HIV-1, HIV-2, and serum pregnancy test (Sections 10.4.4 
and 10.4.5). 
10.2.1 Columbia-Suicide Severity Rating Scale 
The C-SSRS Screening version is a rater-administered instrument used to assess severity of 
suicidal ideation and suicidal behaviour through a series of simple, plain-language questions 
(35). The C-SSRS must be completed at screening to check that exclusion criterion no. 24 
does not apply.    
10.2.2 Demographics  
The following demographic data will be recorded: 

Month and year of birth

Sex

Race: American Indian or Alaska Native, Asian (Japanese), Asian (others),
Black or African American, Native Hawaiian or Other Pacific Islander, White,
Other

Ethnic origin (self-reported by the subject): Hispanic or Latino, not Hispanic or
Latino
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 63 of 156 
10.2.3 Medical history 
Relevant past and concurrent medical history must be recorded and includes: 

Skin disease history: all past and current skin disease history including:
o
Alopecia
o
Vitiligo
o
Herpes simplex

Atopy history:
o
Duration of AD in years
o
Previous AD treatments
o
Asthma
o
Food allergy
o
Hay fever
o
Allergic conjunctivitis
o
Atopic keratoconjunctivitis
o
Eczema herpeticum

Other medical and surgical history including concurrent diagnoses.
Relevant medical history includes also diseases which are specifically listed as exclusion 
criteria and diseases for which specific treatments are listed as exclusion criteria. 
10.2.4 Height and weight 
The subject’s height must be measured (without shoes) and weight must be determined (in 
indoor clothing and without shoes). 
10.2.5 Body surface area involvement 
The total BSA affected by AD will be assessed by the investigator for each section of the body 
and will be reported as a percentage of all major body sections combined. The following body 
regions will be assessed (brackets show the highest possible score for each region): head and 
neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and 
genitals (1%). The total BSA score will be assessed according to the SoP (Section 4).  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 64 of 156 
10.3 Efficacy assessments 
10.3.1 Investigator assessments  
10.3.1.1 Investigator’s Global Assessment 
The IGA is an instrument used in clinical trials to rate the severity of the subject’s global AD 
and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (Panel 9). The IGA score 
will be assessed according to the SoP (Section 4). The assessment will be based on the 
condition of the disease at the time of evaluation and not in relation to the condition at a 
previous visit. Whenever possible, the IGA should be assessed by the same investigator at 
each visit to reduce inter-rater variability. 
Panel 9  Investigator’s Global Assessment 
Score 
Disease severity 
Standard IGA scale 
IGA morphological descriptors 
0 
Clear 
No inflammatory signs of 
atopic dermatitis 
No erythema and no elevation 
(papulation/infiltration). 
1 
Almost clear 
Just perceptible erythema, and 
just perceptible 
papulation/infiltration 
Barely perceptible erythema and/or 
minimal lesion elevation 
(papulation/infiltration) that is not 
widespread. 
2 
Mild disease 
Mild erythema and mild 
papulation/infiltration 
Visibly detectable, light pink 
erythema and very slight elevation 
(papulation/infiltration). 
3 
Moderate disease 
Moderate erythema and 
moderate 
papulation/infiltration 
Dull red, clearly distinguishable 
erythema and clearly perceptible 
but not extensive elevation 
(papulation/infiltration). 
4 
Severe disease 
Severe erythema and severe 
papulation/infiltration 
Deep/dark red erythema, marked 
and extensive elevation 
(papulation/infiltration). 
10.3.1.2 Eczema Area and Severity Index 
The EASI is a validated measure used in clinical practice and clinical trials to assess the 
severity and extent of AD (19). The EASI score will be assessed according to the SoP 
(Section 4). The assessment will be based on the condition of the disease at the time of 
evaluation and not in relation to the condition at a previous visit. Whenever possible, the 
EASI should be assessed by the same investigator at each visit to reduce inter-rater variability. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 65 of 156 
The EASI is a composite index with scores ranging from 0 to 72, with higher values 
indicating more severe and/or more extensive condition. The index will be calculated as 
shown in Panel 10. Briefly, the investigator will assess the severity of 4 AD disease 
characteristics (erythema, induration/papulation, excoriation, and lichenification) on the 
4 body regions (head/neck, trunk, upper extremities, lower extremities); severity will be 
assessed according to the scale shown in Panel 11. For each body region, a severity sum score 
will be calculated which will be multiplied by an area score (Panel 11) and by a weighting 
factor. The EASI score equals the sum of the scores obtained for each body region (Panel 10). 
Panel 10  Calculation of the Eczema Area and Severity Index 
Body region 
Erythema 
Induration/ 
papulation 
Excoriation 
Lichenification 
Area score 
Weighting factor 
Score 
Head/neck 
( SS   + 
   SS   + 
   SS   + 
   SS ) 
x  AS 
x 0.1 
Trunk 
( SS   + 
   SS   + 
   SS   + 
   SS ) 
x  AS 
x 0.3 
Upper extremities 
( SS   + 
   SS   + 
   SS   + 
   SS ) 
x  AS 
x 0.2 
Lower extremities 
( SS   + 
   SS   + 
   SS   + 
   SS ) 
x  AS 
x 0.4 
The EASI score is the sum of the 4 body region scores 
(range 0-72) 
AS, area score; EASI, Eczema Area and Severity Index; SS, severity score. Modified from (27). 
Panel 11  EASI severity score scale and area score scale 
Severity score scale 
Area score scale 
0 
None/absent 
0 
0% affected area 
1 
Mild 
1 
1% to 9% affected area 
2 
Moderate 
2 
10% to 29% affected area 
3 
Severe 
3 
30% to 49% affected area 
Half-points (0.5; 1.5; 2.5) may also be 
used. 
4 
50% to 69% affected area 
5 
70% to 89% affected area 
6 
90% to 100% affected area 
EASI, Eczema Area and Severity Index. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 66 of 156 
10.3.1.3 Scoring Atopic Dermatitis 
The SCORAD is a validated tool to evaluate the extent and severity of AD lesions, along with 
subjective symptoms (20). The maximum total score is 103, with higher values indicating 
more severe disease. SCORAD will be assessed according to the SoP (Section 4). 
The assessment will be based on the condition of the disease at the time of evaluation and not 
in relation to the condition at a previous visit. Whenever possible, SCORAD should be 
assessed by the same investigator at each visit to reduce inter-rater variability. 
The assessment consists of 3 components: A = extent, B = intensity, and C = subjective 
symptoms 
Extent (A) 
The extent of AD is assessed as a percentage of each defined body area and reported as the 
sum of all areas (maximum score = 100%) 
Intensity (B) 
The intensity of 6 specific symptoms of AD (erythema, edema/papulation, oozing/crusting, 
excoriation, lichenification, and dryness) is assessed by the investigator on an average 
representative area using the following scale:  
0 
= 
None/absent 
1 
= 
Mild 
2 
= 
Moderate 
3 
= 
Severe 
Note: dryness is evaluated on uninvolved areas.  
The sum of intensity score of the 6 symptoms will be reported (maximum score = 18). 
Subjective symptoms (C) 
A subjective assessment of the average itch and sleeplessness over the last 3 days/nights is 
recorded for each symptom by the subject on a visual analogue scale, where 0 is no itch (or 
sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum 
possible score of 20. 
The SCORAD is calculated as: A/5+7B/2+C 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 67 of 156 
10.3.2 Subject assessments 
10.3.2.1 Eczema-related Sleep numeric rating scale 
Subjects will rate how much their eczema interfered with their sleep the last night using an 
11-point NRS (0 indicating that it ‘did not interfere’ and 10 indicating that it ‘completely
interfered’). Subjects will complete the Eczema-related Sleep NRS as part of an eDiary each 
day in the morning from Week -2 (visit 2) until Week 52. The Eczema-related Sleep NRS is 
included in the investigator trial file. 
10.3.2.2 Worst Daily Pruritus numeric rating scale 
Subjects will assess their worst itch severity over the past 24 hours using an 11-point NRS 
(‘Worst Daily Pruritus NRS’) with 0 indicating ‘no itch’ and 10 indicating ‘worst itch 
imaginable’. Subjects will complete the Worst Daily Pruritus NRS as part of an eDiary each 
day in the morning from Week -2 (visit 2) until Week 52. The Worst Daily Pruritus NRS is 
included in the investigator trial file.  
10.3.2.3 Average Daily Pruritus numeric rating scale 
Subjects will assess their average itch over the past 24 hours using an 11-point NRS 
(‘Average Daily Pruritus NRS’) with 0 indicating ‘no itch’ and 10 indicating ‘worst itch 
imaginable’. Subjects will complete the Average Daily Pruritus NRS as part of an eDiary each 
day in the morning from Week -2 (visit 2) until Week 52. The Average Pruritus NRS is 
included in the investigator trial file. 
10.3.2.4 Patient Global Impression of Bother 
The Patient Global Impression of Bother (PGI-B) is a single item designed to capture the 
subject’s perception of how bothered they have been by their AD over the past 24 hours at the 
time of completion. A 5-point categorical response scale will be used (‘not at all’, ‘slightly’, 
‘somewhat’, ‘a lot’, ‘very much’). Subjects will complete this item as part of the eDiary each 
day in the morning from Week -2 (visit 2) until Week 52. The PGI-B is included in the 
investigator trial file. 
10.3.2.5 Patient Global Impression of Severity 
The Patient Global Impression of Severity (PGI-S) is a single item designed to capture the 
subject’s perception of overall eczema symptom severity over the last 24 hours on a 4-point 
categorical response scale (‘no symptoms’ to ‘severe’). Subjects will complete this item as 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 68 of 156 
part of the eDiary each day in the morning from Week -2 (visit 2) until Week 52. The PGI-S is 
included in the investigator trial file. 
10.3.2.6 Patient-Oriented Eczema Measure 
The Patient-Oriented Eczema Measure (POEM) is a validated questionnaire used to assess 
disease symptoms in atopic eczema patients in both clinical practice and clinical trials (21). 
The tool consists of 7 items each addressing a specific symptom (itching, sleep, bleeding, 
weeping, cracking, flaking, and dryness). Subject will score how often they have experienced 
each symptom over the previous week on a 5-point categorical response scale (0 = ‘no days’; 
1 = ‘1 to 2 days’; 2 = ‘3 to 4 days’; 3 = ‘5 to 6’ days; 4 = ‘every day’). The total score is the 
sum of the 7 items (range 0 to 28) and reflects disease-related morbidity; a high score is 
indicative of a worse disease severity. The POEM will be completed according to the SoP in 
Section 4. It will be completed electronically on the device supplied to the trial site and is 
included in the investigator trial file. 
10.3.2.7  Dermatology Life Quality Index 
The Dermatology Life Quality Index (DLQI) is a validated questionnaire with content 
specific to those with dermatology conditions. It consists of 10 items addressing the subject’s 
perception of the impact of their skin disease on different aspects of their HQoL over the last 
week such as dermatology-related symptoms and feelings, daily activities, leisure, work or 
school, personal relationships, and the treatment (22). Each item is scored on a 4-point Likert 
scale (0 = ‘not at all ⁄not relevant’; 1 = ‘a little’; 2 = ‘a lot’; 3 = ‘very much’). The total score 
is the sum of the 10 items (0 to 30); a high score is indicative of a poor HQoL. The DLQI will 
be completed according to the SoP in Section 4. It will be completed electronically on the 
device supplied to the trial site and is included in the investigator trial file. 
10.3.2.8 EQ-5D-5L 
The EuroQoL 5-Dimension Health Questionnaire 5 Level (EQ-5D-5L) is a standardised 
measure of health status developed by the EuroQol group to provide a simple, generic 
measure of health for clinical and economic appraisal (23). The EQ-5D-5L is a self-
administered questionnaire used to assess health status ‘today’ and is divided into 2 sections: 
The first section includes 5 dimensions (mobility, self-care, usual activity, pain/discomfort, 
and anxiety/depression); each dimension will be assessed by the subject using a 5-point scale 
(‘no problems’, ‘slight problems’, ‘moderate problems’, ‘severe problems’, and ‘extreme 
problems’). The second section consists of a vertical visual analogue scale anchored at 0 (‘the 
worst health you can imagine’) and 100 (‘the best health you can imagine’). The EQ-5D-5L 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 69 of 156 
will be completed according to the SoP in Section 4. It will be completed electronically on the 
device supplied to the trial site and is included in the investigator trial file. 
10.3.2.9 SF-36 
The SF-36v2 (Acute Recall) is a 36-item general health status assessment. Subjects will be 
asked to answer each question by selecting one of 3 to 6 categorical response options. The 
instrument instructions do not state a specific recall period; however, a recall period is defined 
within most items. The acute recall version, which asks subjects about the last week, will be 
used in this trial (31). 
The SF-36v2 (Acute Recall) yields scores for 8 health domains (physical functioning, role 
physical, bodily pain, general health, vitality, social functioning, role emotional, and mental 
health) and 2 psychometrically derived summary scores (a physical component summary and 
a mental component summary). 
The SF-36 will be completed according to the SoP in Section 4. It will be completed 
electronically on the device supplied to the trial site and is included in the investigator trial 
file. 
10.3.2.10 Work Productivity and Activity Impairment – General Health 
The impact of AD on the subject’s ability to work and perform regular activities will be 
assessed by Work Productivity and Activity Impairment – General Health (WPAI-GH). The 
WPAI-GH questionnaire is an instrument to measure impairments in both paid work and 
unpaid work (36). It consists of 6 items and measures absenteeism, presenteeism as well as 
the impairments in unpaid activity because of health problem during the past 7 days. The 
following 4 main outcomes can be generated from the WPAI-GH:  

Percent work time missed due to health for those who were currently
employed.

Percent impairment while working due to health for those who were currently
employed and actually worked in the past 7 days.

Percent overall work impairment due to health for those who were currently
employed.

Percent activity impairment due to health for all respondents.
The WPAI-GH will be completed electronically on the device supplied to the trial site 
according to the SoP (Section 4) and is included in the investigator trial file. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 70 of 156 
10.3.2.11 Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) is a Likert-scale tool widely used to 
detect states of anxiety and depression in a general hospital setting (24). The tool consists of 
14 items that assess the subject’s anxiety (7 items) and depression (7 items) during the last 
week. Each question is scored from 0 to 3, with high scores indicating a poor state. The 
HADS will be completed electronically on the device supplied to the trial site according to the 
SoP (Section 4) and is included in the investigator trial file. 
10.3.2.12 Treatment Satisfaction Questionnaire for Medicine 
The Treatment Satisfaction Questionnaire for Medicine (TSQM) v. II is a generic 
questionnaire assessing subjects’ satisfaction with the treatment (29). The tool consists of 
11 items addressing effectiveness, side effects, convenience and overall satisfaction. The 
TSQM will be completed electronically on the device supplied to the trial site according to 
the SoP (Section 4) and is included in the investigator trial file. 
10.4 Safety assessments 
10.4.1 Vital signs 
Vital signs (resting blood pressure, pulse, and body temperature) must be assessed according 
to the SoP (Section 4). Vital signs will be measured in supine position following at least 
5 minutes rest. 
For the first 3 IMP dosing visits in both the initial treatment period (i.e., Weeks 0, 2, and 4) 
and in open-label treatment, subjects will be monitored after IMP administration for 
immediate drug reactions for a minimum of 2 hours with vital signs taken every 30 minutes or 
until stable, whichever is later (Section 9.2).  
If an abnormal vital sign at screening is considered by the investigator to be clinically 
significant, it will be up to the investigator’s discretion if the subject should be randomised 
into the trial (respecting exclusion criterion no. 26).  
In case of abnormal findings, the vital sign measurement can be repeated approximately 
15 minutes later with subjects resting in a supine position to verify the first measurement. 
Should the repeated measurement result in a normal value, the measurement must be repeated 
once more. If the third measurement verifies the second (normal) value, the first measurement 
should be considered as false. If the third measurement confirms the first measurement 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 71 of 156 
(abnormal) the second measurement will be considered as false. Only the last value measured 
and considered as correct will be recorded in the eCRF.  
Clinically significant abnormal vital signs at the (first) screening visit will be documented as 
medical history in the eCRF (refer to Appendix 4D for further details). If an abnormal vital 
sign at any other visit than the first screening visit is considered by the investigator to be 
clinically significant, it will be reported as an AE in accordance with the principles for data 
entry (Appendix 4D). 
10.4.2 Physical examination 
A thorough physical examination of the subject including whole body inspection of the skin 
and auscultation of heart, lungs and abdomen; palpation of the abdominal organs and basic 
neurological status must be performed according to the SoP (Section 4). 
If an unacceptable abnormal finding is identified during the physical examination at the 
screening visit, the subject must not be randomised into the clinical trial (respecting exclusion 
criterion no. 26). 
Refer to Appendix 4D for principles for data entry into the eCRF. 
10.4.3 Digital ECG 
A single 12-lead resting digital ECG will be recorded after the subject has been supine for at 
least 5 minutes at the visits indicated in the SoP (Section 4). 
A pre-evaluation of the ECGs will be performed by the investigators to evaluate immediate 
subject safety. At a minimum, date of ECG collection will be recorded in the source 
documents.  
The ECG data will be transferred to a central ECG service company for central evaluation. A 
cardiologist at the ECG service company will analyse and interpret the ECG data. The ECG 
service company will provide ECG evaluation reports to the trial sites. 
The investigator must evaluate all abnormal ECG results (‘clinically significant’ or ‘not 
clinically significant’) and sign and date. The investigator has the final decision on the clinical 
significance of ECG abnormalities. If a result is abnormal at the screening visit and 
considered by the investigator to be clinically significant, it will be up to the investigator’s 
discretion if the subject should be enrolled into the trial (respecting exclusion criterion 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 72 of 156 
no. 26); if such a subject is enrolled, the investigator will provide a justification in the medical 
record. Refer to Appendix 4D for principles for data entry in the eCRF.  
Test dummy transmissions will be undertaken prior to trial conduct to ensure that 
transmissions can be made and that date and time settings are correctly set. 
The collection and transmission of ECG data will be described in a separate ECG manual. 
10.4.4 Pregnancy test 
A serum pregnancy test must be taken at the screening visit in female subjects of 
child-bearing potential as described in the SoP in Section 4. 
A urine pregnancy test (human chorionic gonadotropin; dipstick) must be performed at the 
trial site at baseline prior to randomisation in female subjects of child-bearing potential. The 
test must be repeated every 4 weeks as shown in the SoP in Section 4. 
Note that pregnant subjects must discontinue IMP immediately (Section 9.8.1). 
10.4.5 Laboratory testing 
The following safety samples will be analysed by a central laboratory: chemistry, 
haematology, serology, and serum pregnancy (Panel 12). Urine samples will be tested at the 
trial site with a dipstick; if abnormal, a urine sample will be sent to the central laboratory for 
further analysis. 
A laboratory manual will be provided to the sites that specifies the procedures for collection, 
processing, storage, and shipment of samples, as well as laboratory contact information 
specific to this trial. 
Samples for laboratory testing will be collected according to the SoP (Section 4). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 73 of 156 
Panel 12  Central laboratory testing 
Chemistry 
Haematology 
Sodium 
Potassium 
Creatinine 
Urea nitrogen 
Calcium  
Alkaline phosphatase  
Aspartate aminotransferase  
Alanine aminotransferase  
Gamma glutamyl transferase 
Bilirubin1 
Lactate dehydrogenase  
Cholesterol 
LDL cholesterol 
HDL cholesterol 
Triglycerides 
Glucose (non-fasting) 
Albumin 
Protein 
Tryptase2 
Erythrocytes 
Hematocrit 
Hemoglobin 
Erythrocyte mean corpuscular volume  
Erythrocyte mean corpuscular haemoglobin 
concentration  
Leukocytes  
Neutrophils, neutrophils/total cells 
Lymphocytes, lymphocytes/total cells 
Monocytes, monocytes/total cells 
Eosinophils, eosinophils/total cells 
Basophils, basophils/total cells 
Thrombocytes  
Serology 
Hepatitis B virus surface antigen4
Hepatitis B virus surface antibody4 
Hepatitis B virus core antibody4 
Hepatitis C virus antibody4 
HIV-1 antibody4
HIV-2 antibody4
Immunoglobulin E5 
Urinalysis3 
Serum pregnancy test (females only)4 
Protein 
Glucose 
Ketones 
Occult blood 
Leukocytes 
Nitrite 
Choriogonadotropin beta 
1)
If bilirubin is above upper limit of normal, direct and indirect bilirubin will also be measured.
2)
Only measured in case of suspected anaphylaxis (Section 9.2).
3)
Urine samples will be tested at the trial site (dipstick). In case of abnormal dipstick results, a urine sample
will be sent to the central laboratory for microscopic examination (leukocytes, erythrocytes, and casts).
4)
Measured at screening only.
5)
Not measured at screening.
HDL, high density lipoprotein; LDL, low density lipoprotein. 
The investigator must evaluate all results outside the reference range (‘clinically significant’ 
or ‘not clinically significant’) and sign and date. The signed and dated version will be filed 
with the investigator’s trial documentation. Clinically significant abnormal tests must be 
repeated to confirm the abnormality. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 74 of 156 
The central laboratory will provide results in conventional units to trial sites in North America 
and in SI units to trial sites in Europe, Australia, and Asia; results that are transferred to the 
trial database will be in conventional and SI units. 
Handling, storage, destruction and shipment instructions are provided in a separate laboratory 
manual. 
If a screening laboratory result is abnormal and of clinical significance, it will be at the 
investigator’s discretion to decide if the subject should be enrolled into the trial (respecting 
exclusion criteria no. 26, 27, and 28).  
10.4.6  Pharmacokinetic assessments 
Blood samples for PK assessments must be collected at the time points specified in the SoP 
(Section 4). 
Collection, handling and shipment instructions for PK blood samples are provided in a 
laboratory manual.  
Serum samples for determination of tralokinumab concentrations will be analysed by a 
laboratory using a validated bioanalytical method. Details of the analytical method used will 
be described in the bioanalytical report. 
Samples will be retained for as long as the quality of the material permits evaluation but for 
no longer than 12 months after completion of the clinical trial report (CTR). 
10.4.7 Anti-drug antibodies measurements 
Blood samples will be collected for determination of anti-tralokinumab antibody levels at 
pre-determined time points according to the SoP (Section 4).  
Collection, handling and shipment instructions for ADA blood samples are provided in a 
separate laboratory manual. 
Serum samples for determination of presence or absence ADA will be analysed by a 
laboratory using a validated bioanalytical method. A tiered testing scheme will be employed, 
with the first step being screening. Samples found positive in the screening step will be tested 
in the confirmatory step. Samples confirmed positive for ADA in the confirmatory step will 
undergo ADA endpoint titre determination and will be analysed for the presence of 
neutralising antibodies (nAB). Details of the analytical method used will be described in the 
ADA bioanalytical report. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 75 of 156 
Samples will be retained for as long as the quality of the material permits evaluation but for 
no longer than 15 years after marketing authorisation. 
10.5 Other assessments 
10.5.1 Photography (selected trial sites) 
At selected trial sites, subjects will be asked to participate in a photography component 
involving digital photography assessments to show disease progression over time. 
Participation in this photography component requires that the subject provides additional 
informed consent. 
Digital colour photographs will be taken of the disease area and a representative lesion 
according to the SoP (Section 4). 
The trial sites will use their own equipment to take the photographs. Instructions for 
photography will be provided to the sites in a photography manual. Photography standards 
and procedures are provided to the trial sites by the central photography vendor.  
The photographs will have no other subject identifier than the subject ID and will be 
transmitted electronically to the photography vendor using a secure file transfer protocol. 
Printed copies of the photographs must be included as part of the individual subject source 
documentation.  
LEO may at its discretion use the photographs in publications, posters and similar types of 
information material or media targeting patients and HCPs. The photographs can also be part 
of training material used for training and educational purposes. Steps will be taken to ensure 
that the identity of the subject is protected to the extent possible. 
10.6 Estimate of total blood volume collected 
Blood samples will be drawn for safety (chemistry, haematology, serology, PK, and ADA). 
The total volume of blood to be withdrawn is approximately 285 mL which is less than the 
volume of blood drawn during a blood donation (approximately 500 mL). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 76 of 156 
11Adverse events 
AEs and serious adverse events (SAEs) are defined in Appendix 2. 
Classification of AEs in terms of severity, causality and outcome are defined in Appendix 3. 
11.1 Collection of adverse events 
AEs must be collected from time of first trial-related activity after the subject has signed the 
informed consent form until completion of the clinical trial (defined as the safety 
follow-up visit 16 weeks after last injection). For subjects entering the long-term extension 
trial (LP0162-1337, ECZTEND), any (S)AE with onset before the final visit in the 
LP0162-1326 trial should be reported in the parent trial. If ongoing, the (S)AE will also be 
recorded as medical history in ECZTEND.  
AEs must be assessed by medically qualified personnel. 
At all visits, the subject will be asked a non-leading question by the investigator about AEs, 
for example: “How have you felt since I saw you last?” No specific symptoms should be 
asked for. It is important that the investigator also observes the subject for any changes not 
reported by the subject and records these changes. 
Refer to Appendix 4D for principles for data entry in the eCRF. 
11.2 Reporting of adverse events 
AEs reported by the subject or observed by the investigator must be recorded on the AE form 
of the CRF and should be described in the following manner: 
The AE term must be in precise English medical terminology (i.e. not necessarily the exact 
words used by the subject). Whenever possible, a specific diagnosis should be stated (for 
example ‘allergic contact dermatitis’).  
The duration of the AE must be reported by the start date and stop date of the event. In 
addition, it must be recorded whether the AE started prior to start of IMP. 
AEs must be classified in terms of severity, causality and outcome according to the definitions 
in Appendix 3. 
Action taken with trial treatment: Any action taken with IMP as a consequence of the AE 
must be recorded (dose not changed, dose reduced, dose increased, drug interrupted, drug 
withdrawn, not applicable, unknown). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 77 of 156 
Other action taken: any other action taken as a result of the AE must be recorded (none, 
concomitant medication, concomitant procedure). 
Withdrawn due to AE: it must be recorded whether the AE leads to withdrawal from the trial. 
11.3 Reporting of serious adverse events 
The criteria that define an AE as serious (i.e., an SAE) are defined in Appendix 2. 
11.3.1 Investigator reporting responsibilities 
Any SAE must be reported to LEO on the (paper) SAE Form within 24 hours of first 
knowledge. This report should contain an assessment of available information on seriousness, 
severity, causal relationship to the IMP, comparator or trial procedure, the action taken, the 
outcome to date, and a narrative description of the course of the event. 
The completed SAE form must be faxed or scanned and e-mailed to Global 
Pharmacovigilance, LEO using the e-mail address or fax number below: 
Global Pharmacovigilance, LEO 
E-mail address: drug.safety@leo-pharma.com
Fax number: +45 7226 3287 
It may be relevant for the investigator to enclose other information with the SAE form, such 
as anonymised reports of diagnostic procedures, hospital records, autopsy reports, etc. 
Additionally, Global Pharmacovigilance, LEO may request further information in order to 
fully assess the SAE. The investigator must forward such information to LEO upon request by 
fax or e-mail (see contact details above). 
The investigator must notify the local institutional review board(s) (IRB[s])/ independent 
ethics committee(s) (IEC[s]) of SAEs as required by current applicable legislation for the 
concerned country. 
SAEs occurring after the completion of the clinical trial (i.e., after the safety follow-up visit at 
Week 66) should not be routinely sought or collected. However, such events should be 
reported to LEO (see contact details above) if the investigator becomes aware of them. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 78 of 156 
11.3.2 LEO reporting responsibilities 
Global Pharmacovigilance, LEO is responsible for assessing whether or not an SAE is 
expected. The relevant reference document for this clinical trial is:  
For the IMP, the Investigator’s Brochure, edition 16 and subsequent updates must be used. 
Global Pharmacovigilance, LEO will notify the regulatory authorities and concerned 
investigators of SAEs according to the current applicable legislation for the concerned 
countries.  
The IRB(s)/IEC(s) will be notified of SAEs according to the current applicable legislation for 
the concerned countries.  
For all countries except the US, all SAEs which are assessed as causally related to the IMP(s) 
by either the investigator or LEO (ICH E2A Guideline), and which are unexpected 
(Suspected, Unexpected Serious Adverse Reactions [SUSARs]), are subject to expedited 
reporting to regulatory authorities and IRB(s)/IEC(s) according to the current applicable 
legislation in the concerned countries. Investigators will be notified of such SUSARs and the 
evolving safety profile on an ongoing basis.  
For the US, as per Guidance for Industry and Investigators - Safety Reporting Requirements 
for INDs and BA/BE Studies, only those events for which the sponsor determines there is a 
reasonable possibility of a causal relationship are subject to IND Safety Reporting. 
Investigators will be notified of the evolving safety profile on an ongoing basis. 
11.4 Other events that require expedited reporting 
11.4.1 Pregnancy 
Any pregnancy occurring during the clinical trial must be reported to LEO within 24 hours of 
first knowledge using the (paper) Pregnancy Follow Up Form (Part I). All such pregnancies 
must be followed up until delivery or termination and final outcome must be reported on the 
(paper) Pregnancy Follow Up Form (Part II) within 24 hours of first knowledge. 
The completed Pregnancy Follow Up Forms must be faxed or scanned and e-mailed to Global 
Pharmacovigilance, LEO. Contact details are given in Section 11.3.1. 
Pregnant subjects must permanently discontinue IMP (see Section 9.8.1). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 79 of 156 
11.5 Reporting of other events 
11.5.1 Adverse events of special interest 
The events listed in Panel 13 are considered adverse events of special interest (AESIs) in this 
trial and will require that the investigator provides additional information to LEO. An AESI 
may be serious (requiring expedited reporting, Section 11.3) or non-serious. 
Panel 13  Adverse events of special interest 
Adverse event of special interest 
Additional information to be provided (if 
available1) 
Eczema herpeticum 
Skin findings: 

Lesion type.

Disseminated / localised.

Location.

Present in an area with visible eczema / no
visible eczema / present in areas with and
without eczema.

Monomorphic / polymorphic.
Confirmation of herpes simplex virus 
Malignancies diagnosed after 
randomisation, excluding basal cell 
carcinoma, localised squamous cell 
carcinoma of the skin, and 
carcinoma in situ of the cervix 
Histology report 
Oncology assessment  
Treatments (surgery, radiation, chemotherapy, other) 
Skin infections requiring systemic 
treatment 
Skin swab 

Outcome.
Conjunctivitis 
Aetiology (viral, bacterial, allergic, unknown) 
Bacterial culture outcome (for events with bacterial 
aetiology) 
Diagnosis confirmed by ophthalmologist  
Keratoconjunctivitis 
Aetiology (infectious, non-infectious, other, unknown) 
Bacterial culture outcome (for events with bacterial 
aetiology) 
Diagnosis confirmed by ophthalmologist 
Keratitis 
Aetiology (infectious, non-infectious, other, unknown) 
Bacterial culture outcome (for events with bacterial 
aetiology) 
Diagnosis of herpes simplex keratitis (for events with 
viral aetiology) 
Diagnosis confirmed by ophthalmologist 
1 The additional data to be recorded in the eCRF are not a requirement, but are to be reported 
by the investigator, if available, for example as part of standard clinical practice.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 80 of 156 
11.5.2 Overdose 
An overdose is defined as a subject receiving a dose of IMP in excess of that specified in this 
protocol.  
The term overdose must be documented on the AE form of the CRF. In addition, AEs 
originating from overdose must be documented on a separate line. 
LEO does not recommend specific treatment for an overdose. The investigator will use 
clinical judgment to treat any overdose if necessary. 
11.5.3 Medication error 
Medication error refers to any unintentional error in the dispensing or administration of an 
IMP while in the control of the investigator or subject. Broadly, medication errors fall into 
four categories: wrong medication, wrong dose (including strength, form, concentration, 
amount), wrong route of administration, or wrong subject. 
The medication error must be documented on the AE form in the eCRF. In addition, AEs 
originating from a medication error must be documented on a separate line specifying the 
category of error (see definitions above). 
If the medication error is due to device malfunction, such malfunction must be reported as a 
device complaint as described in Section 9.11. 
11.5.4 Misuse 
Misuse refers to situations where the IMP is intentionally and inappropriately used not in 
accordance with the protocol. 
The term misuse must be documented on the AE form in the eCRF. In addition AEs 
originating from misuse must be documented on a separate line. 
11.5.5 Abuse 
Abuse relates to the sporadic or persistent, intentional excessive use of an IMP which is 
accompanied by harmful physical or psychological effects. 
The term abuse must be documented on the AE form in the eCRF. In addition, AEs 
originating from abuse must be documented on a separate line. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 81 of 156 
11.5.6 Aggravation of condition 
Any clinically significant aggravation/exacerbation/worsening of any medical condition(s), 
compared to screening, must be reported as an AE. 
11.6 Follow-up for final outcome of adverse events 
During the trial, the investigator should follow up for final outcome on all AEs (including 
SAEs). Once a subject leaves the clinical trial, the investigator should follow up on the 
outcome of all non-serious AEs classified as of possible/probable relationship to the IMP for 
2 weeks or until the final outcome is determined, whichever comes first. SAEs must be 
followed up until a final outcome has been established, i.e. the follow-up may continue 
beyond the end of the clinical trial. For SAEs which have stabilised and cannot be expected to 
recover during study or safety follow-up periods, for example chronic illnesses, the final 
outcome should be considered recovered and a statement that the SAE has stabilised should 
be added to the narrative in the SAE form.   
11.7 Handling of an urgent safety measure 
An urgent safety measure is a measure taken to implement an action/protocol deviation under 
an emergency. This is defined within the EU Directive as “…the occurrence of any new event 
relating to the conduct of the trial or the development of the investigational medicinal product 
where that new event is likely to affect the safety of the subjects, the sponsor and the 
investigator shall take appropriate urgent safety measures to protect the subjects against any 
immediate hazard.” (32). 
If the investigator becomes aware of information that necessitates an immediate change in the 
clinical trial procedure or a temporary halt to the clinical trial in order to protect clinical trial 
subjects from any immediate hazard to their health and safety, the investigator can do so 
without prior approval from LEO, regulatory authority(ies), or IRB(s)/IEC(s). 
The investigator must immediately inform LEO - by contacting the clinical project manager 
or medical expert - of this change in the clinical trial procedure or of the temporary halt 
providing full details of the information and the decision making process leading to the 
implementation of the urgent safety measure. 
LEO must act immediately upon receipt of the urgent safety measure notification in 
accordance with internal procedures and local legislation. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 82 of 156 
12  Statistical methods 
12.1 Sample size 
A total of 780 subjects will be randomised 3:1 to initial treatment in this trial (585 subjects in 
the tralokinumab arm; 195 subjects in the placebo arm). The sample size is chosen to ensure 
that sufficient safety information is collected and to ensure a sufficient number of responders 
are re-randomised to maintenance treatment.   
The primary endpoints for initial treatment IGA 0/1 and EASI75 at Week 16 are to be 
evaluated hierarchically testing both hypotheses of no difference between active and placebo 
at the 5% significance level. The hypothesis for IGA 0/1 will be tested first; if significant, the 
EASI75 hypothesis will be tested. 
For the endpoint IGA 0/1 at Week 16, a sample size of 780 subjects randomised at 3:1 will 
provide >99% power to detect a difference between the 2 arms of 30% for tralokinumab and 
10% for placebo at a 5% 2-sided level of significance. For the endpoint EASI75 at Week 16 a 
sample size of 780 will likewise provide >99% power to detect a difference between 
tralokinumab and placebo at Week 16, assuming EASI75 response rates of 40% and 15%, 
respectively. 
With an IGA response rate of 30% at Week 16, 175 IGA responders initially treated with 
tralokinumab are expected to enter the maintenance treatment period (70 subjects on 
tralokinumab Q2W, 70 subjects on tralokinumab Q4W, 35 subjects on placebo). Assuming 
IGA response rates at Week 52 of 80%, 50% and 5%, respectively for Q2W, Q4W, and 
placebo, the power to show a difference at the 4% significance level will be >99% between 
Q2W and placebo and >99% between Q4W and placebo. 
With an EASI75 response rate of 40% at Week 16, 235 EASI75 responders initially treated 
with tralokinumab are expected to enter the maintenance treatment period (94 subjects on 
tralokinumab Q2W, 94 subjects on tralokinumab Q4W, 47 subjects on placebo). Assuming 
EASI75 response rates at Week 52 of 90%, 55% and 5%, respectively for Q2W, Q4W, and 
placebo, the power to show a difference at the 4% significance level will be >99% between 
Q2W and placebo and >99% between Q4W and placebo. 
12.2 Trial analysis sets 
All screened subjects will be accounted for in the CTR. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 83 of 156 
All subjects randomised to initial treatment are included in the full analysis set and will be 
analysed for efficacy up to Week 16. Exclusions from the full analysis set can be considered 
in special cases as described in ICH E9, Section 5.2.1, Full Analysis Set. If it is decided to 
exclude a randomised subject from the full analysis set, a justification addressing ICH E9 will 
be given. 
A per protocol analysis set will be used as an efficacy subset for the analysis of the primary 
endpoints up to Week 16, and analyses based on the per protocol analysis set will be 
performed to support the results obtained for the full analysis set. The per protocol analysis 
set will be defined by excluding subjects from the full analysis set for whom any of the 
following conditions apply:  

Receive no treatment with the IMP.

Provide no assessment of IGA or EASI following start of treatment.

Are known to have taken the wrong IMP throughout the initial treatment
period of the trial.

Do not fulfil all the inclusion criteria no. 3, 6, 7 and 8.
A maintenance analysis set will be defined as all subjects who receive tralokinumab in the 
initial treatment period and who are re-randomised to maintenance treatment. 
A safety analysis set will be defined by excluding subjects from the full analysis set who 
either received no treatment with IMP and/or for whom no post-baseline safety data are 
available.  
A maintenance safety analysis set will be defined as subjects in the full analysis set who are 
re-randomised to maintenance treatment at Week 16 and who have safety data available after 
Week 16. 
An open-label safety analysis set will be defined as subjects in the full analysis set who are 
still in the trial at Week 16, who have safety data available after Week 16 and who at any point 
in time enter the open-label treatment arm. 
Based on the above-mentioned rules, the inclusion/exclusion of subjects from the trial 
analysis sets will be documented in the statistical analysis plan update before breaking the 
randomisation code. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 84 of 156 
12.3 Statistical analysis 
12.3.1 Disposition of subjects 
Subject disposition will be presented separately for subjects in initial treatment, in 
maintenance treatment, and in open-label treatment. For all randomised subjects the reasons 
for permanent discontinuation of IMP and for leaving the trial in the initial treatment period 
will be presented by last visit attended and by treatment group. For the subjects in the 
maintenance safety analysis set, the reasons for permanent discontinuation of IMP and for 
leaving the trial or treatment arm will be presented by last visit attended and by the assigned 
treatment group at Week 16. For the subjects in the open-label safety analysis set, the reasons 
for permanent discontinuation of IMP and for leaving the trial will be presented by last visit 
attended. 
12.3.2 Demographics and other baseline characteristics 
Descriptive statistics of demographics and other baseline characteristics will be presented 
separately for all randomised subjects and for the maintenance analysis set. The presentations 
will be overall and by treatment group. Presentations of age, sex, ethnicity, race, baseline 
disease severity, and Worst Daily Pruritus NRS weekly average at baseline will also be given 
by region and by baseline disease severity (IGA 3 or 4). 
Demographics include age, sex, race, and ethnicity. Other baseline characteristics include vital 
signs (including height, weight, body mass index), duration of AD, concurrent diagnoses 
(from medical history and indications for concomitant medication), concomitant medication, 
and previous AD treatments.  
12.3.3 Exposure and treatment compliance 
12.3.3.1 Exposure 
Exposure to treatment will be presented for the safety analysis set (initial treatment), the 
maintenance safety analysis set (maintenance treatment), and open-label safety analysis set 
(open-label treatment) as days of exposure per treatment group. 
For the full trial period, the days of exposure on tralokinumab irrespective of treatment group 
will be summarised - subtracting potential periods on placebo - for the safety analysis set.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 85 of 156 
12.3.3.2 Treatment compliance 
Adherence to treatment regimen will be recorded in the eCRF. Where home-use is 
appropriate, the subject will be asked at each trial visit if IMP was administered as instructed. 
The log of drug administration may be used as source. If any complications or deviations in 
administration are observed, these will be described as protocol deviations. 
Adherence will be presented for the safety analysis set (initial treatment) and for the 
maintenance safety analysis set (maintenance treatment) for each treatment group. Adherence 
will also be presented for the open-label safety analysis set (open-label treatment). 
12.3.4 Multiple testing procedure 
To control the overall type 1 error rate, the primary analyses of the primary estimands for the 
primary and secondary endpoints for the initial and maintenance treatment will follow the 
testing procedure outlined in Panel 14. The hypothesis relating to a specific endpoint cannot 
be rejected unless all hypotheses relating to endpoints earlier in the hierarchy are also 
rejected.  
Panel 14  Testing procedure for primary, secondary, and maintenance endpoints 
Arrows indicate order of testing when superiority is shown for all endpoints within a box.  
DLQI, Dermatology Life Quality Index; EASI75, at least 75% reduction in Eczema Area and Severity Index 
score; IGA, Investigator’s Global Assessment; Q2W, every 2 weeks; Q4W, every 4 weeks. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 86 of 156 
The procedure will be as follows: 
IGA 0/1 at Week 16 between tralokinumab and placebo is evaluated at a 5% significance 
level. If the test is significant, EASI75 at Week 16 between tralokinumab and placebo is 
evaluated at a 5% significance level.  
If both these tests are significant, the significance level (alpha) will be split between the 
analyses of the 3 secondary endpoints at Week 16 and the analyses of the 2 maintenance 
endpoints at Week 52. These groups of tests are tested in parallel with alpha=1% for the 
endpoints at Week 16 and with alpha=4% for the maintenance endpoints at Week 52.  
The evaluations of the 3 secondary endpoints at Week 16 between tralokinumab and placebo 
will use the Holm method (25) for 3 ordered p-values at a 1% significance level to adjust for 
multiplicity. 
The hypotheses for the maintenance treatment endpoints will be tested sequentially in the 
specified order at the 4% significance level. The next hypothesis will only be tested if the 
former was significant.  
If all p-values for the 3 secondary endpoints at Week 16 are significant, then the hypotheses 
for the maintenance treatment endpoints can be evaluated at a 5% significance level. 
Conversely, if all p-values for the maintenance endpoints are significant, then the hypotheses 
for the 3 secondary endpoints at Week 16 can be evaluated at a 5% significance level.  
12.3.5 Analysis of initial treatment 
12.3.5.1 Analysis of primary endpoints 
Three estimands addressing different aspects of the trial objectives will be defined: 

Primary estimand: ‘composite’.

Secondary estimand: ‘hypothetical’.

Tertiary estimand: ‘treatment policy’.
The applied estimands incorporate two main types of events that influence how the treatment 
effects are estimated: 

Initiation of rescue medication: Some of the estimands use the initiation of
rescue medication as an event that modifies the applied value of an endpoint,
e.g. by defining a subject receiving rescue medication as a non-responder.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 87 of 156 

Permanent discontinuation of IMP: This event occurs when a subject is
permanently withdrawn from the treatment or the trial as described in
Section 8.5. This can either happen at his/her own initiative or at the
investigator’s discretion. The event also includes the possibility of a subject
being lost to follow-up. The timing of the event is defined as the date of the
early termination visit for withdrawn subjects or – in the case of a subject lost
to follow-up – the date of the last known visit to the clinic. As for the rescue
medication, the event type is used to modify an applied endpoint value.
All analyses will be based on the full analysis set unless otherwise specified. 
12.3.5.1.1 Primary estimand: ‘composite’ 
The primary estimand for the primary endpoints will be: 

Treatment difference in response rates of IGA 0/1 and EASI75 after 16 weeks
achieved without rescue medication, regardless of treatment discontinuation.
The primary estimand assesses the expected difference in response rates (defined as response 
obtained without initiation of any rescue medication) after 16 weeks, resulting from initiation 
of a treatment regimen with tralokinumab compared to a treatment regimen with placebo. 
Primary analysis for the primary estimand 
Data retrieved at Week 16 for subjects who have permanently discontinued IMP prior to 
Week 16 will be included in the analysis. Subjects who prior to the Week 16 visit have 
received rescue medication will be considered non-responders, reflecting an assumption that 
initiation of rescue medication indicates failure of the randomised treatment to achieve 
response, and that a (possible) observed positive response after initiation of rescue medication 
is not attributable to the randomised treatment. Missing data for subjects who did not attend 
the Week 16 visit and where rescue medication has not been used prior to Week 16, will be 
imputed as non-responders.  
The difference in response rates between treatment groups will be analysed using the 
Cochran-Mantel-Haenszel test stratified by region (North America, Europe, Australia, and 
Korea) and baseline disease severity (IGA 3 or 4). The treatment estimate and the 
corresponding 95% CI will be presented. The null hypothesis of no difference in response 
rates between tralokinumab and placebo will be tested against the 2-sided alternative that 
there is a difference.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 88 of 156 
The primary endpoints will be tested sequentially at a 5% significance level. IGA 0/1 will be 
tested first, and, if significant, then EASI75 will be tested. If both primary null hypotheses are 
rejected, the secondary endpoints and the maintenance endpoints will be tested. 
Sensitivity analyses for the primary estimand 
Two sensitivity analyses are specified for the primary estimand. In both cases the same 
Cochran-Mantel-Haenszel test as used for the primary analysis will be applied including 
stratification by region and baseline disease severity. 
The purpose of the analyses is to assess the robustness of results of the primary analysis with 
respect to the retrieved data at Week 16 and assumptions regarding missing Week 16 data.  
Sensitivity analysis 1: All subjects who have permanently discontinued IMP prior to Week 16 
will be imputed as non-responders, even if no rescue medication has been used. This is to 
reflect a situation where retrieved efficacy data and concomitant medications could be 
registered less accurately for subjects who have discontinued treatment.  
Sensitivity analysis 2: Rather than imputing all subjects who do not attend the Week 16 visit 
and where rescue medication has not been used as non-responders, the following approach 
will be applied. If subjects have withdrawn due to an AE or due to lack of efficacy, they are 
still considered non-responders. Data missing for other reasons will be imputed using last 
observation carried forward (LOCF), hereby assuming that the last value is a more reliable 
estimate of the missing response (than a non-response). 
Supplementary analysis 
The primary analysis of the primary estimand is repeated based on the per protocol analysis 
set. 
12.3.5.1.2 Secondary estimand: ‘hypothetical’ 
The secondary estimand for the primary endpoints will be: 

Treatment difference in response rates of IGA 0/1 and EASI75 after 16 weeks
if all subjects adhered to the treatment regimen in the sense that they did not
discontinue IMP permanently and no rescue medication was made available
before Week 16.
The secondary estimand assesses the expected difference in response rates achieved when 
adhering to the treatment regimen tralokinumab with no rescue medication as compared to a 
treatment regimen with placebo with no rescue medication.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 89 of 156 
Primary analysis of the secondary estimand 
Data collected after permanent discontinuation of IMP or after initiation of rescue medication 
will not be applied in the analysis.  
IGA 0/1 responder imputation  
Imputation of missing binary IGA 0/1 data at Week 16 will be done using multiple 
imputations of the underlying 5-point IGA values within the 2 groups defined according to 
randomised treatment arm assuming that data is missing at random within each arm. 
1. In each group, intermittent missing values will be imputed using LOCF to obtain a
monotone missing data pattern.
2. An ordinal logistic regression model assuming proportional odds will be fitted to the IGA
value at Week 2. The model will include effects of region, and baseline disease severity
(IGA 3 or 4) as factors. The estimated parameters, and their variances, will be used to
impute missing IGA values at Week 2. 100 copies of the dataset will be generated
(seed=11109926).
3. For each of the 100 copies of the dataset, missing values at Week 4 will be imputed in the
same way as for Week 2. The imputations will be based on a proportional odds logistic
regression model with effects of region and baseline disease severity (IGA 3 or 4) together
with the IGA value at Week 2 as factors. The estimated parameters, and their variances,
will be used to impute missing values at Week 4.
4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14, and
16 with the modification that only the IGA values from the two preceding visits will be
included as factors in addition to region and baseline disease severity. The missing binary
IGA 0/1 response at Week 16 will be derived from the corresponding underlying imputed
IGA value.
EASI75 responder imputation 
Imputation of missing binary EASI75 data at Week 16 will be done using multiple 
imputations of the underlying 72-point EASI values within the two groups defined according 
to randomised treatment arm assuming that data is missing at random within each arm. 
1. Intermittent missing values will be imputed in each group using a Markov Chain Monte
Carlo method to obtain a monotone missing data pattern and 100 copies of the dataset will
be generated (seed=29099726).
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 90 of 156 
2. An analysis of covariance (ANCOVA) model is fitted to the EASI value at Week 2. The
model will include effects of baseline EASI as a covariate, and region, and baseline
disease severity (IGA 3 or 4) as factors. The estimated parameters, and their variances,
will be used to impute missing EASI values at Week 2. 100 copies of the dataset will be
generated (seed=11109926).
3. For each of the 100 copies of the dataset, missing EASI values at Week 4 will be imputed
in the same way as for Week 2. The imputations will be based on the same ANCOVA
model with effects of baseline EASI as a covariate, and region, and baseline disease
severity (IGA 3 or 4) as factors together with the EASI value at Week 2 as covariate. The
estimated parameters, and their variances, will be used to impute missing values at
Week 4.
4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14, and
16 with the modification that only the EASI values from the preceding two visits will be
included as covariates in addition to baseline EASI as a covariate, and region and baseline
disease severity as factors. The missing binary EASI75 response at Week 16 will be
derived from the corresponding underlying imputed EASI value.
Analysis of Week 16 response 
For each of the 100 complete data sets, the difference in response rates (either the IGA 0/1 or 
the EASI75) between treatment groups will be analysed using the Cochran-Mantel-Haenszel 
test stratified by region (North America, Europe, Australia, and Korea) and baseline disease 
severity (IGA 3 or 4). The estimates and standard errors from the 100 analyses will be pooled 
to one estimated treatment difference and associated standard error using Rubin’s rule to draw 
inference. From these pooled estimates, the 95% CI for the treatment difference will be 
calculated. 
Sensitivity analysis for the secondary estimand 
Rather than assuming that observations are missing at random within each treatment arm, it is 
assumed that missing data from subjects who discontinue IMP permanently/receive rescue 
medication in the tralokinumab arm will resemble missing data from subjects from the 
placebo arm who do not discontinue IMP permanently/receive rescue medication. The 
underlying assumption is that the effect of tralokinumab following rescue medication or 
permanent treatment discontinuation is similar to the effect of placebo. It should be noticed 
that this assumption is pronouncedly conservative in favour of placebo as it tends to minimise 
the differences between arms.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 91 of 156 
Imputation of missing data at Week 16 will be done using a pattern mixture model where 
missing data in the tralokinumab arm as well as the placebo arm will be imputed from 
observed data in the placebo arm (using a so-called copy-reference approach). With this 
exemption, the stepwise multiple imputation procedure and subsequent analysis will be 
conducted in the same way as specified for the primary analysis of the secondary estimand. 
12.3.5.1.3 Tertiary estimand: ‘treatment policy’ 
The tertiary estimand for the primary endpoints will be: 

Treatment difference in response rate after 16 weeks between tralokinumab
and placebo regardless of rescue medication and treatment discontinuation.
The tertiary estimand assesses the average difference in response rates, resulting from 
initiation of a treatment regimen with tralokinumab and additional rescue medication as 
compared to a treatment regimen with placebo and additional rescue medication.  
Primary analysis for the tertiary estimand 
Data retrieved at Week 16 for subjects who have permanently discontinued treatment prior to 
Week 16 will be included in the analysis.  
Imputation of missing data at Week 16 will be done using multiple imputations within 
4 groups defined according to randomised treatment arm and whether or not subjects have 
permanently discontinued IMP prior to Week 16. Within a given treatment arm, retrieved data 
from discontinued subjects will be used to impute missing data for other discontinued 
subjects. Similarly, the available data from not discontinued subjects will be used to impute 
data for such patients where the Week 16 value is missing.  
For not discontinued subjects, the stepwise multiple imputations procedure will be conducted 
in the same way as specified for the primary analysis of the secondary estimand. 
For discontinued subjects, it is expected that the number of subjects with retrieved data at 
Week 16 will be too small to facilitate the same imputation model as mentioned above. 
Consequently, an imputation model with only region and baseline effects (IGA as a factor and 
EASI as a covariate [only for EASI75]) will be applied for discontinued subjects. Some 
factors may have to be omitted, depending on the observed data, e.g. if retrieved subjects only 
come from one region or if they all have the same baseline severity. 
The imputed datasets will be analysed in the same way as specified for the primary analysis of 
the secondary estimand. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 92 of 156 
Sensitivity analyses for the tertiary estimand 
Rather than imputing Week 16 data as described in the primary analysis of the tertiary 
estimand, missing observations will be imputed as ‘non-responders’. The assumption reflects 
that discontinued subjects without retrieved data at Week 16 are more likely to be 
non-responders than resembling discontinued subjects with retrieved data at Week 16. 
12.3.5.2 Analysis of secondary endpoints 
The 3 secondary endpoints evaluate the impact of 16 weeks of treatment on (i) severity and 
extent of AD, (ii) itch, and (iii) HRQoL. The corresponding endpoints are (i) the change from 
baseline to Week 16 in SCORAD, (ii) reduction (Y/N) of Worst Daily Pruritus NRS average 
score for the past week (hereinafter ‘Worst Daily Pruritus NRS weekly average’) of at least 4 
from baseline to Week 16, and (iii) change from baseline to Week 16 in DLQI score. 
Subject-reported worst daily itch over the last week prior to baseline will be used to calculate 
the baseline itch (see also inclusion criterion no. 9).  
Reduction of Worst Daily Pruritus NRS weekly average of at least 4 is a binary endpoint, and 
it will be analysed as described for the primary endpoint EASI75 using all three estimands 
with the modification of the ANCOVA imputation model that reduction of Worst Daily 
Pruritus NRS weekly average replaces EASI where preceding values are used as covariates.  
The change from baseline to Week 16 in SCORAD and DLQI, respectively, are continuous 
endpoints and will be analysed as described below. 
All analyses will be based on the full analysis set unless otherwise specified. 
12.3.5.2.1 Primary estimand for the continuous secondary endpoints: 
‘hypothetical’ 
The primary estimand for the continuous secondary endpoints will be: 

Treatment difference in change from baseline to Week 16 in SCORAD and
DLQI, respectively, if all subjects adhered to the treatment regimen in the
sense that they did not discontinue IMP permanently and no rescue medication
was made available before Week 16.
The primary estimand assesses the expected benefit when adhering to the treatment regimen 
tralokinumab with no rescue medication as compared to a treatment regimen with placebo 
with no rescue medication. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 93 of 156 
Primary analysis of the primary estimand (continuous secondary endpoints) 
Data collected after permanent discontinuation of IMP or after initiation of rescue medication 
will not be included in the analysis.  
The endpoints will be analysed using a repeated measurements model on the post baseline 
responses up to Week 16 with an unstructured covariance matrix, Kenward-Roger 
approximation to estimate denominator degrees of freedom, and the mean modelled as 
follows (shown for change from baseline in SCORAD): 
Change from baseline in SCORAD 
= treatment × visit + baseline SCORAD × visit + region + baseline IGA 
This model assumes that data is missing at random within each treatment arm. The estimates 
will be presented with nominal p-values and 95% CI at each visit. The primary comparison 
between tralokinumab and placebo will be at Week 16. 
Sensitivity analysis for the primary estimand (continuous secondary endpoints) 
Rather than assuming that observations are missing at random within each treatment arm it is 
assumed that missing data from subjects who discontinue treatment/receive rescue medication 
in the tralokinumab arm will resemble data from subjects from the placebo arm who do not 
discontinue treatment/receive rescue medication. Imputation of missing data at Week 16 will 
be done using a pattern mixture model where missing data in the tralokinumab arm as well as 
the placebo arm will be imputed from the placebo arm (using a so-called copy-reference 
approach). The procedure for the change from baseline in SCORAD at Week 16 is described 
below. The same procedure will be applied for the DLQI endpoint. 
1. Intermittent missing values will be imputed in each group using a Markov Chain Monte
Carlo method to obtain a monotone missing data pattern and 100 copies of the dataset will
be generated (seed=29099726).
2. For each of the 100 copies of the dataset, an ANCOVA model will be fitted to the
SCORAD value at Week 2 in the placebo group. The model will include effects of
baseline SCORAD as a covariate, and region and baseline disease severity (IGA 3 or 4) as
factors. The estimated parameters, and their variances, will be used to impute missing
values at Week 2 for the placebo group as well as the tralokinumab group
(seed=11109926).
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 94 of 156 
3. For each of the 100 copies of the dataset, missing values at Week 4 will be imputed in the
same way as for Week 2. The imputations will be based on a similar ANCOVA model, but
with SCORAD value at Week 2 included as an additional covariate. The parameters from
the model will be estimated based on data from the placebo group. The estimated
parameters, and their variances, will be used to impute missing values at Week 4 for both
treatment groups.
4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14, and
16 with the SCORAD values from the preceding two visits included as covariates in
addition to baseline SCORAD as a covariate, and region and baseline disease severity as
factors.
For each of the 100 imputed dataset, the change from baseline in SCORAD at Week 16 will 
be analysed using an ANCOVA model with effects of treatment, region, baseline disease 
severity (IGA 3 or 4), and baseline SCORAD value. The estimated difference at Week 16 will 
be derived together with the associated standard error. The estimates and standard errors from 
the 100 analyses are pooled to one estimate and associated standard error using Rubin’s rule 
to draw inference. From these pooled estimates, the 95% CI for the treatment difference will 
be calculated. 
12.3.5.2.2 Secondary estimand for the continuous secondary endpoints: 
‘treatment policy’ 
The secondary estimand for the continuous secondary endpoints will be: 

Treatment differences in change from baseline to Week 16 in SCORAD and
DLQI, respectively, between tralokinumab and placebo regardless of rescue
medication use and treatment discontinuation.
The secondary estimand assesses the average difference in change from baseline in SCORAD 
and DLQI after 16 weeks, resulting from initiation of a treatment regimen with tralokinumab 
and additional rescue medication as compared to a treatment regimen with placebo and 
additional rescue medication.  
Primary analyses for the secondary estimand (continuous secondary endpoints) 
Data retrieved at Week 16 for subjects who have permanently discontinued IMP prior to 
Week 16 will be included in the analysis. Missing Week 16 data will be imputed using 
multiple imputations assuming that data is missing at random within the groups used for 
imputation. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 95 of 156 
Imputation of missing data at Week 16 will be done using multiple imputations within 
4 groups defined according to randomised treatment arm and whether or not subjects have 
discontinued treatment prior to Week 16. Within a given treatment arm, retrieved data from 
discontinued subjects will be used to impute missing data for other discontinued subjects. 
Similarly, the available data from not discontinued subjects will be used to impute data for 
such subjects where the Week 16 value is missing.  
For not discontinued subjects, the stepwise multiple imputations procedure will be conducted 
in the same way as specified for the imputation of the underlying EASI values in the primary 
analysis of the secondary estimand for the binary endpoints. 
For discontinued subjects, it is expected that the number of subjects with retrieved data at 
Week 16 will be too small to facilitate the same imputation model as mentioned just above. 
Consequently, an imputation model with only region and baseline effects (IGA as a factor and 
baseline SCORAD / DLQI as a covariate) will be applied for discontinued subjects. Some 
factors may have to be omitted, depending on the observed data, e.g. if retrieved subjects only 
come from one region or if they all have the same baseline severity. 
Each of the 100 imputed datasets will be analysed and the resulting estimates and standard 
errors pooled as described in the sensitivity analyses for the primary estimand for the 
continuous secondary endpoints. 
Sensitivity analyses for the secondary estimand (continuous secondary endpoints) 
Rather than assuming that observations are missing at random, it is assumed that missing data 
from subjects in the tralokinumab arm who have/have not discontinued treatment prior to 
Week 16 will resemble data from subjects from the placebo arm who have/have not 
discontinued treatment prior to Week 16.  
Imputation of missing data at Week 16 will be done using a pattern mixture model where 
missing data in the tralokinumab arm as well as the placebo arm will be imputed from the 
placebo arm (copy-reference approach). With this exemption, the multiple imputation 
procedure and analysis will be conducted in the same way as described for the primary 
analysis of the secondary estimand for the continuous secondary endpoints. 
12.3.5.3 Analysis of additional secondary endpoints 
To support the primary endpoints, EASI50 at Week 16, EASI90 at Week 16 and the change 
from baseline to Week 16 in EASI score will be analysed and presented for the full analysis 
set. EASI50 and EASI90 will be analysed as described for the primary analysis of the primary 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 96 of 156 
estimand for the primary endpoints and the change from baseline to Week 16 will be analysed 
as described for the primary analysis of the primary estimand for the continuous secondary 
endpoints. 
To support the secondary endpoints on severity and extent of AD, at least 75% reduction in 
SCORAD score (SCORAD75) at Week 16, and SCORAD50 at Week 16 will be analysed and 
presented for the full analysis set. Both endpoints will be analysed as described for the 
primary analysis of the primary estimand for the primary endpoints. 
To support the secondary endpoint on worst daily itch, the change from baseline to Week 16 
in Worst Daily Pruritus NRS weekly average, and the reduction of Worst Daily Pruritus NRS 
weekly average of at least 3 (from baseline to Week 16) will be analysed and presented for the 
full analysis set. The change from baseline to Week 16 in Worst Daily Pruritus NRS weekly 
average will be analysed as described for the primary analysis of the primary estimand for the 
continuous secondary endpoints. The reduction of Worst Daily Pruritus NRS weekly average 
of at least 3 (from baseline to Week 16) is a binary endpoint and will be analysed as described 
for the primary analysis of the primary estimand for the primary endpoints. 
To support the secondary endpoint on HQoL, the binary endpoint reduction from baseline to 
Week 16 of DLQI of ≥4 points will be analysed and presented for the subjects in the full 
analysis set with a baseline DLQI ≥4 similarly to the analysis described for the primary 
analysis of the primary estimand for the primary endpoints.  
12.3.5.4 Analysis of other endpoints 
12.3.5.4.1 Efficacy over time 
To further pursue the objectives supported by the five Week 16 endpoints in the confirmatory 
test hierarchy, these endpoints (as well as the change in Worst Daily Pruritus NRS [weekly 
average]) will be evaluated at each scheduled assessment up to Week 14 or each week up to 
Week 15: 

IGA 0/1 at each scheduled assessment until Week 14.

EASI75 at each scheduled assessment until Week 14.

Change in SCORAD from baseline to each scheduled assessment until
Week 14.

Change from baseline to each week through Week 1 to 15 in Worst Daily
Pruritus NRS (weekly average).
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 97 of 156 

Reduction of Worst Daily Pruritus NRS (weekly average) of at least 4 from
baseline to each week through Week 1 to 15.

Change in DLQI score from baseline to each scheduled assessment until
Week 14.
Nominal p-values for test of a treatment difference and 95% CI for the difference will be 
presented at each scheduled visit (or each week for Worst Daily Pruritus NRS) using the same 
approach as applied for the primary analysis of the relevant endpoint in the primary estimand. 
For the binary endpoints, the same Cochran-Mantel-Haenszel test as for the Week 16 
assessment will be applied. For the continuous endpoints, the repeated measurements model 
already described previously for the Week 16 assessments facilitates that the p-values, 
treatment differences and 95% CIs can be derived for each visit up to Week 14 (or Week 15 
for the change in Worst Daily Pruritus NRS) in the same analysis that already will be made 
for the corresponding Week 16 assessments. 
12.3.5.4.2 Patient-reported outcomes 
The PROs POEM, DLQI, EQ-5D-5L, SF-36, WPAI-GH, HADS, and TSQM will be 
summarised by treatment group and visit using descriptive statistics. The summaries will be 
made separately for the initial treatment and the maintenance treatment. Data from the initial 
treatment period will be presented for the full analysis set and data from the maintenance 
treatment period will be presented for the maintenance analysis set.  
The PROs collected in the eDiaries on a daily basis (Worst Daily Pruritus NRS, Average Daily 
Pruritus NRS, Eczema-related Sleep NRS, PGI-B, and PGI-S) will all be summarised over 
time by treatment group using descriptive statistics. The summaries will be separate for the 
initial treatment and the maintenance treatment. Data from the initial treatment period will be 
presented for the full analysis set and data from the maintenance treatment period will be 
presented for the maintenance analysis set. 
The Average Daily Pruritus NRS collected over the last week prior to baseline will be used to 
calculate the baseline average daily itch. A minimum of 4 Average Daily Pruritus NRS scores 
out of the 7 days is required to calculate the baseline average score. 
To investigate a possible early onset of itch relief, a reduction in Worst Daily Pruritus NRS 
weekly average of at least 3 from baseline to Week 2 will be summarised by treatment group 
and analysed as described for the primary analysis of the primary estimand for the primary 
endpoints. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 98 of 156 
In the subgroup of subjects with either HADS anxiety subscale score ≥8 or HADS depression 
subscale score ≥8 at baseline, the proportion of subjects with both HADS anxiety subscale 
score <8 and HADS depression subscale score <8 at Week 16 will be summarised by 
treatment group and analysed as described for the primary analysis of the primary estimand 
for the primary endpoints.  
In the subgroup of subjects with a baseline POEM score of at least 4, the proportion of 
subjects with a reduction in POEM score of at least 4 at Week 16 will be summarised by 
treatment group and analysed as described for the primary analysis of the primary estimand 
for the primary endpoints. 
The change from baseline to Week 16 in Eczema-related Sleep NRS weekly average, HADS, 
POEM, SF-36, WPAI-GH, and the EQ-5D-5L index will be summarised by treatment group 
and domain, where applicable, and analysed as described above for the primary analysis of 
the primary estimand of the continuous secondary endpoints. For the Eczema-related Sleep 
NRS score, the mean over the last 7 days prior to randomisation will be used as the baseline 
value. 
The treatment satisfaction (TSQM) at Week 16 will be summarised by treatment group and 
domain and compared between treatments using an analysis of variance model including 
treatment, region and baseline IGA as factors. 
For the PGI-B, a day of ‘no or slight bother’ is defined as answering the question with ‘not at 
all’ or ’slightly’. The subjects’ number of days of ‘no or slight bother’ will be tabulated per 
treatment group for the initial treatment period. The mean number of days will be presented 
with 95% CIs and compared between the 2 treatment groups using an analysis of variance 
model including treatment, region, and baseline IGA as factors. In this analysis, data collected 
after permanent discontinuation of IMP or after initiation of rescue medication will be 
disregarded. 
12.3.6 Analysis of maintenance treatment  
12.3.6.1 Analysis of maintenance endpoints 
For the two dichotomous maintenance endpoints, IGA 0/1 and EASI75 at Week 52, an 
adapted version of the primary estimand for the primary endpoints will be considered: 

Treatment difference in response rates of IGA 0/1 and EASI75 after 52 weeks
achieved without rescue medication and without transfer to open-label
treatment
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 99 of 156 
The adapted estimand takes into account that throughout the maintenance period subjects will 
be actively discontinued from the treatment randomised at Week 16 and transferred to the 
open-label tralokinumab arm if they meet the prespecified treatment failure criteria described 
in Section 7.1. 
This estimand assesses the expected difference in response rates (defined as response obtained 
without initiation of any rescue medication and without transfer to open-label treatment) after 
52 weeks in patients responding to tralokinumab at Week 16 (as measured by a positive 
IGA 0/1 or EASI75 response), resulting from a maintenance treatment regimen with 
tralokinumab Q2W or tralokinumab Q4W compared to a treatment regimen with placebo. 
Primary analysis for the maintenance estimand 
All subjects who prior to the Week 52 visit have received rescue medication, including TCS, 
and/or been transferred to the open-label tralokinumab arm will be considered 
non-responders.  
This reflects an assumption that initiation of rescue medication or transfer to open-label 
treatment indicates failure of the re-randomised treatment assigned at Week 16, and that a 
(possible) observed positive response thereafter is not attributable to the treatment received 
from Week 16. In addition, all subjects with missing endpoint data at Week 52 visit will be 
imputed as non-responders. 
The 4 hypotheses of primary interest for maintenance treatment will be tested sequentially 
with the next hypothesis in the sequence only being tested if the previous one was significant. 
The multiple testing procedure planned to control the overall type 1 error rate for the trial is 
described in detail in Section 12.3.4. The maintenance endpoints will be evaluated in the 
following order: 

No difference between Q2W and placebo for IGA 0/1 at Week 52.

No difference between Q2W and placebo for EASI75 at Week 52.

No difference between Q4W and placebo for IGA 0/1 at Week 52.

No difference between Q4W and placebo for EASI75 at Week 52.
For the IGA 0/1 endpoint, the analysis will be based on the subjects in the maintenance 
analysis set who obtained an IGA of 0/1 at Week 16 without rescue medication. For the 
EASI75 endpoint, the analysis will be based on the subjects in the maintenance analysis set 
who obtained an EASI75 at Week 16 without rescue medication.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 100 of 156 
For each endpoint (IGA 0/1 and EASI75 at Week 52) the estimated response rates and 
corresponding 95% CIs, and the pairwise treatment differences will be presented. The 
difference in response rates between treatment groups will be analysed using the 
Cochran-Mantel-Haenszel test stratified by region. The null hypotheses of no difference in 
response rates will be tested against the two-sided alternative that there is a difference.  
Sensitivity analysis for the maintenance estimand 
In a sensitivity analysis, data missing at Week 52 for subjects who did not receive rescue 
medication, did not transfer to open-label and did not withdraw from the trial due to AE or 
lack of efficacy will be imputed using LOCF. 
Pooled analyses across both LP0162-1325 and LP0162-1326 
In order to achieve more precise estimates of clinical response within treatment groups in the 
maintenance period, analyses of IGA 0/1 and EASI75 at Week 52 will be performed on 
pooled data from the 2 trials LP0162-1325 and LP0162-1326. For each endpoint (IGA 0/1 
and EASI75 at Week 52) the estimated response rates and corresponding 95% CIs and the 
pairwise treatment differences will be presented. The difference in response rates between 
treatment groups will be analysed using the Cochran-Mantel-Haenszel test stratified by region 
within trial. The pooled analyses will only be presented in marketing authorisation 
applications. 
12.3.6.2 Analysis of other maintenance endpoints 
12.3.6.2.1 Time to relapse 
The following 2 types of relapse will be considered and analysed: 

Relapse according to IGA: first assessment of an IGA ≥2 or initiation of rescue
medication after initiation of maintenance treatment among subjects in the
maintenance analysis set who obtained an IGA 0/1 at Week 16 without rescue
medication.

Relapse according to EASI75: first time of not achieving EASI75 or initiation of
rescue medication after initiation of maintenance treatment among subjects in the
maintenance analysis set who obtained an EASI75 at Week 16 without rescue
medication.
Kaplan-Meier curves of time to relapse will be estimated and presented by treatment for the 
maintenance analysis set. In a supplementary exploratory analysis, tralokinumab Q2W vs. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 101 of 156 
placebo and tralokinumab Q4W vs. placebo will be compared using a log-rank test stratified 
by region.  
Subjects leaving the trial without meeting the relapse criteria will be censored at the date of 
the last assessment visit.  
12.3.6.2.2 Continued treatment for non IGA responders 
The number of responders according to IGA 0/1 at Week 52 will be tabulated for the subgroup 
of subjects in the maintenance analysis set who are re-randomised meeting the EASI75 
criterion but not the IGA 0/1 criterion at Week 16. 
12.3.6.2.3 Supportive maintenance 
To support the maintenance objective, the response IGA 0/1 or EASI75 at Week 52 will be 
presented and analysed as described above for the primary analysis of the maintenance 
estimand for subjects in the maintenance analysis set who did not receive rescue medication 
prior to Week 16.  
12.3.7 Analysis of safety 
The analyses of safety will be based on the safety analysis sets. The reporting of safety data 
will be presented separately for the initial treatment, the maintenance treatment, and the 
open-label treatment.  
12.3.7.1 Adverse events 
AEs will be coded during the course of the trial according to Medical Dictionary for 
Regulatory Activities (MedDRA). AEs will be presented by preferred terms and primary 
system organ class (SOC). 
Treatment-emergent AEs will be summarised, however, all AEs recorded during the course of 
the trial will be included in the subject data listings. An event will be considered 
treatment-emergent if started after the first use of IMP or if started before the first use of IMP 
(applicable if subject had a wash-out) and worsened in severity thereafter. The tabulations 
described in the following will only include the treatment-emergent events. In each of the 
tabulations, AEs will be defined by MedDRA preferred terms within primary SOC. 
An overall summary of the number of treatment-emergent AEs, number (percentage) of 
subjects with any treatment-emergent AEs, SAEs, deaths, premature discontinuations from the 
trial due to AEs, treatment-related AEs and severe AEs will be presented. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 102 of 156 
The number of AEs and the number of subjects experiencing each type of AE will be 
tabulated by treatment group. The percentage of subjects with AEs in the initial treatment 
period will be compared between treatment groups by a chi-square test or Fisher’s exact test 
(if expected cell count < 5). 
The severity for each type of AE will be tabulated by treatment group.  
The causal relationship to IMP for each type of AE will be tabulated by treatment group. 
Related AEs are defined as AEs for which the investigator has not described the causal 
relationship to IMP as ‘not related’. The number of related AEs and the number of subjects 
experiencing each type of related AE will be tabulated. The percentage of subjects with 
related AEs in the initial treatment period will be compared between treatment groups by a 
chi-square test or Fisher’s exact test (if expected cell count <5). 
SAEs and AESIs will be evaluated separately. A narrative for each SAE will be given. AESIs 
and AEs leading to withdrawal from trial will be tabulated and listed.  
12.3.7.2 Vital signs 
The change in vital signs (blood pressure, heart rate, body temperature) from baseline to each 
visit will be summarised by visit and treatment group as mean, standard deviation, median, 
minimum and maximum values for the safety analysis set, the maintenance safety analysis 
set, and the open-label safety analysis set. 
12.3.7.3 Clinical laboratory evaluation 
The change in each of the laboratory parameters from baseline to each visit will be 
summarised by visit and treatment group as mean, standard deviation, median, minimum and 
maximum values for the safety analysis set, the maintenance safety analysis set, and the 
open-label safety analysis set. 
Laboratory parameters will be classified as ‘low’, ‘normal’ or ‘high’, depending on whether 
the value is below, within or above the reference range, respectively. A shift table will be 
produced showing the categories at baseline against those at end of treatment. Subjects with 
laboratory parameters outside the reference range will be listed. 
12.3.7.4 Pharmacokinetics 
All the PK samples in the trial are trough samples. The Ctrough concentration will be listed by 
treatment group and descriptive statistics will be provided.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 103 of 156 
Ctrough values from subjects with positive ADA/nAb will be compared to values from subject 
with negative ADA/nAb if data permits.  
The PK data will be merged with those from other clinical trials with tralokinumab for a 
population-based meta-analysis. Results of the meta-analysis will be presented in a separate 
pharmacometrics report outside of the CTR. 
12.3.7.5 Anti-drug antibodies 
ADA status (positive versus negative) at each visit will be summarised by treatment group for 
initial, maintenance and open-label treatment. If considered relevant, descriptive statistics 
including number of subjects, mean, standard deviation, median, and range of the actual ADA 
titres by treatment group and visit will be provided. The ADA status across the trial for each 
subject (positive versus negative) will also be classified and summarised by treatment group.  
The association of ADA status across the trial (positive vs. negative) with AEs/SAEs may be 
evaluated. In addition, the association of ADA titres (≥ median titre in positive subjects versus 
< median titre) with AE/SAEs may be evaluated for ADA-positive treated subjects only. The 
ADA-positive subjects across the trial may also be divided into persistent positive versus 
transient positive. A subject will be considered as persistent positive if he/she has positive 
ADA for at least 2 consecutive visits with ADA assessment. Otherwise, the subject will be 
considered as transient ADA positive. The associations between ADA and AE/SAEs may be 
summarised for both persistent positive subjects versus transient positives subjects.  
For subjects who develop ADA, the IGA score and change in EASI at end of treatment will be 
listed.  
Evaluations of nAB will be conducted on those serum samples that test positive for ADA. The 
test sample is deemed positive or negative for the presence of nAb to tralokinumab relative to 
a pre-determined (in assay validation), statistically derived cut point. 
For ADA, all subjects with titre information will be listed. 
12.3.8 Interim analysis 
No interim analysis is planned. 
12.3.9 Analysis of data per last subject’s Week 52 visit 
To support submission for regulatory approval, the trial will be unblinded once all randomised 
subjects have completed the Week 52 visit. All pre-specified analyses related to the initial and 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 104 of 156 
maintenance treatment period will be based on the data cut-off date of the last subject’s 
Week 52 visit. The CTR will include all data from all randomised subjects from the initial and 
maintenance treatment period and all available data from the open-label treatment period and 
safety follow-up period as per data cut-off date. 
Once all subjects have completed the open-label treatment period and safety follow-up period, 
an addendum to the original CTR will be written, summarising the final results from the 
open-label treatment period and safety follow-up period. 
12.3.10 
General principles 
Unless otherwise stated, all significance tests will be two-sided using the 5% significance 
level. All CIs will be presented with 95% degree of confidence. 
An observed-cases approach will be used for tabulations of data by visit (i.e. involving only 
those subjects who attended each specific visit). 
Categorical data will be summarised using the number and percentage of subjects in each 
category and treatment group. Continuous data will be summarised using the mean, median, 
standard deviation, minimum and maximum values. 
All the analyses specified in the protocol will be reviewed in relation to the blinded data 
actually obtained and the statistical analysis plan update will be finalised before breaking the 
randomisation code. 
Any changes from the statistical analysis planned in this clinical trial protocol will be 
described and justified in a protocol amendment, the statistical analysis plan update and/or in 
the CTR dependent on the type of deviation.  
12.3.11 
Handling of missing values 
Procedures for handling of missing values are included under the sections describing the 
individual analyses. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 105 of 156 
13  References 
1. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and
other health and demographic factors: a US population-based study. J Allergy Clin
Immunol. 2013;132(5):1132-1138.
2. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A
population-based survey of eczema prevalence in the United States. Dermatitis.
2007;18(2):82-91.
3. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.
4. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023)1109-1122.
5. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis
is associated with a decrement in health-related quality of life. Int J Dermatol.
2002;41(3):151-158.
6. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for
treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatol Venereol.
2012;26(9):1176-1193.
7. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al.
Guidelines of care for the management of atopic dermatitis: section 2. Management and
treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol.
2014;71(1):116-132.
8. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al.
Guidelines of care for the management of atopic dermatitis: section 3. Management and
treatment with phototherapy and systemic agents. J Am Acad Dermatol.
2014;71(2):327-349.
9. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in
lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459-464.
10. Omori-Miyake M, Yamashita M, Tsunemi Y, Kawashima M, Yagi J. In vitro assessment of
IL-4- or IL-13-mediated changes in the structural components of keratinocytes in mice
and humans. J Invest Dermatol. 2014;134(5):1342-1350.
11. Aleksza M, Lukács A, Antal-Szalmás P, Hunyadi J, Szegedi A. Increased frequency of
intracellular interleukin (IL)-13 and IL-10, but not IL-4, expressing CD4+ and CD8+
peripheral T cells of patients with atopic dermatitis. Br J Dermatol. 2002;147(6):1135-
1141.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 106 of 156 
12. Purwar R, Werfel T, Wittmann M. IL-13-stimulated human keratinocytes preferentially
attract CD4+CCR4+ T cells: possible role in atopic dermatitis. J Invest Dermatol.
2006;126(5):1043-1051.
13. Oh MH, Oh SY, Lu J, Lou H, Myers AC, Zhu Z, Zheng T. TRPAA1-dependent pruritus in
IL-13-induced chronic atopic dermatitis. J Immunol. 2013;191(11):5371-5382.
14. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of
interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest
Dermatol. 2009;129:742-751.
15. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two
phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016
Dec 15;375(24):2335-2348.
16. May RD, Monk PD, Cohen ES, Manuel D, Dempsey F, Davis NH, et al. Preclinical
development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe
uncontrolled asthma. Br J Pharmacol. 2012;166(1):177-193.
17. Thom G, Minter R. Optimization of CAT-354, a therapeutic antibody directed against
interleukin-13, using ribosome display. Methods Mol Biol. 2012;805:393-401.
18. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of
human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-
interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096-1103.
19. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and
severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol.
2001;10(1):11-18.
20. European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the
SCORAD index. Consensus report of the European task force on atopic dermatitis.
Dermatology. 1993;186(1):23-31.
21. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development
and initial validation of a new tool for measuring atopic eczema severity from the patients'
perspective. Arch Dermatol. 2004;140(12):1513-1519.
22. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical
measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216.
23. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single
European currency for EQ-5D health states. Results from a six-country study. Eur J Health
Econ. 2003;4(3):222-231.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 107 of 156 
24. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand.
1983;67(6):361-370.
25. Holm S. A simple sequentially rejective multiple test procedure. Scan J Stat.
1979;6(2):65-70.
26. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement:
updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.
27. Harmonising Outcome Measures for Eczema (HOME). EASI scoring table for aged 8 and
over [homepage on the Internet]. Available from:
http://www.nottingham.ac.uk/homeforeczema/index.aspx [cited 21-Nov-2016].
28. Bancroft AJ, Artis D, Donaldson DD, Sypek JP, Grencis RK. Gastrointestinal nematode
expulsion in IL-4 knockout mice is IL-13 dependent. Eur J Immunol. 2000;30(7):2083-
2091.
29. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR.
Validation of a general measure of treatment satisfaction, the Treatment Satisfaction
Questionnaire for Medication (TSQM), using a national panel study of chronic disease.
Health Qual Life Outcomes. 2004;2:12.
30. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised
nomenclature for allergy for global use: report of the Nomenclature Review Committee of
the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832-
836.
31. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.
Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
32. European Parliament and Council of The European Union. Directive 2001/20/EC of
4 April 2001 on the approximation of the laws, regulations and administrative provisions
of the Member States relating to the implementation of good clinical practice in the
conduct of clinical trials on medicinal products for human use [2001], article 10.
33. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol.
1980;92(Suppl):44-47.
34. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et
al. Second symposium on the definition and management of anaphylaxis: Summary report
-- Second National Institute of Allergy and Infectious Diseases/Food Allergy and
Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-397.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 108 of 156 
35. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification
Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the
FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;
164(7):1035-1043.
36. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work
productivity and activity impairment instrument. Pharmacoeconomics.
1993;4(5):353-365.
37. World Health Organization. WHO model prescribing information: drugs used in skin
diseases. Geneva. 1997.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 109 of 156 
Appendix 1: Protocol summary 
Name of  
investigational 
medicinal product 
Tralokinumab 
Name of active 
substance 
Human recombinant IL-13 monoclonal antibody. 
Title of trial/ 
trial ID/ 
EudraCT no./ 
ClinicalTrials.gov 
no. 
A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the 
efficacy and safety of tralokinumab monotherapy in subjects with 
moderate-to-severe atopic dermatitis (AD) who are candidates for systemic 
therapy – ECZTRA 2 (ECZema TRAlokinumab trial no. 2) / 
LP0162-1326 / 2016-004201-13 / NCT03160885 
International 
coordinating 
investigator 
Eric Simpson, MD, MCR 
Sponsor’s name/ 
address 
LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark 
Estimated number 
of trial sites and 
distribution 
Approximately 130 sites in North America, Europe, Australia, and Korea. 
Main objectives 
Primary objective: 
To evaluate the efficacy of tralokinumab compared with placebo in treating 
moderate-to-severe AD. 
Secondary objectives: 
To evaluate the efficacy of tralokinumab on severity and extent of AD, itch, 
and health-related quality of life compared with placebo. 
Maintenance objective: 
To evaluate maintenance of effect with continued tralokinumab dosing up to 
52 weeks compared to placebo for subjects achieving clinical response at 
Week 16. 
Methodology 
Overview 
The trial will consist of a screening period of 2 to 6 weeks (Weeks -6/-2 to 0), 
an initial treatment period of 16 weeks (Weeks 0 to 16) and a maintenance 
treatment period of 36 weeks (Weeks 16 to 52). A 14-week off-treatment 
follow-up period for the assessment of safety is also included (Weeks 52 to 66). 
All subjects will use an emollient at least twice daily for at least 14 days before 
randomisation and will continue this treatment throughout the trial. 
Trial design 
Subjects found eligible following the screening period will be randomised 3:1 
to tralokinumab 300 mg Q2W or placebo. Randomisation will be stratified by 
region and disease severity. 
Subjects achieving a clinical response at Week 16 (defined as Investigator’s 
Global Assessment [IGA] of 0 or 1 on a 5-point scale ranging from 0 [clear] to 
4 [severe], or at least 75% reduction in Eczema Area and Severity Index 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 110 of 156 
[EASI] score from baseline [EASI75]) will continue into maintenance 
treatment that will continue until Week 52.  
Subjects randomised to tralokinumab in the initial treatment period will be 
re-randomised 2:2:1 to one of the following Q2W maintenance regimens 
stratified by region and IGA response at Week 16 (IGA 0/1 or IGA >1): 

Tralokinumab 300 mg Q2W.

Alternating dose administrations tralokinumab 300 mg and placebo
(‘tralokinumab Q4W’).

Placebo.
Subjects randomised to placebo in the initial treatment period who achieve a 
clinical response at Week 16 (defined by IGA of 0 or 1, or EASI75) will 
continue to receive placebo Q2W in the maintenance treatment period. 
Subjects not achieving a clinical response at Week 16 as well as those who 
meet the criteria listed below during maintenance treatment will be transferred 
to open-label tralokinumab 300 mg Q2W treatment with optional use of TCS 
up to Week 52. 
Transfer to open-label treatment 
Subjects with IGA=0 at Week 16: IGA of at least 2 and not achieving EASI75 
over at least a 4-week period (i.e., over 3 consecutive visits). 
Subjects with IGA=1 at Week 16: IGA of at least 3 and not achieving EASI75 
over at least a 4-week period (i.e., over 3 consecutive visits).   
Subjects with IGA >1 at Week 16: Not achieving EASI75 over at least a 
4-week period (i.e., over 3 consecutive visits).
For selected countries
Subjects transferring to open-label treatment will have the option to
self-administer tralokinumab in their home after adequate training (at 3 dosing
visits in the open-label period after additional consent has been obtained) by
site staff at the investigator’s discretion.
Number of subjects 
to be enrolled 
A total of 780 subjects will be randomised 3:1 to initial treatment (585 subjects 
to tralokinumab; 195 subjects to placebo). 
Main criteria for 
inclusion 

Age 18 and above.

Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria
for AD.

Diagnosis of AD for ≥1 year.

Subjects who have a recent history of inadequate response to treatment
with topical medications or for whom topical treatments are otherwise
medically inadvisable.

AD involvement of ≥10% body surface area at screening and baseline.

An EASI score of ≥12 at screening and 16 at baseline.

An IGA score of ≥3 at screening and at baseline.

A Worst Daily Pruritus numeric rating scale (NRS) average score of ≥4
during the week prior to baseline.

Stable dose of emollient twice daily (or more, as needed) for at least
14 days before randomisation.
Main criteria for 

Active dermatologic conditions that may confound the diagnosis of
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 111 of 156 
exclusion 
AD. 

Use of tanning beds or phototherapy within 6 weeks prior to
randomisation.

Treatment with systemic immunosuppressive/immunomodulating
drugs and/or systemic corticosteroid within 4 weeks prior to
randomisation.

Treatment with TCS and/or TCI within 2 weeks prior to randomisation.

Active skin infection within 1 week prior to randomisation.

Clinically significant infection within 4 weeks prior to randomisation.

A helminth parasitic infection within 6 months prior to the date
informed consent is obtained.

Tuberculosis requiring treatment within the 12 months prior to
screening.

Known primary immunodeficiency disorder.
Investigational 
medicinal products 
Tralokinumab 
150 mg/mL solution for subcutaneous (SC) injection in an accessorised 
pre-filled syringe, 1.0 mL fill volume. Each kit contains 1 syringe. 
Placebo 
Placebo solution for SC injection in an accessorised pre-filled syringe, 1.0 mL 
fill volume. Each kit contains 1 syringe. 
Duration of 
treatment 
Screening period (including wash-out, if applicable) up to 6 weeks, treatment 
period of 52 weeks (last dose of IMP administered at Week 50), follow-up 
period of 14 weeks (subjects may enter the long-term extension trial 
[LP0162-1337, ECZTEND], at any time during the safety follow-up period).  
Main assessments 
Investigator assessments 

Investigator’s Global Assessment (IGA).

Eczema Area and Severity Index (EASI).

Scoring Atopic Dermatitis (SCORAD).
Subject assessments 
A total of 12 patient-reported outcomes (PROs) will be collected. The 
following 5 PROs will be assessed on a daily basis using an electronic diary: 
Worst Daily Pruritus NRS, Average Daily Pruritus NRS, Eczema-related Sleep 
NRS, Patient Global Impression of Bother (PGI-B), and Patient Global 
Impression of Severity (PGI-S). 
The following 7 PROs will be completed at the trial site during site visits: 
Patient Oriented Eczema Measure (POEM), Dermatology Life Quality Index 
(DLQI), EQ-5D-5L, SF-36 (acute recall), Work Productivity and Activity 
Impairment – General Health (WPAI GH), Hospital Anxiety and Depression 
Scale (HADS), and Treatment Satisfaction Questionnaire for Medicine 
(TSQM). 
Safety assessments 
Vital signs, physical examination, ECG, laboratory testing, pharmacokinetics 
(PK), anti-drug antibodies, and adverse event reporting. 
Other assessments 
Photographs. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 112 of 156 
Primary endpoints 

IGA score of 0 (clear) or 1 (almost clear) at Week 16.

EASI75 at Week 16.
Secondary 
endpoints 
Secondary endpoints 

Change in SCORAD from baseline to Week 16.

Reduction of Worst Daily Pruritus NRS (weekly average) of at least 4
from baseline to Week 16.

Change in DLQI score from baseline to Week 16.
Additional secondary endpoints 

AE/SAE frequency by preferred term.

Frequency of anti-drug antibodies.

EASI50 at Week 16.

EASI90 at Week 16.

Change from baseline to Week 16 in EASI score.

SCORAD75 at Week 16.

SCORAD50 at Week 16.

Change from baseline to Week 16 in Worst Daily Pruritus NRS
(weekly average).

Reduction of Worst Daily Pruritus NRS (weekly average) of at least 3
from baseline to Week 16.

Reduction from baseline to Week 16 of DLQI of ≥4 points among
subjects with baseline DLQI ≥4.
Maintenance endpoints 

IGA of 0/1 at Week 52 among subjects with IGA of 0/1 at Week 16
achieved without rescue medication after initial randomisation to
tralokinumab.

EASI75 at Week 52 among subjects with EASI75 at Week 16 achieved
without rescue medication after initial randomisation to tralokinumab.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 113 of 156 
Statistical methods 
Primary endpoints 
The difference in response rates between treatment groups will be analysed 
using the Cochran-Mantel-Haenszel test stratified by region and disease 
severity.  
The primary endpoints will be tested sequentially at a 5% significance level. 
First IGA 0/1 and, if significant, EASI75. If both primary null hypotheses are 
rejected, the secondary endpoints will be tested. 
Secondary endpoints 
The change from baseline to Week 16 in SCORAD will be analysed using a 
repeated measurements model on the post baseline responses up to Week 16. 
Reduction of Worst Daily Pruritus NRS weekly average of at least 4 is a binary 
endpoint, and as such it will be analysed as described for the primary endpoint. 
Change from baseline to Week 16 in DLQI will be analysed the same way as 
change in SCORAD. 
Maintenance endpoints 
The 4 hypotheses of primary interest for maintenance treatment will be tested 
sequentially with the next hypothesis in the sequence only being tested if the 
previous one was significant. The maintenance endpoints will be evaluated in 
the following order: 

No difference between Q2W and placebo for IGA 0/1 at Week 52.

No difference between Q2W and placebo for EASI75 at Week 52.

No difference between Q4W and placebo for IGA 0/1 at Week 52.

No difference between Q4W and placebo for EASI75 at Week 52.
For each endpoint (IGA 0/1 and EASI75 at Week 52) the estimated response 
rates and corresponding 95% CIs, and the pairwise treatment differences will 
be presented. The difference in response rates between treatment groups will be 
analysed using the Cochran Mantel-Haenszel test stratified by region.  
A multiple testing procedure to control the overall type 1 error rate for the trial 
will be used. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 114 of 156 
Appendix 2: Definitions of adverse events and serious adverse events 
Adverse event definition 
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product. (ICH Harmonized Tripartite Guideline for Good Clinical Practice, 
E6 (R1)). 
This definition includes: 

accidental injuries, events related to trial procedures, reasons for any
unfavourable and unplanned change in medication (drug and/or dose),
clinically significant worsening of pre-existing conditions, or reasons for
admission to hospital or surgical procedures unless these were planned before
enrolment. It also includes AEs commonly observed and AEs anticipated based
on the pharmacological effect of the IMP. In addition, any laboratory
abnormality assessed as clinically significant by the investigator must be
recorded as an AE.
Serious adverse event definition 
An SAE is any untoward medical occurrence that 

results in death.

is life-threatening.

requires inpatient hospitalisation or prolongation of existing hospitalisation.
Planned hospitalisation or planned prolonged hospitalisation do not fulfill the
criteria for being an SAE but should be documented in the subject’s medical
record.

results in persistent or significant disability/incapacity.

is a congenital anomaly/birth defect.
or 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 115 of 156 

is a medically important condition. Events that may not be immediately life-
threatening or result in death or hospitalisation but may jeopardise the subject
or may require intervention to prevent one of the other outcomes listed in the
definition above. Examples are intensive treatment in an emergency room or at
home for allergic bronchospasm, blood dyscrasias and convulsions that do not
result in hospitalization, development of drug dependency or drug abuse.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 116 of 156 
Appendix 3: Classification of adverse events 
Severity 
The severity of the AE should be described in terms of mild, moderate or severe according to 
the investigator’s clinical judgement. 
Mild 
An AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living. 
Moderate 
An AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to 
the subject. 
Severe 
An AE that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention. 
If the severity of an AE worsens, a new AE should be recorded. 
Causality 
The causal relation of the AE to the use of the IMP should be described in terms of probable, 
possible or not related according to the following: 
Probably 
related 
Follows a reasonable temporal sequence from administration of the IMP. 
Could not be reasonably explained by the subject’s clinical state, 
environmental or toxic factors or other therapies administered to the 
subject. 
Follows a known pattern of response to the IMP. 
Disappears or decreases on cessation or reduction in dose of the IMP. 
Reappears or worsens upon re-challenge. 
Possibly 
related 
Follows a reasonable temporal sequence from the administration of the 
IMP. 
Could also be reasonably explained by the subject’s clinical state, 
environmental or toxic factors or other therapies administered to the 
subject. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 117 of 156 
Follows a known pattern of response to the IMP. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 118 of 156 
Not related 
Does not follow a reasonable temporal sequence from administration of the 
IMP. 
Is better explained by other factors like the subject’s clinical state, 
environmental or toxic factors or other therapies administered to the 
subject. 
Does not reappear or worsen upon re-challenge. 
Does not follow a known pattern of response to the IMP. 
Outcome 
The outcome of the event should be classified and handled as follows: 
Recovered/ 
resolved 
The event has stopped. The stop date of the event must be recorded. 
Recovering/ 
resolving 
The subject is clearly recovering from an event. The event is not yet 
completely resolved.  
Not 
recovered/ 
not resolved 
Event is still ongoing. 
Recovered/re
solved with 
sequelae 
The event has reached a state where no further changes are expected and the 
residual symptoms are assumed to persist. An example is hemiparesis after 
stroke. 
The stop date of the event must be recorded. In case of a SAE, the sequelae 
should be specified. 
Fatal 
The subject has died as a consequence of the event. Date of death is recorded 
as stop date for the AE. 
Unknown 
Unknown to investigator, e.g. subject lost to follow-up. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 119 of 156 
Appendix 4: Trial governance considerations 
Appendix 4A: Regulatory and ethical considerations 
This trial will be conducted in accordance with the protocol and with the following: 

Consensus ethical principles derived from international guidelines including the
current version of the Declaration of Helsinki and Council for International
Organizations of Medical Sciences (CIOMS) International Ethical Guidelines.

Current version of applicable ICH Good Clinical Practice (GCP) Guidelines.

Applicable laws and regulations.
The appropriate regulatory authority(ies) must be notified of/approve the clinical trial as 
required.  
The protocol, protocol amendments, subject information leaflet including the informed 
consent form (ICF), Investigator’s Brochure, and other relevant documents (for example 
advertisements) must be submitted to an IRB/IEC by the investigator (in collaboration with 
LEO, if applicable) and reviewed and approved by the IRB/IEC prior to enrolment of 
subjects.  
Any amendments to the protocol must be approved by/receive favourable opinion from 
relevant regulatory authorities and IRBs/IECs as required prior to the implementation. 
The investigator will be responsible for the following: 

Providing written summaries of the status of the trial to the IRB/IEC annually or more
frequently in accordance with the requirements, policies, and procedures established
by the IRB/IEC.

Notifying the local IRB/IEC of SAEs or other significant safety findings as required
by IRB/IEC procedures.

Providing oversight of the conduct of the trial at the trial site and adherence to
applicable national and international legislation.
Appendix 4B: Informed consent process 
Subjects shall receive written and verbal information concerning the clinical trial. This 
information will emphasise that participation in the clinical trial is voluntary and that the 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 120 of 156 
subject may withdraw from the clinical trial at any time and for any reason. All subjects will 
be given an opportunity to ask questions and will be given sufficient time to consider before 
consenting. 
The subject’s signed and dated informed consent to participate in the clinical trial must be 
obtained prior to any clinical trial related procedure being carried out in accordance with ICH 
GCP (4.8) and all applicable laws and regulations. The authorised person obtaining the 
informed consent must also sign the ICF. 
Subjects must be re-consented to the most current version of the ICF(s) during their 
participation in the trial, if required.  
A copy of the ICF(s) must be provided to the subject or the subject’s legally authorised 
representative.  
Subject card 
At screening, subjects will be provided with a card stating that they are participating in a 
clinical trial and which contains contact address(es) and telephone number(s) of relevant trial 
site staff, including the number for the investigator in case of emergency situations. The 
subject card also includes a local telephone number for the emergency unblinding CRO to be 
used if the investigator or delegated site staff cannot be reached or if unblinding in the IWRS 
cannot be performed. 
Appendix 4C: Subject and data confidentiality 
This clinical trial protocol as well as all other information, data and results relating to this 
clinical trial and/or to the IMP is confidential information of LEO and shall not be used by the 
investigator for purposes other than this clinical trial. 
The investigator agrees that LEO may use any and all information, data and results from this 
clinical trial in connection with the development of the IMPs and, therefore, may disclose 
and/or transfer information, data and/or results to other investigators, regulatory authorities 
and/or commercial partners. 
Subjects will be assigned a unique identifier (subject ID) by LEO. Any subject’s records or 
datasets that are transferred to LEO will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
Subjects must be informed that their personal trial-related data will be used by LEO in 
accordance with local data protection law.   
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 121 of 156 
The subject must be informed that his/her medical records may be examined by Clinical 
Quality Assurance auditors or other authorised personnel appointed by LEO, by appropriate 
IRB/IEC members, and by inspectors from regulatory authorities. 
Processing of personal data 
This protocol specifies the personal data on trial subjects (for example age, gender, health 
condition, height, medical history, test results, etc.) which shall be collected as part of the 
clinical trial and processed during and after trial completion. 
Personal data collected as part of the clinical trial will be transferred to/from the 
institution/investigator, LEO and third parties acting on behalf of LEO. 
Processing of personal data on behalf of LEO requires a written agreement between LEO and 
the relevant party which covers collection, processing and transfer of personal data in the 
clinical trial. In certain cases an agreement on transfer of personal data may also be required. 
Investigators and LEO must ensure that collection, processing and transfer of personal data 
are in compliance with applicable legislation on data protection and privacy. 
Subjects (or their legally acceptable representative) must be asked to consent to the collection, 
processing and transfer of their personal data to EU and non-EU countries for the purpose of 
conducting the clinical trial, research and development of new or existing products/services, 
improving existing products/services, applying for marketing authorisations for 
products/services, marketing of products/services and other related activities. 
LEO has obtained the necessary authorisations for the processing of personal data collected in 
the trial. 
Appendix 4D: Record keeping, quality control, and data handling 
Case report forms 
Data will be collected by means of electronic data capture unless transmitted to LEO or 
designee electronically (e.g., laboratory data). The investigator or staff authorised by the 
investigator will enter subject data into electronic CRFs. Data recorded in the eCRFs will be 
accessible to the trial site and LEO personnel immediately after entry. The CRFs must be 
maintained in an up-to-date state by the trial site at all times. 
The investigator must verify the correctness of the data entered by the site by electronically 
dating and signing all CRFs used. This signature information will be kept in the audit trail and 
cannot be altered. Any correction(s) made by the investigator or authorised site staff to the 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 122 of 156 
CRF after original entry will be documented in the audit trail. Changes to data already 
approved will require the re-signature by the investigator. The person making the change to 
the data, and the date, time and reason for the change will be identified in the audit trail. 
Principles for data entry 
Clinically significant abnormal findings at the (first) screening visit will be documented as 
medical history in the eCRF. 
If an abnormal finding (vital signs, physical examination, laboratory tests, ECG) at any other 
visit than the (first) screening visit is considered by the investigator to be clinically 
significant, it will be reported as an AE in accordance with Section 11.2. Further, any 
clinically significant deterioration of a pre-existing condition as well as any new clinically 
significant sign, symptom or illness observed after screening will be reported as an AE in 
accordance with Section 11.2. 
Source data 
For all data recorded, the source document must be defined in a source document agreement 
or similar document at each trial site. There must only be one source defined at any time for 
any data elements. 
Source data should as a general rule be recorded in the subject’s medical record or other 
defined document normally used at the trial site. Source data not normally collected as a 
routine part of the clinical practice at the site may be entered on a worksheet. Clinical 
assessments/safety evaluations must be signed by medically qualified investigators.  
If the worksheet does not become part of the subject’s medical record, the following should as 
a minimum be added to the subject’s medical record: 

Date(s) of conducting the informed consent process, including date of
provision of subject information.

A statement from the investigator to verify that each of the eligibility criteria
are met.

Subject ID.

The fact that the subject is participating in a clinical trial in AD including
treatment arms of tralokinumab or placebo for 52 weeks (68 weeks in selected
countries).

Other relevant medical information.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 123 of 156 
Trial monitoring 
During the course of the trial ,CRA(s) will visit the trial site. These visits have the following 
objectives: (i) to perform ongoing source data verification to confirm that data entered into the 
CRF by authorised site personnel are accurate, complete, and verifiable from source 
documents; (ii) to confirm that the safety and rights of subjects are being protected; and (iii) 
to confirm that the trial is being conducted in accordance with the currently approved protocol 
and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
The monitoring visit intervals will depend on the trial site’s recruitment rate, the compliance 
of the trial site with the protocol and GCP. 
In order to perform their role effectively, CRAs and persons involved in quality assurance and 
inspections will need direct access to source data, e.g. medical records, laboratory reports, 
appointment books, etc. If the electronic medical record does not have a visible audit trail, the 
investigator must provide the CRA with signed and dated printouts. In addition, relevant site 
staff should be available for discussions at monitoring visits and between monitoring visits 
(e.g. by telephone). 
Protocol compliance 
Protocol deviations will be documented and notified to the investigator. LEO will assess all 
protocol deviations and decide if any of these deviations must be reported to the regulatory 
authorities as a serious breach of GCP and the protocol, as required by local legislation. 
Protocol deviations will be included in the CTR. 
Sponsor audits, IRB/IEC review, and regulatory agency inspections 
The clinical trial will be subject to audits conducted by LEO or inspections from domestic or 
foreign regulatory authorities or from IRBs/IECs. Audits and inspections may take place 
during or after the trial. The investigator and the site staff as well as LEO staff have an 
obligation to cooperate and assist in audits and inspections. This includes giving auditors and 
inspectors direct access to all source documents and other documents at the trial site relevant 
to the clinical trial. This includes permission to examine, verify and reproduce any records 
and reports that are important to the evaluation of the trial. 
If the trial site is contacted for an inspection by competent authorities, LEO must be notified 
immediately. 
Data handling 
Subject data should be entered into the CRF as soon as possible after each visit in accordance 
with the requirements described in the Clinical Trial Agreement, if applicable. Queries for 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 124 of 156 
discrepant data will be generated automatically by the system upon entry or manually by the 
CRA, sponsor’s medical expert, or the data manager. All queries will be raised electronically 
within the electronic data capture system. This systematic validation will ensure that a clean 
and consistent database is provided for the statistical analysis. 
An electronic PRO (ePRO) solution will be used to capture patient-reported data (data from 
questionnaires completed at the trial site and eDiary data). By the use of an ePRO, data will 
be available immediately after data entry and available for monitors and site personnel, 
including the investigator, with read access only. The ePRO system is a separate application 
from the eCRF and data captured from the eCRF and the ePRO will be stored on different 
servers during data capture. Data from both systems will be included in the final trial 
database. 
External data transfers from vendors to LEO will be transmitted and handled via a secure file 
transfer protocol site.  
Transmissions of electronic data from external data providers and of ePRO data to the clinical 
database are illustrated in Panel 15. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 125 of 156 
Panel 15  Transmission of electronic data 
CTR, clinical trial report; ECG, electrocardiogram; eCRF, electronic case report form; ePRO, electronic 
patient-reported outcome. 
Archiving of trial documentation 
The investigator at each trial site must make arrangements to store the essential trial 
documents including the Investigator Trial File (ICH E6, Guideline for Good Clinical 
Practice) until LEO informs the investigator that the documents are no longer to be retained or 
longer if required by local regulations. 
In addition, the investigator is responsible for the archiving of all relevant source documents 
so that the trial data can be compared against source data after the completion of the trial (for 
example in case of an inspection from regulatory authorities). 
The investigator is required to ensure the continued storage of the documents even if the 
investigator leaves the trial site or retires before the end of the required storage period. 
No records may be destroyed during the retention period without the written approval of 
LEO. No records may be transferred to another location or party without written acceptance 
from LEO. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 126 of 156 
The destruction process must ensure confidentiality of data and must be done in accordance 
with local regulatory requirements. 
For archiving purposes, each investigator will be supplied with a copy of the eCRFs and 
ePRO data for all subjects enrolled at the trial site. This is done after completion of the trial 
and before access to the eCRF/ePRO is revoked. Audit trail information will be included. 
eCRFs and ePRO data must be available for inspection by authorised representatives from 
LEO, from regulatory authorities and/or IEC/IRBs. 
Appendix 4E: Registration, reporting and publication policy 
Basic information of this clinical trial will be registered in the global data registry, 
www.clinicaltrials.gov before the first subject enters into the trial. The trial may also become 
registered in other online data registries, according to applicable law and regulations. 
Results of this clinical trial will be posted on the corporate website of LEO in accordance with 
LEO’s Position on Public Access to Clinical Trial Information, latest 12 months after trial 
completion. Results may also become reported in www.ClinicalTrials.gov, 
www.clinicaltrialsregister.eu and national data registries in accordance with applicable law 
and regulations after clinical trial completion or premature termination.   
In the case of a multi-centre trial the first publication will be a joint multi-centre publication. 
Multi-centre publications will be prepared in collaboration between LEO and the members of 
a writing group, which shall be appointed by LEO. 
Publication by an investigator of his/her trial results shall not be made public before the first 
multi-centre publication. 
If no multi-centre publication has been submitted for publication within 18 months after the 
clinical trial has been completed or terminated at all trial sites and all data have been received, 
defined as database lock of the clinical trial, the investigator shall have the right to publish the 
results from the clinical trial generated by the investigator, subject to the following notice 
requirements: 
Prior to submitting or presenting a manuscript relating to the clinical trial to a publisher, 
reviewer or other outside person, the investigator shall provide to LEO a copy of all such 
manuscripts, and LEO shall have rights to review and comment. Upon the request of LEO, the 
investigator shall remove any confidential information (other than results generated by the 
investigator) prior to submitting or presenting the manuscripts. The investigator shall, upon 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 127 of 156 
the request of LEO, delay the publication or presentation to allow LEO to protect its 
inventions and other intellectual property rights described in any such manuscripts. In case the 
first multi-centre publication is still ongoing and has not been made public at the time of 
notification, LEO and the writing group may also delay the publication or presentation if the 
manuscript is deemed to harm the ongoing multi-centre publication. 
In case of publications made by the investigator after the first multi-centre publication has 
been published, the above-mentioned requirements must still be followed. 
LEO complies with recommendations from the International Committee of Medical Journal 
Editors and with the positions of the International Federation of Pharmaceutical 
Manufacturers & Associations (IFPMA), European Federation of Pharmaceutical Industries 
and Associations (EFPIA), Japan Pharmaceutical Manufacturers Association (JPMA) and 
Pharmaceutical Research and Manufacturers of America (PhRMA) on disclosure of 
information about clinical trials, trial results and authorship. 
Appendix 4F: Insurance 
LEO has taken out relevant insurances covering the subjects in the present clinical trial in 
accordance with applicable laws and regulations. 
Appendix 4G: Financial disclosure 
Investigators will provide LEO with sufficient, accurate financial information as requested to 
allow LEO to submit complete and accurate financial certification or disclosure statements to 
the appropriate regulatory authorities. Investigators are responsible for providing information 
on financial interests during the course of the clinical trial and for 1 year after completion of 
the clinical trial, or for a longer period of time if required by local legislation. 
Appendix 4H: Committee structure 
Patient safety will be carefully assessed by an independent Data Monitoring Committee 
(DMC). All members will be independent of the trial (i.e. they will not be participating 
investigators or employees at participating sites) and of LEO (i.e. they will not be LEO 
employees). The DMC members are experienced with clinical trials and will be responsible 
for assessing the safety of the subjects through assessment of the safety of the treatment 
regimen during the trial and through monitoring the overall conduct of the trial. Refer to 
Appendix 8 for a list of trial committee members. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 128 of 156 
The DMC will review data on a regular basis. Additional meetings may also be called on an 
ad hoc basis, as requested by the DMC or LEO. All data collected at the time of the data 
cut-off/scheduled meetings will be included in the summaries for the DMC, including data 
from subjects still ongoing in the trial. The DMC will examine summaries and listings of 
AEs, specific laboratory parameters and subject disposition data as detailed in the DMC 
Charter. Full details of the analyses to be presented to the DMC will be specified in a separate 
DMC statistical analysis plan.  
The DMC will have an independent statistician and an independent administrator who will 
remain independent of the trial management team.  
The chairman of the DMC, in conjunction with the other members, will communicate their 
recommendations to LEO’s clinical project manager after each meeting. The chairman of the 
DMC will provide written reports to LEO after each formal review to indicate the 
committee’s recommendation regarding safety concerns and trial continuation. Further details 
on all aspects relating to the DMC are provided in the DMC charter. 
Appendix 4I: Trial and site closure 
Premature termination of trial or trial site 
LEO, the investigator, the IRB/IECs or competent authorities may decide to stop the clinical 
trial, part of the trial or a trial site at any time, but agreement on procedures to be followed 
must be obtained. 
If a clinical trial is suspended or prematurely terminated, the investigator must inform the 
subjects promptly and ensure appropriate therapy and follow-up. As specified by applicable 
regulatory requirements, the investigator or LEO must promptly inform IRB/IECs and 
provide a detailed written explanation. Relevant competent authorities must be informed. 
The trial must be terminated if the perception of the benefit/risk ratio (judged from clinical 
signs and symptoms, (S)AEs and/or remarkable safety laboratory changes) becomes 
unfavourable for the continuation of the trial. 
Reasons for the early closure of a trial site by LEO or investigator may include but are not 
limited to: 

Failure of the investigator to comply with the protocol, the requirements of the
IRB/IEC or local health authorities, LEO’s procedures, or GCP guidelines.

Inadequate recruitment of subjects by the investigator.
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 129 of 156 

Discontinuation of further IMP development.
Completion of trial 
Investigators will be informed when subject recruitment is to cease. Trial enrolment will be 
stopped at a trial site when the total requested number of subjects for the clinical trial has 
been obtained, irrespective of the specific site’s planned inclusion number. 
Trial sites will be closed upon trial completion. LEO will undertake arrangements for the 
collection and disposal of any unused trial material that the investigator is not required to 
keep in his/her files. A trial site is considered closed when all required documents and trial 
supplies have been collected and a trial site closure visit has been performed. 
When the randomisation code has been broken, the investigators will receive information 
about the treatment allocation for the subjects randomised at their respective sites and will be 
asked to record this in the subject’s medical record. 
Appendix 4J: Responsibilities 
The international coordinating investigator (ICI) is responsible for the approval of the 
(consolidated) clinical trial protocol, including any amendment(s) and the CTR on behalf of 
all clinical trial investigators and as agreed to in an International Coordinating Investigator 
Agreement. 
The national coordinating investigators are responsible for national issues relating to the 
clinical trial as agreed to in a National Coordinating Investigator Agreement. 
Each participating investigator is responsible for all aspects of the clinical trial conduct at 
his/her trial site as agreed to in a Clinical Trial Agreement. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 130 of 156 
Appendix 5: Hanifin and Rajka (1980) diagnostic criteria for AD 
From Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;92 
(Suppl):44-47. 
Major Features: must have 3 or more of the following: 

Pruritus

Typical morphology and distribution:
o
Flexural lichenification or linearity in adults
o
Facial and extensor involvement in infants and children

Chronic or chronically-relapsing dermatitis

Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis)
Minor Features: should have 3 or more of the following: 

Xerosis

Ichthyosis, palmar hyperlinearity, or keratosis pilaris

Immediate (type 1) skin-test reactivity

Raised serum IgE

Early age of onset

Tendency toward cutaneous infections (especially S. aureus and herpes simplex) or
impaired cell-mediated immunity

Tendency toward non-specific hand or foot dermatitis

Nipple eczema

Cheilitis

Recurrent conjunctivitis

Dennie-Morgan infraorbital fold

Keratoconus

Anterior subcapsular cataracts

Orbital darkening

Facial pallor or facial erythema

Pityriasis alba

Anterior neck folds

Itch when sweating

Intolerance to wool and lipid solvents

Perifollicular accentuation

Food intolerance

Course influenced by environmental or emotional factors

White dermographism or delayed blanch
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 131 of 156 
Appendix 6: Guidance for anaphylaxis diagnosis 
Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson FN Jr, Bock SA, Branum A, et al. Second 
symposium on the definition and management of anaphylaxis: Summary report -- Second National 
Institute of Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network symposium. J 
Allergy Clin Immunol. 2006;117(2):391-397. 
The National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy and Anaphylaxis 
Network Guidance for Anaphylaxis Diagnosis (FAAN) define anaphylaxis as a serious allergic 
reaction that is rapid in onset and may cause death. They recognize 3 categories of anaphylaxis, with 
criteria designated to capture from 80% of cases (category 1) to >95% of all cases of anaphylaxis (for 
all 3 categories).  
Clinical criteria for diagnosing anaphylaxis 
Anaphylaxis is highly likely when any one of the following 3 criteria are fulfilled: 
1) Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal
tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)
AND AT LEAST ONE OF THE FOLLOWING: 

Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak
expiratory flow [PEF], hypoxemia)

Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (eg,
hypotonia [collapse], syncope, incontinence)
2) Two or more of the following that occur rapidly after exposure to a likely allergen for that
patient (minutes to several hours):

Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen
lips-tongue-uvula)

Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF,
hypoxemia)

Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope,
incontinence)

Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)
3) Reduced BP after exposure to known allergen for that patient (minutes to several hours):
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 132 of 156 

Infants and children: low systolic BP (age specific) or greater than 30% decrease in
systolic BP

Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that
person’s baseline
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 133 of 156 
Appendix 7: Country-specific requirements 
KOREA 
Section 8.2 Inclusion criteria – inclusion criterion no. 2 
Age 18 and above. 
In Korea, inclusion criterion no. 2 will be as follows: Age 19 and above. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 134 of 156 
Appendix 8: Contact list 
Contact list of LEO, protocol authors, vendors, and trial committees 
Contact details for the clinical project manager, national lead CRA (NLCRA), and sponsor’s 
medical expert are provided to the trial sites as a separate contact list. 
Sponsor 
LEO Pharma A/S (referred to as ‘LEO’ or ‘the sponsor’ in this clinical trial protocol) is the 
sponsor of the clinical trial: 
LEO Pharma A/S  
Industriparken 55 
DK-2750 Ballerup 
Denmark 
Protocol authors 
Eric Simpson, MD, MCR, International coordinating investigator, Department of 
Dermatology, Oregon Health and Science University, Portland, Oregon, USA 
, M.Sc. Stat, Principal Statistician, LEO Pharma A/S, Denmark 
,, MD, Senior Global Medical Science Lead, LEO Pharma A/S, Denmark 
, MD, Senior PV Advisor, LEO Pharma A/S, Denmark 
, M.Sc. Pharm, Clinical Project Manager, LEO Pharma A/S, Denmark 
, PhD, Medical Communication Scientist, LEO Pharma A/S, Denmark 
eDoc-00648766 - Version
5. 0
PPD
PPD
PPD
PPD
PPD

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 135 of 156 
CROs/vendors 
Service 
Name and address 
Data management 
Quanticate Ltd. 
Bevan House, 9-11 Bancroft Court, Hitchin, Hertfordshire 
SG5 1LH 
United Kingdom 
ePRO 
CRF Health Management Ltd. 
3rd Floor, Brook House, 229-243 Shepherds Bush Road, 
Hammersmith, London, W6 7AN 
United Kingdom 
ECG 
Cardiabase S.A.S. 
Villa Alsacienne, 78 Avenue du XXe Corps, 54000 Nancy 
France 
Central Lab 
ACM Global Central Laboratory 
23 Hospital Fields Road, York YO10 4DZ 
United Kingdom 
PK analysis and ADA 
Covance Laboratories Ltd. 
Otley Road, Harrogate, North Yorkshire, HG3 IPY 
United Kingdom 
Photography 
Canfield Scientific, Inc. 
253 Passaic Ave., Fairfield NJ 07004 
United States 
IWRS 
Quanticate Ltd. 
Bevan House, 9-11 Bancroft Court, Hitchin, Hertfordshire 
SG5 1LH 
United Kingdom 
CMO  
Almac Clinical Services Ltd. 
Almac House, 20 Seagoe Industrial Estate, Craigavon BT63 
5QD, United Kingdom 
CRO services in Korea 
intellim Corporation 
18F, Mainichi Intecio, 3-4-5 Umeda, Kita-ku, Osaka 530-0001 
Japan 
Emergency unblinding CRO 
C3i, Inc.  
25 Lindsley Drive, Morristown, NJ 07960  
United States of America 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 136 of 156 
Trial committees  
Data Monitoring Committee 
Role 
Name and affiliation 
Chairman 
, Dr. med. Dr. phil. 
Technical University of Munich, Germany 
Member 
, MD 
University of Michigan, USA 
Member 
, BSc MSc CStat CSci 
S-cubed Biometrics Ltd, UK 
eDoc-00648766 - Version
5. 0
PPD
PPD
PPD

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 137 of 156 
Appendix 9: WHO model prescribing information for classification of 
topical corticosteroids 
Hydrocortisone and betamethasone are examples of low- and high-potency topical 
corticosteroids (TCS). TCS have been ranked in terms of potency into 4 groups consisting of 
7 classes. Class I TCS are the most potent and Class VII TCS are the least potent (Panel 16). 
Efficacy and side-effects are greatest with the Class I ultra-high-potency preparations which 
should only be used for limited time periods (2‒3 weeks).  
Representative preparations by group are listed in the table below according to the WHO 
model prescribing information for drugs used in skin diseases (37). These groups may vary 
depending on the formulation and concentration and should be considered approximate. In 
general, ointments are more potent than creams or lotions. Potency is also increased when 
TCS are used under occlusive dressings or in intertriginous areas. 
Panel 16  Classification of topical corticosteroids 
Potency 
Class Topical corticosteroid 
Formulation 
Ultra high 
I 
Clobetasol propionate 
Cream, 0.05% 
Diflorasone diacetate 
Ointment, 0.05% 
High 
II 
Amcinonide 
Ointment, 0.1% 
Betamethasone dipropionate 
Ointment, 0.05% 
Desoximetasone 
Cream or ointment, 0.025% 
Fluocinonide 
Cream, ointment, or gel, 0.05% 
Halcinonide 
Cream, 0.1% 
III 
Betamethasone dipropionate 
Cream, 0.05% 
Betamethasone valerate 
Ointment, 0.1% 
Diflorasone diacetate 
Cream, 0.05% 
Triamcinolone acetonide 
Ointment, 0.1% 
Moderate 
IV 
Desoximetasone 
Cream, 0.05% 
Fluocinolone acetonide 
Ointment, 0.025% 
Fludroxycortide 
Ointment, 0.05% 
Hydrocortisone valerate 
Ointment, 0.2% 
Triamcinolone acetonide 
Cream, 0.1% 
V 
Betamethasone dipropionate 
Lotion, 0.02% 
Betamethasone valerate 
Cream, 0.1% 
Fluocinolone acetonide 
Cream, 0.025% 
Fludroxycortide 
Cream, 0.05% 
Hydrocortisone butyrate 
Cream, 0.1% 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 138 of 156 
Panel 16  Classification of topical corticosteroids (continued) 
Potency 
Class Topical corticosteroid 
Formulation 
Moderate 
V 
Hydrocortisone valerate 
Cream, 0.2% 
Triamcinolone acetonide 
Lotion, 0.1% 
Low 
VI 
Betamethasone valerate 
Lotion, 0.05% 
Desonide 
Cream, 0.05% 
Fluocinolone acetonide 
Solution, 0.01% 
VII 
Dexamethasone sodium phosphate 
Cream, 0.1% 
Hydrocortisone acetate 
Cream, 1% 
Methylprednisolone acetate 
Cream, 0.25% 
Source: WHO model prescribing information: drugs used in skin diseases (37). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 139 of 156 
Appendix 10: Protocol amendment history 
The Protocol amendment summary of changes table for the current amendment is located 
directly before the table of contents. 
Amendment 3 (12-Dec-2017) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall rationale for the amendment 
The reason for the amendment is due to a request for changes from the Health Authorities in 
the US after their review of the protocol.  
Note: The table below describes the changes in each section. Changes have either been 
summarised (written with plain text only) or marked as tracked changes (text added to the 
protocol is written in bold and deleted text has a line through it). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 140 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 6.1 
Trial objectives and 
endpoints: Initial 
treatment period of 
Weeks 0 to 16 
EASI90 has been added as an additional 
secondary endpoint. 
Added to further substantiate 
the clinical relevance of the 
treatment effect on the 
change from baseline to 
Week 16 in EASI score.  
Section 6.1 
Trial objectives and 
endpoints: Initial 
treatment period of 
Weeks 0 to 16 
The following other objective has been 
added: 
To evaluate the efficacy over time of 
tralokinumab on severity and extent of AD, 
itch, and health related quality of life 
compared with placebo. 
Added to allow for an 
evaluation of the efficacy of 
tralokinumab over time on 
severity and extent of AD, 
itch, and health-related 
quality of life compared with 
placebo. 
The following endpoints have been added as 
other endpoints: 

IGA 0/1 at each scheduled assessment
until Week 14.

EASI75 at each scheduled assessment
until Week 14.

Change in SCORAD from baseline to
each scheduled assessment until
Week 14.

Change from baseline to each week
through Week 1 to 15 in Worst Daily
Pruritus NRS (weekly average).

Reduction of Worst Daily Pruritus NRS
(weekly average) of at least 4 from
baseline to each week through Week 1 to
15.

Change in DLQI score from baseline to
each scheduled assessment until
Week 14.
Added to allow for an 
evaluation of the efficacy of 
tralokinumab over time on 
severity and extent of AD, 
itch, and health-related 
quality of life compared with 
placebo. 
The following other endpoints have been 
removed: 

Reduction of Worst Daily Pruritus NRS
(weekly average) of at least 4 from
baseline to Week 2

Change from baseline to Week 2 in
Worst Daily Pruritus NRS (weekly
average).
Removed because these 
2 endpoints are covered by 
the new endpoints above 
(change from baseline to 
each week; reduction from 
baseline to each week). 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 141 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 6.1 
Trial objectives and 
endpoints: Initial 
treatment period of 
Weeks 0 to 16 
The following endpoints have been added as 
other endpoints: 

HADS anxiety and HADS depression
scores <8 at Week 16 in subjects with
baseline HADS anxiety or HADS
depression subscale scores of ≥8.

Reduction from baseline to Week 16 of
POEM of ≥4 points among subjects with
baseline POEM ≥4.
To evaluate the 
patient-reported outcomes 
and health care resource 
utilisation. 
Section 6.2 
Trial objectives and 
endpoints: 
Maintenance 
treatment period of 
Week 16 to 52 for 
responders at 
Week 16 

IGA of 0/1 at Week 52 among subjects
with IGA of 0/1 at Week 16 achieved
without rescue medication after initial
randomisation to tralokinumab.

EASI75 at Week 52 among subjects
with EASI75 at Week 16 achieved
without rescue medication after initial
randomisation to tralokinumab.

IGA 0/1 or EASI75 at Week 52 among
subjects with IGA 0/1 or EASI75 at
Week 16 achieved without rescue
medication.
The maintenance endpoints of IGA 0/1 and 
EASI75 at Week 52 for subjects achieving 
clinical response at Week 16 without rescue 
medication are considered secondary 
endpoints. 
To evaluate the maintenance 
of effect achieved with 
tralokinumab.  
Section 7.1 
Overall trial design 
A 16 14-week off treatment follow-up period 
for the assessment of safety is also included 
(Weeks 52 to 66). 
All subjects will complete a 1614-week off 
treatment follow-up period for the assessment 
of safety and ADA at Week 66. 
Clarification that the 
follow-up period has a 
duration of 14 weeks since 
the maintenance period and 
the open-label arm both 
include the Week 52 visit. 
Since the last dose of IMP is 
administered at Week 50, the 
follow-up visit will occur 
16 weeks after last IMP 
administration. 
Transfer to open-label may occur at any visit 
while the subject is in the maintenance 
treatment period but no earlier than 
Week 22. 
Clarification that transfer to 
open-label requires a 
persistent worsening of 
disease observed over 
3 consecutive visits in the 
maintenance period. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 142 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 8.2 
Inclusion criteria 
(no. 9) 
Worst Daily Pruritus NRS at baseline will be 
calculated from daily assessments of worst 
itch severity (Worst Daily Pruritus NRS) 
during the 7 days immediately preceding 
randomisation (Day -6 to 0). 
Clarification of how Worst 
Daily Pruritus NRS at 
baseline will be calculated. 
Inclusion criteria 
(no. 11) 
The subjects must have used the 
contraceptive method continuously for at 
least 1 month prior to the pregnancy test at 
baseline. 
Clarification that female 
subjects of childbearing 
potential must have used a 
highly effective form of birth 
control for at least 1 month 
prior to baseline. 
Section 11.5.6 
Aggravation of 
condition 
Any clinically significant aggravation/ 
exacerbation/worsening of any medical 
condition(s), compared to baseline screening, 
must be reported as an AE. 
Clarification that AE 
reporting starts at screening, 
not baseline. This is in 
alignment with the 
information given in  
Section 11.1 and 
Appendix 4D. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 143 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 12.2 
Trial analysis sets 
A per protocol analysis set will be used as an 
efficacy subset for the analysis of the 
primary endpoints up to Week 16 
The per protocol analysis set will be defined 
by excluding subjects from the full analysis 
set for whom any of the following conditions 
apply:  

receive no treatment with the IMP.

provide no efficacy data assessment of
IGA or EASI following start of
treatment.

are known to have taken the wrong IMP
throughout the initial treatment period of
the trial.

do not fulfil all the disease defining
inclusion criterion (i.e. inclusion
criterion no. 3) inclusion criteria no. 3, 
6, 7 and 8.  
Further exclusion of subjects or subject data 
will be decided upon after a blinded review of 
the data, reviewing all the remaining in- and 
exclusion criteria, but focusing on 
concomitant medication that may affect AD 
and also considering compliance/adherence 
and violations of visit windows. 
Specification that the per 
protocol analysis set will be 
used for analysis of the 
primary endpoints only. 
To pre-define the criteria 
leading to exclusion from the 
per protocol analysis set, 
rather than deferring until a 
blinded review of the data. 
Section 12.3.1 
Disposition of 
subjects 
For all randomised subjects the reasons for 
permanent discontinuation of IMP and for 
leaving the trial in the initial treatment period 
will be presented by last visit attended and by 
treatment group. For the subjects in the 
maintenance safety analysis set, the reasons 
for permanent discontinuation of IMP and 
for leaving the trial or treatment arm will be 
presented by last visit attended and by the 
assigned treatment group at Week 16. For the 
subjects in the open-label safety analysis set, 
the reasons for permanent discontinuation 
of IMP and for leaving the trial will be 
presented by last visit attended. 
Clarification that reasons for 
permanent discontinuation of 
IMP will be presented. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 144 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 12.3.2 
Demographics and 
other baseline 
characteristics 
The presentations will be overall and by 
treatment group. Presentations of age, sex, 
ethnicity, race, baseline disease severity, and 
Worst Daily Pruritus NRS weekly average at 
baseline will also be given by region and by 
baseline disease severity (IGA 3 or 4). 
Baseline disease severity 
added since this is also a 
stratification factor, in 
addition to region. 
Section 12.3.5.1 
Analysis of primary 
endpoints 
This section has been amended to implement 
the concept of estimands together with the 
pre-specification of sensitivity analyses. The 
primary analyses of the primary endpoints are 
unchanged compared to the statistical 
analysis plan provided in the original protocol 
dated 17-Mar-2017. 
To pre-specify the method of 
handling missing data. 
Section 12.3.5.2 
Analysis of 
secondary 
endpoints 
This section has been amended to implement 
the concept of estimands together with the 
pre-specification of sensitivity analyses. The 
primary analyses of the secondary endpoints 
are unchanged compared to the statistical 
analysis plan provided in the original protocol 
dated 17-Mar-2017. 
To pre-specify the method of 
handling missing data. 
Section 12.3.5.3 
Analysis of 
additional 
secondary 
endpoints 
This section has been updated to describe the 
statistical analysis of the additional secondary 
endpoint EASI90. 
To describe the statistical 
analysis of new endpoint. 
Section 12.3.5.4.1 
Efficacy over time 
This is a new section describing the statistical 
analysis of the 6 new other endpoints which 
address efficacy over time. 
To describe the statistical 
analysis of new endpoints. 
Section 12.3.5.4.2 
Patient-reported 
outcomes 
This section has been updated to include a 
description of the statistical analysis of the 
following 2 new other endpoints: 

HADS anxiety and HADS depression
scores <8 at Week 16 in subjects with
baseline HADS anxiety or HADS
depression subscale scores of ≥8

Reduction from baseline to Week 16 of
POEM of ≥4 points among subjects with
baseline POEM ≥4.
To describe the statistical 
analysis of new endpoints. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 145 of 156 
Section number 
and name 
Description of change 
Brief rationale 
The description of the analysis of the 
following 2 endpoints have been removed 
from this section: 

Reduction of at least 4 from baseline to
Week 2 in Worst Daily Pruritus NRS
weekly average

Change from baseline to Week 2 in
Worst Daily Pruritus NRS weekly
average.
The analysis of these 
endpoints is now covered by 
the new section 12.3.5.4.1. 
For the PGI-B, a day of ‘no or slight bother’ 
is defined as answering the question with ‘not 
at all’ or ‘slightly’. The subjects’ number of 
days of ‘no or slight bother’ will be tabulated 
per treatment group for the initial treatment 
period. The mean number of days will be 
presented with 95% CIs and compared 
between the 2 treatment groups using an 
analysis of variance model including 
treatment, region, and baseline IGA as 
factors. In this analysis, data collected after 
permanent discontinuation of IMP or after 
initiation of rescue medication will be 
disregarded. 
Clarification regarding data 
collected after permanent 
discontinuation of IMP or 
after initiation of rescue 
medication, to align with the 
primary estimand for the 
continuous secondary 
endpoints. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 146 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 12.3.6.1 
Analysis of 
maintenance 
endpoints 
The main changes are as follows: 

An estimand framework has been
introduced for the analysis of the
maintenance endpoints. The primary
analysis provided in the statistical
analysis plan in the original protocol
dated 17-Mar-2017 is unchanged.

Clarification has been added on the
analysis set for the maintenance
endpoints IGA of 0/1 at Week 52 and
EASI75 at Week 52.

The sensitivity analysis allowing TCS
treatment under certain conditions has
been removed (mild to moderate
strengths [WHO classification] TCS, on
≤250 cm2 affected BSA, for ≤5
consecutive days, not more often than
every 4 weeks, <3 courses from
Week 16 to Week 50 and last course is
completed prior to the Week 50 visit,
allowing at least a 2-week washout prior
to the Week 52 assessment).

An LOCF sensitivity analysis has been
introduced.
To conduct a sensitivity 
analysis which is similar to 
the sensitivity analysis no. 2 
for the primary estimand for 
the primary endpoints. The 
sensitivity analysis described 
in the original 
protocol – which allowed 
TCS under certain 
conditions – is inconsistent 
with the rescue medication 
algorithm applied in the 
initial treatment period. 
Section 12.3.6.2.1 
Time to relapse 
Initiation of rescue medication is now 
considered an event of relapse, rather than a 
censoring of the time to relapse. 
A clarification has been added that only 
subjects who achieve response at Week 16 
without rescue medication will be included in 
the analysis.  
Initiation of rescue 
medication is unlikely to be 
independent of the time to 
relapse, hence it is not 
considered appropriate to 
consider it a censoring event. 
Clarification that the log-rank test will be 
stratified by region and that this test is 
considered a supplementary exploratory 
analysis. 
The log-rank test will be 
stratified according to 
region, to align with the 
analysis of the binary 
maintenance endpoints. 
Clarification that the 
log-rank test is considered a 
supplementary exploratory 
analysis. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 147 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 12.3.6.2.3 
Supportive 
maintenance 
To support the maintenance objective, the 
response IGA 0/1 or EASI75 at Week 52 will 
be presented and analysed as described 
above for the primary analysis of the 
maintenance estimand for all subjects in the 
maintenance analysis set who did not receive 
rescue medication prior to Week 16 The 
estimated response rates and corresponding 
95% CIs, and the pairwise treatment 
differences will be presented. 
To clarify that only subjects 
who achieve response at 
Week 16 without rescue 
medication will be included 
in the analysis.  
Section 12.3.9 
Analysis of data per 
last subject’s 
Week 52 visit 
This is a new section which specifies that the 
trial will be unblinded once all randomised 
subjects have completed the Week 52 visit. 
All pre-specified analyses related to the initial 
and maintenance treatment period will be 
based on the data cut-off date of the last 
subject’s Week 52 visit. 
To support submission for 
regulatory approval. 
Appendix 1 
Protocol summary 
Updated with the changes described above, as 
applicable. 
To reflect updated text in 
protocol. 
Appendix 4B 
Informed consent 
process 
Subjects must be re-consented to the most 
current version of the ICF(s) during their 
participation in the trial, if required. 
Clarification that subjects 
will only be re-consented to 
a new version of the ICF(s), 
if deemed necessary. 
Appendix 4H 
Committee 
structure 
Refer to Appendix 8 for contact details on all 
a list of trial committee members. 
As the DMC has been 
established, the list of 
committee members has 
been included; however, 
contact details are not 
provided in the protocol. 
Appendix 8 
Contact list 
Members of the DMC have been listed. 
DMC has now been 
contracted. 
Throughout 
Minor editorial and document formatting 
revisions. 
Minor, have therefore not 
been summarised. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 148 of 156 
Amendment 2 (28-Aug-2017) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union. 
Overall rationale for the amendment 
The reason for the amendment is due to a request for changes from the Health Authorities in 
Europe after their review of the protocol.  
Note: In the table below, text added to the protocol is written in bold and deleted text has a 
line through it. 
Section 
number and 
name 
Description of change 
Brief rationale 
Section 2 
Trial 
identification 
ClinicalTrials.gov number: 
NCT03160885 
ClinicalTrials.gov identifier received 
and it has therefore been added. 
Section 3 
Schematic of 
trial design 
Section 4 
Schedule of 
procedures 
Section 7.1 
Overall trial 
design 
Section 7.3 
End of trial 
definition 
All subjects in the trial will have a safety 
follow-up visit (end of trial visit) 
16 weeks after last injection of IMP, 
including those that are offered 
participation in the long-term extension 
trial conducted under a separate protocol 
(LP0162-1337).  
Details regarding enrolment of subjects 
into the long-term extension have been 
removed. 
To ensure that safety follow-up 
information is collected for all 
subjects enrolled in this trial, and to 
ensure that a safety evaluation can be 
made based on data collected after 
IMP has been discontinued. 
Furthermore, the evaluation of anti-
drug antibodies is considered to be 
most reliable when samples are taken 
in the absence of IMP. 
Details regarding enrolment of 
subjects into trial LP0162-1337 will 
be described in the protocol for 
LP0162-1337. 
Section 4 
Schedule of 
procedures 
2 blood samples (PK and anti-drug 
antibodies) have been added at Week 4 
(visit 5). 
To better monitor potential 
development of immunogenicity. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 149 of 156 
Section 
number and 
name 
Description of change 
Brief rationale 
Section 4 
Schedule of 
procedures 
Section 7.1 
Overall trial 
design 
Appendix 1 
Protocol 
summary 
The criteria for transfer to open-label 
treatment have been changed: 
(i) Persistent IGA of 2 and not achieving
EASI75 over at least a 4-week period 
(i.e., subjects must have IGA of 2 and 
not achieve EASI75 at 3 consecutive 
visits). 
(ii) On a single occasion, an IGA of at
least 3 and not achieving EASI75. 
(iii) On a single occasion not achieving
EASI50 with an IGA of at least 2. 
Subjects with IGA=0 at Week 16:  
IGA of at least 2 and not achieving 
EASI75 over at least a 4-week period 
(i.e., over 3 consecutive visits). 
Subjects with IGA=1 at Week 16:  
IGA of at least 3 and not achieving 
EASI75 over at least a 4-week period 
(i.e., over 3 consecutive visits).   
Subjects with IGA >1 at Week 16:  
Not achieving EASI75 over at least a 
4-week period (i.e., over 3 consecutive
visits).
To keep subjects who entered 
maintenance treatment with IGA 0/1 
in maintenance treatment until they 
have a sustained 2-step change in IGA 
(IGA of 0 becoming ≥2; IGA of 1 
becoming ≥3). 
Section 4 
Schedule of 
procedures 
Section 7.1 
Overall trial 
design 
Section 8.2 
Inclusion 
criteria 
Section 9.4 
Background 
treatment 
(emollients) 
Appendix 1 
Protocol 
summary 
All subjects must use an emollient twice 
daily (or more, as needed) 
Clarification that the use of 
background treatment (emollients) is 
at least twice daily or more, as 
needed. This change has been 
implemented throughout the 
document.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 150 of 156 
Section 
number and 
name 
Description of change 
Brief rationale 
Section 4 
Schedule of 
procedures 
Section 7.1 
Overall trial 
design 
The following text has been added to 
footnote no. 1 in Panel 2:  
Similarly, for subjects who only 
require a 2-week wash out, screening 
visits 1 and 2 will be combined 
(Week -2). 
In Section 7.1, the following text has 
been added under Screening period: 
Similarly, if only a 2-week wash-out is 
required, screening visits 1 and 2 will 
be combined (Week -2; visit 2). 
Specification that the 2 screening 
visits (visits 1 and 2) will be 
combined for subjects who only 
require a 2-week wash-out. 
Section 5.1 
Atopic 
dermatitis 
Treatment recommendations for AD 
include topical therapies, the main being 
topical corticosteroids (TCS). 
Unfortunately, TCS and topical 
calcineurin inhibitors (TCIs) have 
limited efficacy in patients with 
moderate to severe disease. TCS and 
non-biologic other treatment options 
like topical calcineurin inhibitors (TCI) 
and systemic therapies are all associated 
with toxicities with long-term use (6-8). 
Corrections as no toxicities have been 
reported with long-term treatment 
with TCIs. 
Section 5.5 
Benefit/risk 
assessment 
A number of theoretical potential risks 
have been identified that are described in 
the current Investigator’s Brochure, 
including hypersensitivity reactions, 
infusion reactions, immune complex 
disease, and severe infections, 
malignancies, and interference with 
reproductive function 
Infusion reactions have been deleted 
from the list since they are not 
relevant for this trial. Malignancies 
and interference with reproductive 
function added to align with the 
Investigator’s Brochure. 
Section 8.3 
Exclusion 
criteria 
10. Receipt of any marketed (i.e.
immunoglobulin, anti-IgE) or
investigational biologic agent, including
dupilumab
18. History of anaphylaxis following
any biologic therapy.
Dupilumab is now approved in USA, 
and has therefore been added to 
exclusion criterion no. 10. 
Clarification on which kind of 
previous anaphylaxis will lead to 
exclusion. A large proportion of 
subjects with moderate to severe AD 
will have had food allergies and other 
allergies during childhood, manifested 
as anaphylaxis, with no relevance for 
later risk of anaphylactic reactions to 
tralokinumab. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 151 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 8.5 
Discontinuation 
Section 4 
Schedule of 
procedures 
Subjects who permanently discontinue 
treatment IMP for any reason will be asked to 
attend an early termination visit and return 
to the trial site for 1 or 2 additional visits as 
indicated below depending on the time of 
discontinuation of IMP should attend an early 
termination visit and a safety follow-up visit 
16 weeks after last administration of IMP (see 
the SoP [Section 4] for data to be collected at 
these visits). The investigator will review any 
AEs which will be followed up according to 
Section 11.6, if the subject agrees. 
Subjects who permanently discontinue IMP 
prior to Week 16 will be asked to attend: 

Early termination visit.

Nominal Week 16 visit (16 weeks after
randomisation).

Safety follow-up visit (16 weeks after
last administration of IMP).
Subjects who discontinue IMP at Week 16 
or after Week 16 will be asked to attend:  

Early termination visit.

Safety follow-up visit (16 weeks after
last administration of IMP).
If a subject withdraws from the trial, he/she 
may request destruction of any samples taken 
and not tested, and the investigator must 
document this in the site’s trial records.  
Reason(s) for discontinuation from IMP and 
withdrawal from the trial must be recorded 
in the medical records 
Clarification that subjects who 
permanently discontinue IMP 
prior to Week 16 should also 
be assessed at the nominal 
Week 16 visit. This will allow 
sensitivity analyses of the 
primary endpoints and 
secondary endpoints in the 
initial treatment period.  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 152 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 9.11 
Reporting 
product 
complaints 
Any defects or issues with the IMP as well as any 
device deficiency (including malfunctions, use 
errors, and inadequate labelling) must be reported 
to Global Pharmacovigilance, LEO on the 
trial-specific (paper) Device Complaint Form 
within 3 days of first knowledge. Critical 
complaints (defined as any issue, defect, or device 
deficiency that has or potentially could have a 
serious impact for the subject [e.g., SAE or large 
particles in the syringe]) must be reported to 
Global Pharmacovigilance, LEO within 24 hours. 
This report Complaint forms should contain a 
detailed description of the defect, issue, or 
malfunction device deficiency, including whether it 
the malfunction led to an AE. (S)AEs which occur 
due to a defect or issue with the IMP or due to a 
device deficiency will be reported by the 
investigator as described in Sections 11.2 and 
11.3. 
Clarification that product 
complaints related to the 
IMP itself must also be 
reported as product 
complaints.  
Clarification that any 
device deficiency must 
be reported as a product 
complaint. 
Clarification that critical 
complaints are subject to 
expedited reporting. 
Clarification that adverse 
events in connection 
with product complaints 
are to be reported as 
adverse events or serious 
adverse events as 
appropriate. 
Section 10.1 
Overview 
Investigator assessments (performed only by 
adequately trained investigators; the same 
investigator should perform all the evaluations for a 
given subject throughout the entire trial period) in 
the following order: 
1.
SCORAD component C, then component
A and B.
2.
IGA.
3.
EASI.
Clarification that 
SCORAD component C 
(completed by the 
subject) will be 
completed prior to any 
investigator assessments. 
Section 10.3.1.1 
Investigator’s 
Global 
Assessment 
Clinical signs and morphological descriptors have 
been added to the IGA scale in Panel 9. 
Added following a 
request from the FDA. 
Section 10.3.1.2 
Eczema Area 
and Severity 
Index 
Footnote added to Panel 11 on the EASI severity 
score scale:  
Half-points (0.5; 1.5; 2.5) may also be used. 
Clarification that the 
EASI severity score 
scale also includes half-
points (in alignment with 
the eCRF and the trial 
manual).  
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 153 of 156 
Section number and 
name 
Description of change 
Brief rationale 
Sections 10.3.2.1 
Eczema-related Sleep 
numeric rating scale 
to 10.3.2.12 
Treatment Satisfaction 
Questionnaire for 
Medicine 
All 12 questionnaires are provided in the 
investigator trial file and not in a trial 
manual. 
Clarification on where 
questionnaires are filed. 
Section 10.4.5  
Laboratory testing 
The central laboratory will provide 
results in conventional units to trial 
sites in North America and in SI units 
to trial sites in Europe, Australia, and 
Asia; the trial sites in the units preferred 
by the trial sites while the results that are 
transferred to the trial database will 
always be in conventional and SI units. 
Clarification regarding the 
units of the clinical laboratory 
assessments provided to the 
trial sites across regions.  
Clarification that results 
transferred to the trial database 
will be in both conventional 
and SI units. 
Section 10.4.7 
Anti-drug antibodies 
measurements 
Samples will be retained for as long as 
the quality of the material permits 
evaluation but for no longer than 
15 years after marketing 
authorisation. 
Clarification regarding storage 
of ADA samples. 
Section 10.6 Estimate 
of total blood volume 
collected 
Total volume of blood to be withdrawn 
has been changed from 270 mL to 
285 mL 
2 blood samples (PK and 
anti-drug antibodies) have been 
added at Week 4 
Section 11.4.1 
Pregnancy 
Pregnant subjects must permanently 
discontinue from the trial IMP (see 
Section 9.8.1). 
Alignment between 
Section 9.8.1 and 11.4.1. 
Section 11.5.1 
Adverse events of 
special interest 
Malignancies diagnosed after 
randomisation, excluding basal cell 
carcinoma, localised squamous cell 
carcinoma of the skin, and carcinoma 
in situ of the cervix 
Conjunctivitis, keratoconjunctivitis, 
and keratitis added as adverse events of 
special interest. The additional 
information about these events that the 
investigators will provide to LEO is also 
included in Panel 13. 
Basal cell carcinoma, localised 
squamous cell carcinoma of 
the skin, and carcinoma in situ 
of the cervix will be reported 
on standard AE forms as no 
additional information (e.g., 
histology report, oncology 
assessment, treatments) 
regarding these conditions 
need to be reported. 
These event types are common 
in the target population and 
should be monitored closely as 
per request from the 
authorities. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 154 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 12.3.6.1 
Analysis of 
maintenance 
endpoints 
The pooled analyses will only be 
presented in marketing authorisation 
applications. 
Clarification that the pooled 
analyses of data from 
LP0162-1325 and LP0162-1326 
will be presented in marketing 
authorisation applications. 
Section 12.3.7.1 
Adverse events 
An overall summary of the number of 
treatment-emergent AEs, number 
(percentage) of subjects with any 
treatment-emergent AEs, SAEs, 
deaths, premature discontinuations 
from the trial due to AEs, treatment-
related AEs and severe AEs will be 
presented. 
Number of treatment-emergent 
AEs and deaths added to comply 
with ClinicalTrials.gov reporting 
requirements. 
Appendix 8 
Contact list 
Update of the protocol authors. 
Due to change in responsibilities of 
the sponsor’s personnel. 
Appendix 9 
WHO model 
prescribing 
information for 
classification of 
topical 
corticosteroids 
New appendix 
Guidance for the investigators 
regarding the classification of 
topical corticosteroids as well as 
examples have been added to the 
protocol. In Section 9.7 (Rescue 
treatment), a cross reference to 
Appendix 9 has also been added. 
Throughout 
Minor editorial and document 
formatting revisions 
Minor, have therefore not been 
summarised. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 155 of 156 
Amendment 1 (15-Jun-2017) 
This amendment is considered to be non-substantial based on the criteria set forth in 
Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the 
European Union because it neither significantly impacts the safety or physical/mental 
integrity of participants nor the scientific value of the trial.  
Overall Rationale for the Amendment 
The reason for the amendment is due to a request for changes from the Health Authorities in 
Europe after their review of the protocol.  
Note: In the table below, text to be added to the protocol is written in bold. Text to be deleted 
will have a line through it. 
Section number 
and name 
Description of change 
Brief rationale 
Section 9.3.2 
Emergency 
unblinding of 
individual 
subject treatment 
An emergency unblinding request can 
be made by the investigators, other 
HCPs who are not members of the 
trial staff, or authorised LEO 
personnel. 
Provisions are in place for 24-hour 
emergency unblinding of individual 
subject treatment. If emergency 
unblinding is required, the requester 
investigator can unblind a subject’s 
treatment in the IWRS. For a 
requester who is not a member of 
the trial staff and who does not 
without have access to the IWRS 
(e.g., an HCP not involved in the trial 
a physician at an emergency room), 
a local contact number for the 
emergency unblinding CRO is 
provided on the subject card (see 
Appendix 4B) to be used if the 
investigator or delegated site staff 
cannot be reached. 
Clarification regarding the 
procedure for emergency 
unblinding of the individual 
subject’s treatment. 
Emergency unblinding CRO 
Clarification throughout the 
section that the unblinding 
CRO is to be used for 
emergency unblinding only. 
eDoc-00648766 - Version
5. 0

Trial ID: LP0162-1326 
Date: 14-Aug-2018 
Version: 5.0 
Page 156 of 156 
Section number 
and name 
Description of change 
Brief rationale 
Section 11.7 
Handling of an 
urgent safety 
measure 
LEO must act immediately upon 
receipt of the urgent safety measure 
notification in accordance with the 
internal procedures and local 
legislation. 
Clarification that the handling 
of urgent safety measures will 
be in accordance with local 
legislation. 
Appendix 4 B 
Informed 
consent process 
At screening, subjects will be 
provided with a card stating that they 
are participating in a clinical trial and 
which contains contact address(es) 
and telephone number(s) of relevant 
trial site staff including the number 
for the investigator in case of 
emergency situations. The subject 
card also includes a local telephone 
number for the emergency 
unblinding CRO to be used if the 
investigator or delegated site staff 
cannot be reached or if unblinding 
in the IWRS cannot be performed. 
Clarification that the subject 
card also includes emergency 
numbers for emergency 
unblinding by the investigator 
and the emergency unblinding 
CRO (as also clarified in 
Section 9.3.2). 
Appendix 4D 
Record keeping, 
quality control, 
and data 
handling 
Protocol deviations will be 
documented and notified to the 
investigator. LEO will assess all 
protocol deviations and decide if 
any of these deviations must be 
reported to the regulatory 
authorities as a serious breach of 
GCP and the protocol, as required 
by local legislation. Protocol 
deviations will be included in the 
CTR. Protocol deviations will be 
assessed by LEO and included in the 
CTR. 
Clarification that it will be 
evaluated whether protocol 
deviations (non-compliances) 
must be reported to the 
regulatory authorities as a 
serious breach of GCP and the 
protocol.  
Appendix 8 
Contact list 
Not yet contracted 
C3i, Inc. 
25 Lindsley Drive, Morristown, 
NJ 07960  
United States of America 
The name and address for the 
emergency unblinding CRO 
(described in Section 9.3.2) has 
been added. 
eDoc-00648766 - Version
5. 0

Signature Page for eDoc-00648766 v5.0
Electronic signatures made within eTMF LEO are considered to be a
legally binding equivalent of traditional handwritten signatures.
Reason for signing: Approved
Manage
ver Verdict(s)
Name: 
Capacit
Date of signature: 16-Aug-2018 17:23:02
GMT+0000
Reason for signing: Approved
Manage
Verdict(s)
Name: 
Capacit
Date of signature: 17-Aug-2018 06:57:29
GMT+0000
Reason for signing: Approved
Manage
s)
Name: 
Capacit
Date of signature: 17-Aug-2018 10:02:36
GMT+0000
eDoc-00648766 - Version
5. 0
PPD
PPD
PPD